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Abstract
Machine learning (ML) methods have been applied to the analysis of a range of biological
systems. This thesis evaluates the application of these methods to the problem domain of
skin permeability. ML methods offer great potential in both predictive ability and their
ability to provide mechanistic insight to, in this case, the phenomena of skin permeation.
Historically, refining mathematical models used to predict percutaneous drug absorption
has been thought of as a key factor in this field. Quantitative Structure-Activity Rela-
tionships (QSARs) models are used extensively for this purpose. However, advanced ML
methods successfully outperform the traditional linear QSAR models. In this thesis, the
application of ML methods to percutaneous absorption are investigated and evaluated.
The major approach used in this thesis is Gaussian process (GP) regression method.
This research seeks to enhance the prediction performance by using local non-linear models
obtained from applying clustering algorithms. In addition, to increase the model’s quality,
a kernel is generated based on both numerical chemical variables and categorical experi-
mental descriptors. Monte Carlo algorithm is also employed to generate reliable models
from variable data which is inevitable in biological experiments. The datasets used for
this study are small and it may raise the over-fitting/under-fitting problem. In this research
I attempt to find optimal values of skin permeability using GP optimisation algorithms
within small datasets. Although these methods are applied here to the field of percutaneous
absorption, it may be applied more broadly to any biological system.
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Chapter 1
Introduction
1.1 Motivation
In recent years, there has been an increasing interest in the need for better predictions of
percutaneous (through the skin) absorption within the pharmaceutical and cosmetic indus-
tries as well as in fields relating to toxicological issues, such as pesticide usage. The skin
permeability measurements are especially important because skin is a permeable mem-
brane which works as a controllable medium to pass the chemicals through the skin, blood
stream, and the underlining tissue. Therefore, this research could be very interesting in bio-
logical systems. To carry out research on in vivo or in vitro experiments, the excised skin
of the hairless animals (including rats, mice and pigs) or the skin of human cut through
surgery could be used, although such studies have limitations due to the time taken and the
expense in carrying them out (Lien and Gaot (1995)). Historically refining mathematical
models used to predict percutaneous drug absorption have been thought of as a key factor in
this field to avoid issues from ethical, cost effectiveness to suitability of treatment. For ex-
ample, although they do not provide accurate predictions, Quantitative Structure-Activity
Relationships (QSARs) models are used extensively for having understandable mathem-
atical equations (Flynn (1990); El Tayar et al. (1991); Potts and Guy (1992); Moss et al.
(2002); Cronin and Schultz (2003)).
Visualising the datasets reveals that relationship between absorption and the physi-
cochemical features of the compound is non-linear (Moss et al. (2009, 2011); Sun et al.
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(2012); Chen et al. (2007)) and the linear QSAR methods are not beneficial to predict the
chemical’s absorption rate through the skin. Consequently, computational models espe-
cially machine learning methods are further employed for this purpose. Studies carried
out by Lim et al. (2002) and Chen et al. (2007) show that artificial neural network (ANN)
technique outperforms the linear methods for predicting percutaneous absorption of the
chemicals. Similarly, ensemble approach combining KNN and linear models performs bet-
ter than simple linear methods to predict the permeability (Neumann et al. (2006)). Studies
performed byMoss et al. (2009); Lam et al. (2010); Xue et al. (2004) illustrate that the other
ML regression techniques such as Gaussian Process (GP) and Support Vector Machine
(SVM) , gave much better results than the traditional linear QSAR models. Furthermore,
the importance of optimisation techniques in ML methods such as SVM to be used for
QSAR/QSPR purpose is discussed in Norinder (2003). Michielan and Moro (2010) review
and compare the performance of various ML regression and classification techniques in
QSAR strategies. These approaches include GP, Partial Least Squares (PLS), ANN, SVM,
Decision Trees (DTs), and Random Forest (RF). Reviewing the results, they concluded that
that SVM has demonstrated a good performance in a large number of regression and clas-
sification problems. In addition, studies by Shah et al. (2012) show that both GP and SVM
can achieve comparable overall results and each of them may outperform the other one in
the various chemical property space.
The major challenge of this research is the small size of the datasets. This is due to
the difficulties in measuring the permeability of the compounds in the labs. Preparation
and sampling work for a single chemical in the lab can take around three days and may
need 6 to 24 repeated experiments. Therefore, the cost of experimentally generating only
one estimation is as much as £25,000 - £30,000, hence the expansion of research in model
development. Therefore, obtaining large datasets is very demanding and expensive.
The aim of this study is to deal with small datasets to predict the target values efficiently.
Each dataset contains the structural chemicals features (numerical descriptors) and the ex-
perimental conditions conditions (nominal features). For each of the compounds, there
is a measured corresponding target value. Therefore, this study seeks to examine various
2
computational models for predicting the percutaneous absorption rate of the chemicals us-
ing machine learning techniques, mainly the Gaussian Processes algorithm. Moreover, the
prediction performances are enhanced by the optimisation methods applied to the GP.
1.2 Contribution
The novel contributions of this study includes:
• This study provides a review that compares the performance of linear and non lin-
ear regression methods to predict the permeability of the compounds. It illustrates
that the Gaussian Process regression method can be a thorough replacement for
QSAR/QSPR methods used in the pharmaceutical science domain. Moreover, local
non-linear models can be built up by using clustering algorithms. This study provides
a detailed investigation on the effect of size of the data, feature ranges and experi-
mental conditions. It shows that temperature and diffusion cell type affect the model
performance and they should be considered when the models are trained.
• One of the main objectives of this research is to deal with small size datasets. As
they may increase the over-fitting and under-fitting problem, finding the solutions to
cope with small datasets is highly investigated. Hyper-prior techniques for hyper-
parameter optimisation in the GP, shows good improvement in the prediction per-
formance compared to the previous models.
• As the datasets contain both numerical and categorical data, a new kernel function is
implemented to be used in the GP. This kernel uses a mix of numerical and categorical
data and shows to result in small increase in the model performance. However, in this
study only 3 categorical (nominal) data are used and the performance may improve
more if more categorical descriptors are recognised and employed.
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1.3 Publications on this thesis
1.3.1 Journal paper
• The application of machine learning to the modelling of percutaneous absorp-
tion: an overview and guide by P Ashrafi, GP Moss, SC Wilkinson, N Davey, Y
Sun - SAR and QSAR in Environmental Research, 2015 (see Appendix C.1)
1.3.2 Conference paper
• The importance of hyperparameters selection within small datasets by P Ashrafi,
Y Sun, N Davey, R Adams, MB Brown, Maria Prapopoulou, Gary Moss- Interna-
tional Joint conference on Neural Networks (IJCNN), 2015 (see Appendix C.2)
1.3.3 Conference poster abstracts
• The effect of quality and consistency of data on the development of predictive
machine learning models for percutaneous absorption by P. Ashrafi, Y Sun , N
Davey, RG Adams, MB Brown, SC Wilkinson, GP Moss - presented in 14th confer-
ence on Perspectives in Percutaneous Penetration. France, April 2014 (see Appendix
C.3.1)
• Investigation of inconsistency in a skin permeability dataset using the Monte
Carlo method by P. Ashrafi, Y Sun , N Davey, RG Adams, SC Wilkinson, GP
Moss - presented in the 15th conference on Perspectives in Percutaneous Penetration.
France, April 2016 (see Appendix C.3.2)
• The effect of experimental conditions on the development of quantitative models
of skin permeation by P. Ashrafi, Y Sun , N Davey, RG Adams, SC Wilkinson, GP
Moss - presented in the 15th conference on Perspectives in Percutaneous Penetration.
France, April 2016 (see Appendix C.3.3)
• Assessment of chemical enhancers of transdermal drug delivery by support vec-
tor regression By A Shah, P Ashrafi, Y Sun, RG Adams, N Davey, SC Wilkinson,
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GP Moss - presented in the 15th conference on Perspectives in Percutaneous Pene-
tration. France, April 2016 (see Appendix C.3.4)
1.4 Terminology abbreviations
The words and expressions used frequently in the skin data studies and in this thesis are
shown as follows:
Terminology Abbreviation
Quantitative Structure-Activity Relationships QSAR
Quantitative Structure− Property Relationships QSPR
The computational methods have been used in this study include:
Terminology Abbreviation
machine learning ML
negative log likelihood NLL
correlation coefficient CorrCoef
standardised log loss SLL
mean standardised log loss MSLL
improvement over naïve ION
mean squared error MSE
principal component analysis PCA
Gaussian Processes GP
Support Vector Machines/Regression SVM/SVR
conjugate gradient CG
evolutionary algorithms EA
Single layer network SLN
k-nearest neighbour KNN
growing neural gas GNG
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1.5 The structure of this thesis
Chapter 2 reviews the literature about the skin layers, permeability routes and traditional
methods have been used to estimate the permeability of the compounds through human and
animal skins.
Chapter 3 shows the datasets have been used for the purpose of this study along with
their experimental and feature details. All the machine learning and computational meth-
ods employed in this study are discussed in Chapter 4. These methods include GP defin-
ition and application along with its various covariance functions and the ways in which
the hyper-parameters are optimised. In addition, it discusses the other regression methods
such as SVR, SLN and KNN. Finally, the GNG clustering method is illustrated and the
chapter finishes by all the performance measurement methods that are used for evaluation
and comparison of the experiments results.
Chapter 5 shows the methods have been used to display the PCA plots. These plots are
useful to visualise the numerical and categorical features of the data and see their relation-
ships. The main experiments on the datasets using GP with various number of numerical,
nominal data descriptors and covariance functions are discussed in Chapter 6. In this
chapter the performance of the other regression methods are compared with the GP. Addi-
tionally, GNG clustering technique is applied to the all human data and the performance of
the data in the new clusters are compared to the original datasets. At the end of this Chapter
a solution to data inconsistency issue is also revealed.
Chapter 7, various hyper-parameter optimisation methods (in GP) are applied to the
11 datasets including both human and animal sets. Additionally, the features ranges, their
size and the effect of these two factors on the model performance are also examined.
Chapter 8, reviews all the results and findings of this thesis in summary. Furthermore,
in this chapter the contribution that is made by this thesis and future work are discussed
with details.
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Chapter 2
Skin Permeability and the Traditional
QSAR/QSPR Approaches
This chapter will review the physiology and structure of the skin, including the different
layers of the skin, the physicochemical properties required of a chemical for successful
permeation of the skin, and the conditions (both in vitro experimental and in vivo environ-
mental) which may affect the absorption rate of the chemical compounds through the skin.
In addition, this chapter will discuss the historical QSAR approaches used to model the
percutaneous penetration of the skin.
2.1 Introduction
The analysis of percutaneous (across the skin) absorption of exogenous (external) chem-
icals, in fields as diverse as pharmaceuticals, cosmetics, pesticides and the bulk handling
of industrial chemicals, has become increasingly important over the last 20-25 years. It
started from Flynn (1990), El Tayar et al. (1991) and Potts and Guy (1992), although in
a pharmaceutical / cosmetic / toxicological sense this work started by Moss and Cronin
(2002). Quantitative Structure-Activity Relationships (QSARs) or Quantitative Structure−
Property Relationships (QSPR) are widely used to relate the physicochemical properties
of a penetrant to its skin permeation (Cronin and Schultz (2003)). The QSAR models
in skin and other biological or environmental systems are popular because they can both
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yield predictions for new chemicals and describe the mechanism of action (in this case,
the mechanism of skin permeability, which is based on the important physical properties
of a molecule which influence the permeability process). So, any such model has to offer
both these advantages if it is to be used by physical and biological scientists with little or
no experience in model development or use. That is why the improved quality of machine
learning methods, which don’t have an equation, is so important and why the Feature Se-
lection is also important as it can help define issues of mechanistic relevance. In most of
QSAR/ QSPR models, multiple linear regression is the method used in most publication.
However, visualising the data in a large number of cases shows non-linear relationships
between the data and the target to be predicted. In addition, the current approaches are
limited by the nature of the models chosen and the nature of the dataset. The important
point to be noted is that the collection of reliable data is difficult due to the reason that the
skin can be quite variable, affected by the site where it has come from and the individual
from whom it is taken. Therefore, the accuracy of the model is related to the variability of
the data and variability of data depends on the biological variation, variation in methods
used and in the quality of the work carried out (Chilcott et al. (2005)). It is important to
emphasise that variability can not be entirely removed from a biological system, so one
should consider this case to generate good models.
There are a wide range of experimental protocols for assessing the skin permeability. In
order to measure the percutaneous absorption and being able to find relationship between
methods, we should consider assessing the relative permeability in the same circumstances
such as the same sites of the skin and the temperature in area at which the studies are per-
formed. If the experiments performed properly, there should not be any effect on the results.
In addition to the biological variation, any change in the conditions (buffers, solvents, etc.),
will change the results significantly and produce different outcomes. Knowledge of this
will have to be considered in the models. From this, one can see that while there are a
small number of protocols (flow-though and static cells) but there are a large number of
ways of changing experiments (temperature, etc) and it may also affect the results remark-
ably.
It is mentioned previously, and this is important to emphasises that measuring the per-
meability coefficient of a single chemical can take around three days of preparatory and
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sampling work and entail some 6 to 24 repeated experiments (usually a minimum of six
repeats of the same study but, depending on the purpose of the study- research, regulatory
product submission, up to twenty-four repeats may be required and so on). Therefore, the
cost of experimentally generating only one estimation is as much as £25,000 - £30,000.
Hence the expansion of research in model development is needed.
2.2 Skin histological layers
The largest organ of our body is skin which covers any area of about two square metres.
Skin protects the body organs from external harmful molecules. It also controls the tem-
perature of the body with the sweating system. The pain can be transferred from the skin
to the nerves via a range of specialist receptors, such as nociceptors. Skin consist of three
main layers called the epidermis, the dermis and the subcutis layers from outside to inside.
A diagram (Figure 2.1) of the human skin from skin care forum shows these layers with
more details (© KLEINHANS RED, Source: www.skin-care-forum.basf.com).
The first, outermost, layer is the epidermis. It consists of 5 layers: the stratum ba-
sale, the stratum spinosum (prickle cell layer), the stratum granulosum (granular layer),
the stratum lucidum and the stratum corneum (horny layer) from inside to outside. The
thickness of the epidermis varies in different types of skin. it may be from only 0.05 mm
thick on the eyelids, to 1.5 mm thick on the palms and the soles of the feet. The stratum
corneum is the main barrier of the skin for the external chemicals to enter the skin. It
includes dehydrated and keratinised multilayer (bricks in vertical columns) in a lipid en-
vironment. Stratum corneum consists of two amorphous lipophilic (ability of a compound
to dissolve in fats) and the hydrophilic (solubility of the chemical in water) layers. The
lipophilic layer which is the main part of this layer, contains keratin and skin fat. Hydro-
philic layer in contrast, include mostly corneocytes and natural moisturizing agents. The
stratum corneum is a dense tissue, swelling more than many times its own thickness, in the
water. The area between the cells is filled with cohesive laminae. Each cell is contained by
a proteinaceous ingredient envelope.
The next layer is the dermis and is located exactly underneath of the epidermis layer.
Its thickness is variable. Based on the site of the body it is located, it could vary from 0.1
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to 0.4 cm which is 10-20 times thicker than the epidermis layer. This layer’s responsibility
is to provide flexibility and tensile strength for the skin. It includes collagen embedded
in a gel texture area mix of mucopolysaccharides. It provides protection for internal body
organs from injury and infection. In addition, the epidermal layer obtains the necessary
nutrition from this layer.
Finally, the last inner layer, the subcutaneous layer, is located beneath the epidermis
and dermis. Its fatty tissue has the responsibility to protect the skin from heat and shock.
This layer carries the nutrition to the upper layers through the blood vessels and it also can
transmit the pain through the nerves located in this layer. The thickness of the subcutaneous
layer can be different in various body locations. The lower layer of this layer covers the
muscles and the periosteum of the bones.
Apart from the skin layers, many appendages such as hair follicles, sebaceous glands,
eccrine and apocrine sweat glands are linked to the skin. Normally, human skin consists
of 40–70 hair follicles and 200– 250 sweat ducts per cm2 of skin. The sebaceous glands
are responsible for lubricating the skin surface and maintain the pH at around 5. Eccrine
or sweat glands play an important role in heat exchange and temperature maintenance and
they also respond to emotional stress.
As mentioned earlier, the chemicals applied to the surface of the skin should pass the
stratum corneum which is the main barrier of the skin. It is likely that lipophilic chemicals
tend to remain in the stratum corneum; however, the skin appendages can provide a path-
way that molecules can enter the lower layers of the skin without having to pass through
the stratum corneum barrier of the skin. There are a number of pathways for passing the
chemicals through the skin which are so called polar and lipophilic pathways (Williams
(2003); Moss and Cronin (2002)). The reservoir effect is where the drug diffuses into the
stratum corneum. This is the slowest process in skin absorption, called the rate-limiting
step. So, when chemicals pass into the skin the rate of passage across the stratum corneum
is normally slow and the concentration builds up over time. This is the reservoir effect. It
also means that, when a product is removed from the skin surface treatment / delivery is not
at an end as there will still be drug in the stratum corneum which can be delivered deeper
into the skin (Moss et al. (2015)).
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2.2.1 Skin layers thickness
In general, the stratum corneum provides a most important barrier to the passage of applied
chemical through the skin. So, it is important to consider the thickness of this layer of the
skin at which the experiments have been performed and also to consider which layers of
the skin are excised and used in in vitro experiments. The stratum corneum’ s thickness
varies from 10 and 40 mm on different body sites. Figure 2.1 shows the details of each layer
of the human skin.
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Figure 2.1: Skin layers from skin care forum (© KLEINHANS RED, Source: www.skin-
care-forum.basf.com)
2.3 Physicochemical properties of the skin
In this section we define some of the terms related to skin and also the physicochemical
properties of the skin we will see later in the QSAR/QSPR equations.
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• The first term is permeation: it is defined by the amount of movement of drug
through the membrane which includes partitioning of the molecules through the dif-
ferent layers of the skin.
• The next term is penetration: the amount by which the molecules enter into the
tissue which does not necessarily includes passing the molecules out of the tissue.
• Diffusion is described by movements of molecules through a domain, for example:
from a high concentration liquid to a low concentration liquid.
• The diffusion coefficient (D) of the molecule through the skin, defines how easily
the permeant traverse through the tissue. It is expressed in units of area/time(cm2/h
or cm2/s).
• Partitioning demonstrates the molecular distribution from one domain to another,
such as from a lipid aqueous domain to water.
In addition some physicochemical properties such as partition coefficient, membrane thick-
ness and lag time are defined as follows:
• Partition coefficient (P ) illustrates the distribution of the molecules between two
phases. To study the percutaneous absorption of exogenous chemicals, the partition
coefficient usually employed, is the partition coefficient between octanol and water.
Octanol simulates the stratum corneum lipids of the outer most layer of the skin
to see how the molecules may traverse between stratum corneum and water (or the
receptor in in vitro studies).
• Membrane thickness (h) shows the membrane thickness for various numerical cal-
culations of the chemicals permeation. This measurement is usually difficult due to
the thickness of the skin might be variable based on the skin hydration. In addition,
it is not clear that the barrier to permeation only exists in stratum corneum or it may
also occur in the epidermal layer of the skin. Due to the difficulty to measure the
thickness of the skin membrane, researchers have estimated more reasonable ways
through the stratum corneum than a simple assessment of the thickness. These re-
searches revealed that traverse of the chemicals through the skin may occur through
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different pathways (such as appendages) which are not simply obtained by measuring
the thickness of the skin.
• Lag time (L) is the period that lasts during the rate of permeation through the mem-
brane is increasing. It is obtained by measuring the time which the pseudo-steady
state portion of a plot of the cumulative amount traverses the skin (Williams (2003)).
2.3.1 Flux (Jmax ) and permeability coefficient ( Kp) definitions
J and Kp indicate the rate of absorption through the skin. Jmax is the maximum dose of
solute able to be delivered over a specific period of time and area that it is applied. These
measurements predict the drug absorption uptake and toxicity, both of which are related to
uptake or transport of cosmetics and other chemicals. The first law defined by Fick (1855)
is mainly used to describe the ability of a compound to pass through the unit area of the
skin and it is described by the below equation:
J = D∂C
∂x
(2.1)
where J defines the rate of transfer per unit per area of the surface, defined by mol/cm2/h)
(i.e. the flux), C is the concentration of the diffusion substance, x is the spatial co-ordinate
measures normal to the section and D is the diffusion coefficient, or diffusivity. Its dimen-
sion is area per unit time, which is defined by m2/h or cm2/s.
Fick’s second law specifies that the change of concentration during the time in a partic-
ular region is proportional to the change in the concentration gradient at the same point; it
is defined by Martin et al. (1993):
∂C
∂ t
= D
∂ 2C
∂x2
(2.2)
solving Fick’s second law is usually difficult due to its dependency to boundary conditions
for an experiment and that is why usually the first law is used. More details can be found
in Moss et al. (2015).
The dermal permeability coefficient, Kp, is defined by the equations:
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Jss = KpCv (2.3)
or
Kp =
Jss
Cv
(2.4)
where Cv illustrates the concentration of the penetrant in the vehicle when sink conditions
apply, Jss is the steady-state flux of the solute. Kp expresses the permeability coefficient
(cm/s or cm/h) which is the concentration-corrected flux and allows chemicals of different
aqueous solubilities to be compared in a single data set. Permeability coefficient is depend-
ent on the vehicle used. If the concentration (Cv) and the solubility (Sv) of the solute in
the vehicle are known, Jmax may be estimated from the experimental steady-state flux (Jss).
Jmax defines the maximum steady-state flux of the solute (Jss ) and it is obtained from dilute
solutions as follows:
Jmax =
Sv
Cv
Jss (2.5)
Kp can also be obtained by below equation:
Kp =
Km.D
h
(2.6)
where D is the average diffusion coefficient (cm2/s or m2/h), Km represents the partition,
or distribution coefficient between the stratum corneum and the vehicle and finally h is the
thickness of the skin.
From the aspect of the passage of chemicals through the skin, the stratum corneum
is essentially a lipid layer, which interfaces with an aqueous medium placed underneath
it. For penetration of lipophilic chemicals through the stratum corneum, they are trans-
ferred directly into an aqueous medium, therefore highly lipophilic compounds could not
pass from the stratum corneum and mainly remain in it. Hence, there should be a num-
ber of pathways at which compounds may penetrate through the skin—the so-called polar
and lipophilic pathways (Bronaugh and Maibach (1989)). Based on what was mentioned
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earlier, it might be inferred that some descriptors such as hydrophobicity (typically quanti-
fied by the logarithm of the octanol–water partition coefficient) may have a high influence
on the absorption rate of the skin. In addition, physicochemical properties such as mo-
lecular weight/size and possibly electronic properties such as hydrogen bonding play im-
portant roles in skin permeation. These properties obtained from graph theory and counts
of paths and connections between individual atoms. Due to the difficulty in interpreting
the topological indices, the use of other descriptors should be considered in a QSAR. To
predict the permeability of a chemical, QSAR models should consider the physicochemical
and/or structural properties of the compounds (Williams (2003); Moss et al. (2002)). These
descriptors should be appropriate for that particular passive diffusion process. A consid-
erable point to be noticed is that it is not only important to have a precise prediction of
the chemicals permeation through the skin, but also for designing the drugs and for their
effective passage through the skin, it is important to also take the physical mechanism into
account. That is to examine which of the chemical features have the most important role
in chemicals permeability and consider that when it comes to formulating the drugs (Lam
et al. (2010)).
In the next sections, the use of descriptors in QSAR models are explained in more
details.
2.4 The importance of experimental conditions
One important consideration is to understand the specific experimental conditions under
which an experiment has been conducted, as even small changes could potentially alter the
outcome of the experiment substantially. These conditions include temperature of the skin/
environment, the device used to apply the chemical to the skin (the formulation, or the
vehicle), the cell type used in the experiment and the body site that chemical applied to the
skin surface, in vitro or in vivo experiments. It is also interesting to know that repeating the
same experiment with the same chemical applied to the same skin, may result in different
measured permeability values due to the difficulty in keeping the experimental conditions
constant at all times (for example temperature). A very important notion which should
be born in mind is to develop predictive models for skin penetration based on QSAR, all
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the data used for this purpose, should be measured using the same protocol, with the skin
from the same animal (source), the same site and under the same circumstances such as
the same workers and laboratory. Otherwise, the error of the model will be increased and
the validity of the model generated based on this data will be decreased. Therefore, it is
likely that QSAR models described in this research are subject to experimental errors if the
mentioned laws have not been complied with.
2.4.1 Temperature
The effect of changing temperature on the physiological structure and activity of the skin is
highly complex, affecting both local blood flow and metabolism. However, in the vast ma-
jority of published studies of skin absorption it has been demonstrated that the absorption
rate will increase as the temperature increases and that it decreases in lower temperatures
by up to one order of magnitude (Woolfson and McCafferty (1993)).
2.4.2 Static and flow-through diffusion cells
A diffusion cell is a cell contains receiver compartment and it is defined as one of the
experimental conditions. There are two diffusion cell types:
• Static diffusion cell: an application containing the chemical is applied over the up-
per excised human/ animal surface of the membrane and the permeant samples are
collected from the beneath in the stirred compartment periodically like every 2 or 4
hours.
• Flow-Through diffusion cell: the chemical molecules passing through the mem-
brane are carried away by the solvent flowing underneath of the membrane and the
samples are also collected periodically.
There are devices to automate the measurement of the chemicals fractions in the solvent to
calculate the efflux solvent. In this research, we investigate the effect of using the static or
flow-through cells on the prediction performances.
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2.4.3 Regional variation (body site)
It is important to know that rate of absorption in the same individual could vary widely
across different skin sites. Studies by Scheuplein (1967) and Elias et al. (1981) imply that
skin permeability can be ranked in different body sites by the below descending ranking:
posterior auricular skin (behind ear) > scrotum > head and neck > abdomen > forearm
>thigh > instep > heel > plantar
2.5 Risk assessments in human/animal data
It is difficult to assess the skin permeability of the chemicals using only in vivo experi-
ments, especially when applying new compounds to the skin. General pharmaceutical/ risk
assessment in vitro models is that it is difficult to obtain biological tissue. In addition, us-
ing specific cells from species is laborious. Another important point to be considered is
that, testing on live animals and human volunteers need lots of risk assessments. Usually
human skin from various sources, such as cosmetic surgery and amputations are employed
in vitro studies of the skin permeability. Due to the fact that obtaining human skin data is
difficult, some other animal’s skin, particularly pigs, were found to be most comparable to
permeation into and across human skin. Rodent skin, by contrast, has been shown to poorly
mimic human skin despite its widespread use in toxicology studies. In this research, we
investigate the similarity of using the animal skin data compared to the human skin data to
see whether they have the same mechanism in terms of permeability. There is also a debate
on reducing animal testing which depends on whether the models show similar or different
mechanistic information, to support or refute the use of animals in such experiments, as an-
imal testing has increased in recent years within the EU. The following section represents
more details about the human and animal skin variation.
2.5.1 Human and animal skin variation
The study by Moss et al. (2011) examines pig, rat, mouse, human and artificial skin data.
It reveals that permeation across rodent (mouse and rat) and pig skin is similar. In addition,
the artificial skin can not be a good replacement for animal or human skin. It also appears
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that the nature of the data and the size affect the model quality. This suggests that, in order
to construct reliable models to predict the permeability of different mammalian membranes,
we should consider including as much as commonality as possible in the models.
2.6 QSAR/QSPR models
Over the last 30 years extensive research has been carried out on finding the relation
between the skin permeability of the compounds and the physicochemical properties of
their molecules. This led to the prior studies of quantitative structure predictive models
(QSPRs) which have noted the importance of employing such properties to predict the ab-
sorption rate of the chemicals through the skin. In these studies, skin permeability could
be defined as either flux or permeability coefficients. To date, various methods have been
developed and introduced to measure QSPR values. In many of these studies, the direct lin-
ear relationship between hydrophobicity and skin permeability has been reported (Roberts
et al. (1977); Scheuplein (2011)). Although QSAR models could be derived from these
research, each model can be defined for a particular or specific chemicals. In addition to
the mentioned problem, there is a physicochemical variety in some of the descriptors. The
results also reveal co-linearity relationship between some descriptors such as molecular
weight and hydrophobicity. These findings indicate that it is not possible to discriminate
the effect of hydrophobicity from molecular size on permeability of molecules.
Table 2.1 shows a list of the most cited QSAR models for predicting percutaneous
absorption from Moss et al. (2012) paper. In this table Kp is the permeability coefficient
(as cm/s or cm/h); logKow , Ppct and logP define the octanol–water partition coefficient;
Kpsc is the permeation coefficient of the lipid fraction of the stratum corneum; Kpol is the
permeation coefficient of the protein fraction of the stratum corneum; Kaq is the permeation
coefficient of the aqueous permeation layer; MW (g/mol) is the molecular weight. The
Dalton, is also sometimes used as a unit of molecular weight (molar mass), especially in
biochemistry, with the definition 1 Dalton = 1 g/mol. MPt is the melting point (C).
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Table 2.1: Most cited QSAR models for estimating the percutaneous absorption (Moss
et al. (2012))
Name of the model and the citations* Algorithm
Potts and Guy (1992) logKp = 0.71logKow 0.0061MW  6.3
Brown and Rossi (1989) Kp = 0.1
h
P0.75oct
120+P0.75oct
i
Cleek and Bunge (1993) Kad jp =
Kp
1+(1400.Kp.
p
MW )
Cronin et al. (1999) logKp = 0.77logP–0.0103MW−2.33
Wilschut et al. (1995) Kp = 11
Kpsc+Kpol
+ 1Kaq
Barratt (1995) logKp = 0.82logPoct–0.0093MW–0.039MPt–2.36
Moss and Cronin (2002) logKp(cm/h) = 0.74logP–0.0091MW–2.39
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2.6.1 The Flynn(1990) data-set and the related QSAR analysis
In 1990 a publication by Flynn (1990) on 97 permeability coefficient for 94 compounds,
provided the largest and most significant data in skin permeability of in vitro experiments
on human skin (with the exception of in vivo studies for toluene, ethylbenzene and styrene).
The data were gathered from 15 different compilations, while they were all obtained from
in vitro human skin studies. It is therefore, likely that such data has several sources for
experimental error, due to the variability in their laboratory experiments. This variability
could also be noted more, if the human skin obtained from different sites of the body under
different experimental circumstances such as temperature. However, this publication was
a significant source of data used in next researches and had a key role in development of
QSAR models. Some of the major studies using Flynn (1990) dataset, are going to be
reviewed as follows.
To predict the skin permeability from this data-set, Flynn points out that skin permeab-
ility was highly affected by the molecular weight and also partition between aqueous and
non-aqueous layers (hydrophobicity in terms of the octanol–water partition coefficient).
Flynn stated a simple algorithm regarding the skin permeability based on molecular weight
and hydrophobicity/hydrophilicity of the chemicals which is illustrated in Table 2.2 on the
following page. To have a better visibility on the algorithm, the relationships are also plot-
ted in Figure 2.2. This algorithm indicates that the skin permeability (logKp) is directly re-
lated to size of molecule, in addition to the hydrophilic and hydrophobic properties; which
indicates very hydrophilic and hydrophobic compounds had low and high skin permeabil-
ity respectively, and additionally they are separated based on the high and low molecular
weights. In his publication, he did not provide a statistical fit assessment of this model.
The data provided by Flynn has been used and analysed by many researchers afterward.
One of the QSAR models, demonstrated by Potts and Guy (1992) using Flynn (1990)
dataset as :
logKp = 0.71 logKow 0.0061MW  6.3 (2.7)
which was for 93 observations.
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Table 2.2: Permeability coefficient (logKp) estimation based on the Flynn algorithm (Flynn
(1990) )
Compounds with lowMW Compounds with highMW
(<150 Dalton) (>150 Dalton)
logKow < 0.5 logKp = -3 logKp = -5
0.5  logKow 3.0 logKp = logKow -3.5
0.5  logKow 3.5 logKp = logKow -5.5
logKow > 3.0 logKp = -0.5
logKow > 3.5 logKp = -1.5
Figure 2.2: Permeability coefficient (logKp) relationship with MW and logKow, based on the
Flynn algorithm (Flynn (1990) )
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At the same time with Potts and Guy in 1995, Abraham et al. (1995) conducted a re-
search on the Flynn dataset. Their later research in 1997 (Abraham et al. (1997)) and 1999
(Abraham et al. (1999)) on the 46 non-electrocyte compounds notified that some com-
pounds such as steroids, have problems in their permeability coefficients. Additionally,
their work showed the importance of hydrogen bonding in QSAR models. The positive
coefficient with the parameters of molecular size, shows the correlation of the paramet-
ers with hydrophobicity (logKow). Another important model was proposed by Moss and
Cronin (2002), where logKp(cm/h) = 0.74logP–0.0091MW–2.39. We should note dif-
ferent methods have been used to calculate logP values (Moss et al. (2002)). Later in
2003 another model was introduced by Cronin and Schultz (2003), where logKp(cm/h) =
0.77logP–0.010MW–2.23 for 107 observations. In addition to the former researches, a
recent study has been done by Magnusson et al. (2004) on five datasets. In this study,
epidermal permeability coefficients (Kp) are optimally correlated to solute octanol–water
partition coefficient (Kow) and molecular weight (MW ) was found to be the dominant de-
terminant of Jmax for on the literature data set: logJmax =  3.90  0.0190MW (n=87,
r2 =0.847, p<0.001). Adding the other physicochemical properties by forward stepwise
regression could improve the predictions by a few amount. This equation was also valid-
ated with the other four datasets and the complete dataset. The datasets include full- and
split-thickness skin data and their study revealed that the dermal resistance had only a small
effect on the overall Jmax. These datasets and the results are explained in greater detail in
Chapters 3 and 7.
In this thesis, it is shown that trainable non-linear machine learning models outperform
the traditional QSAR/QSPR prediction models for skin permeability.
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Chapter 3
The Descriptions of Datasets
To do the experiments of this study, 16 datasets are used. The datasets include the physi-
cochemical properties of the chemical compounds. Depending on the data different target
is defined in each dataset. The datasets are collated from various sources and they are from
the in vivo and in vitro experiments performed in the labs using the chemicals applied to
the human and the the non-human (animals) skins.
I divide the datasets into four major groups. These four groups include human skin
datasets, animal skin datasets (Mouse, rat and pig), magnusson datasets (Magnusson et al.
(2004)) and the enhanced ratio dataset (Pugh et al. (2005)). The human datasets are collated
by Prapopoulou (2012) as one set, which has been divided by her into 16 sub sets and we
have used 6 of these subsets in this study. Animal datasets are also gathered by Prapopoulou
(2012).
The aim of this chapter is therefore to explain the nature of the data sets, including the
sources of their data, the descriptors used to characterise the members of the data set and
to discuss the rationale for subdividing the dataset into representative subsets.
3.1 Terminology
All the physicochemical properties of chemicals in the datasets along with their units are
illustrated in the following list:
• Molecular weigh(MW; g/mol)
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• Molecular refractivity(MR; J mol 1 K 1 )
• Melting point (MPt; C)
• Hydrophobicity (P or Kow ; shown with log values, no units)
• Solubility parameter (SP; (cal/cm3)1/2))
• Counts of the hydrogen bond donors (HD; no units) and acceptors (HA; no units)
• Chain lengths of carbon atoms (CC; no units)
• H-bonding atoms (HB, no units)
• Solubility(S; shown with log values, unit mol/L)
In addition, the common pharmaceutical expressions/definitions used in this chapter are as
follows:
• Stratum corneum: The outermost layer and the main barrier of the skin.
• Jmax/flux: The maximum dose of solute able to be delivered over a specific period of
time and area that it is applied (mol cm 2 min 1 or µg cm 2 h 1).
• Kp: The permeability coefficient (cm/s or cm/h) which is the concentration-corrected
flux(cm/s or cm/h)
• ER: The enhancement ratio of enhancers.
3.2 Human skin datasets
The datasets used in this section are collated from various sources. They are in vitro human
skin permeability studies whose core is the Flynn (1990) data set as modified by Moss and
Cronin (2002) and added new chemicals by Prapopoulou (2012). There are six datasets in
this category which range in size from n=9 to n=86. The number of data points in each
dataset is obtained after refining the data by removing the missing data and repetitions. In
some of the datasets, there are chemicals with variable target values (data inconsistency).
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The variability in the data depends on the biological variation and variation in methods
used and in the quality of the work carried out (Chilcott et al. (2005)). Therefore, it results
in needing multiple repeats of an experiment. It should be noted that this variability can not
be entirely removed from a biological system. In order to deal with this issue in compu-
tational methods, the mean of target values are used for the same chemicals with different
permeability values (inconsistent data). In Chapter 6, section 6.6 the Monte Carlo method
is employed as another technique to solve the data variability problem.
Therefore the data refinement can be summarised in the below steps:
1. If a chemical has any missing value in the vector of its features, that chemical is
deleted from the data.
2. The chemicals that have the same molecular features and target values are omitted.
3. For the same chemicals (with same molecular features) and different target values,
the mean of those target values are used and assigned to the chemical and the repe-
titions are removed. So, at the end each chemical has only one target value assigned
to it.
In addition, in gathering all the human data, a complete human dataset with 145 chemic-
als (after data refinement) is obtained which is used in the experiments in the following
chapters. Table 3.1 shows the original and refined number of data points in each dataset.
There is also a degree of overlap between the datasets. For instance, dataset E includes
the majority of chemicals in datasets A and B. Similarly, dataset F includes most chemicals
in dataset C. All the common data among the original datasets are shown in Table 3.2. The
reason for this is that the datasets are divided based on their experimental conditions and
they may share some experimental features. This can be useful to see the same chemical
prediction performance in different datasets. It can be especially used in pharmaceutical
filed to examine which chemicals can be considered together to provide a model that can
be used for the prediction purpose.
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Table 3.1: Number of data-points in human datasets
Datasets sizes Human A Human B Human C Human D Human E Human F Complete Human
# Original datasets 11 42 38 99 92 148 642
# After refining datasets 9 25 21 57 51 86 145
Table 3.2: Summary of the common data among the subsets
Similarities Human A Human B Human C Human D Human E Human F
Human A 11 9 0 3 10 0
Human B 9 42 0 20 41 0
Human C 0 0 38 32 0 36
Human D 3 20 32 99 32 59
Human E 10 41 0 32 92 0
Human F 0 0 36 59 0 148
3.2.1 Chemical features
There are seven measured molecular physicochemical properties for each member of the
dataset. They are molecular weight (MW) which ranges from 18.02 to 454.45 g/mol, mo-
lecular refractivity (MR; 0 to 116.22 J mol 1 K 1 ), melting point (MPt; -142 to 866C) ,
P (hydrophobicity; -4.47 to 8.39, log values, no units), solubility parameter (SP; 7.51 to
32.83 (cal/cm3)1/2), counts of the hydrogen bond donors (HD; 0 to 6, no units) and ac-
ceptors (HA; 0 to 10, no units) on each molecule. The absorption rate is measured by the
permeability coefficient, Kp (as either cm/h or cm/s) and adjusted to cm/h in these studies;
values range from -6.32 to 0.34 (log values). Usually the log of P is reported because the
values of P have a wide range between 10 7 to 107. For the same reason, the log is nor-
mally reported for percutaneous absorption Kp (Williams (2003)). It is important to bear in
mind that there are a number of missing or zero values assigned to MR and MPt features,
which might be problematic.
It should be noted that these values are not the same scale. For example MW of 1 to
10 is not the same as MR or log P 1 to 10. Therefore, before performing the experiments,
these values are normalised as Z-score. In this method, the average values of the features
(vector of average values) are first subtracted from the data and the results then are divided
by the d-dimensional standard deviation of the features.
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3.2.2 Experimental condition features
The experimental conditions for each dataset are also various . For example in some cases
the temperature at which absorption measured was skin temperature but for some of them
the temperature was set to a specific amount. The experimental conditions include temper-
ature (numerical feature) and diffusion cell types (explained in Chapter 6), the body site
and the skin layer at which the chemical is applied are nominal features. These features are
important to be considered as they can have a large effect on the permeability of the chem-
ical through the skin. As an example, one obtains different permeability coefficient values
when the chemical is applied to the skin of upper arm and forearm of the same person.
The skin thickness are 0.2-0.5 mm (dermatome) for dataset A and can be varied from
full thickness, dermatome (with any length), epidermal and stratum corneum for datasets
B-F. Sites are abdominal for dataset A and all types for datasets B-F. The cell type in which
the chemical applies to the skin is flow-through for datasets A, B and E, it is static in
datasets C and F and mix of both static and flow-through cells for dataset D. The nominal
features that are used for further experiments in Chapter 6 are the skin thickness, body site
and cell type.
The temperature is constant (37ºC) in human sets A to D, while it varies in the human
E from 31º to 37ºC, and in the human F dataset from 22ºC to 45ºC. The temperatures
32ºC at the surface of the skin are considered as 37ºC (human sets A to D). The other
experimental conditions are the ‘time’ which is the duration that the experiment has been
completed, vehicle and receptor fluid. For more information, the experimental features
of the datasets are summarised in Table 3.3. The datasets, their chemical features and
experimental conditions are reported in Appendix B, section B.1.
3.2.3 Human sets numerical features analysis
To have a better visualisation on the features and their ranges in each dataset, the six data-
sets with the same features in addition to their logKp ranges are plotted in box-plot separ-
ately in Figure 3.1. From this figure, the differences among the features and permeability
ranges of the 6 datasets can be seen and the features’ statistics can be used later for the
purpose of data and performance analysis. The figure shows that, human datasets D and F
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Table 3.3: Summary of the experimental conditions for the human datasets
Conditions/Datasets Human A Human B Human C Human D Human E Human F
Skin thickness dermatome 0.2-0.5 mm **All types **All types **All types **All types **All types
Site Abdominal Cell All body sites All body sites All body sites All body sites All body sites
Cell type Flow-through Flow-through Static Flow-through/Static Flow-through Static
Temperature 37ºC 37ºC 37ºC 37ºC from 31º to 37ºC from 22º to 45ºC
Time 24 – 72 h 24 – 72 h 24 – 72 h Not specified Not specified Not specified
Vehicle *Specific vehicles *Specific vehicles *Specific vehicles Any Any Any
Receptor fluid Normal saline Normal saline Normal saline Any Any Any
*Specific vehicles: Water, physiological buffer, propylene glycol, ethanol, methanol
** All types: Full thickness, dermatome, epidermal, stratum corneum
seem to cover the same range of chemical features but not temperature ( which is constant,
37ºC in dataset D) and dataset F covers a slightly larger target range than dataset D. Dataset
A seems to cover a smaller range on MW, MPt, MR, SP, HA and target values compared to
the other datasets which is probably due to the small size of this dataset.
3.3 Animal skin dataset and chemical features
The animal datasets used for this research are mouse, rat and pig datasets as they are com-
monly used as reasonable replacements for human data. However, thickness of the stratum
corneum, the number of appendages per unit area and the amount of lipids in the skin of
human are different from many of animals (Moss et al. (2011)). However, the experiments
since 1992 on animal skin are usually validated with human skin data and in this study it is
also investigated (see Chapter 2, section 2.5).
There are five measured molecular physicochemical properties in each dataset. They
includeMW which ranges from 18.02 to 959.17, SP ( 8.14 to 32.83), logP ( -4.27 to 8.10),
HA ( 0 to 11) and HD (0 to 8) and the permeability coefficient, Kp(cm/h) ranging from
-6.29 to 0.10 (log values). As there were a lot of missing values for MR and MPt, they
have not been used for the experiments. The datasets are collated from the same sources as
the human datasets (Flynn (1990), Moss and Cronin (2002) and Prapopoulou (2012)). The
sizes of these datasets after refining and removing the repetitions can be found in Table 3.4.
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Figure 3.1: Ranges of features and targets in human datasets
Table 3.4: Number of data-points in animal datasets
Datasets sizes Mouse Rat Pig
# After refining datasets 46 26 14
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Table 3.5: Summary of the experimental conditions for the animal datasets
Conditions/Datasets Mouse Rat Pig
Skin thickness Full thickness **All types Full thickness and epidermal
Site All body sites All body sites Outer ear
Cell type Flow-through/Static Flow-through/Static Flow-through/Static
Temperature 25ºC and 37ºC 30ºC and 37ºC from 30ºC to 37ºC
Time Not specific Not specific 4, 24, 48h
Vehicle Any Any *Specific vehicles
Receptor fluid Mainly Saline Any phosphate buffered saline PH 7.4
*Specific vehicles: Water, physiological buffer, propylene glycol, ethanol, aqueous saturated solution, isotonic phosphate buffered saline
(pH7.4) with ethanol, propylene glycol, Azone
** All types: Full thickness, dermatome, epidermal, stratum corneum
3.3.1 Animal sets experimental conditions
Table 3.5 illustrates the experimental conditions for mouse, rat and pig datasets. The
mouse, rat and pig datasets features and full details can be found in Appendix B, Tables
B.2.1.2, B.2.2.2 and B.2.3.2, respectively.
3.3.2 Animal sets numerical features analysis
Figure 3.2 shows the features’ ranges and the permeability coefficient ranges related to
each compound. It can be seen in the plots that mouse dataset covers a larger range in all
features. Although pig dataset has the smallest number of chemical compounds, it covers
the largest range of permeability coefficient values (logKp).
3.4 Magnusson datasets
Datasets in this group are obtained from Magnusson et al. (2004). Authors either acquired
Jmax values from aqueous solution across human skin or estimated them from experimental
data and correlated them with solute physicochemical properties. Jmax (mol per cm2 per
h) is the maximum dose of solute which can be delivered over a given period of time and
within a defined area from a given vehicle. The database consist of five separate sets: (1)
Mag-set A, include a training set of 87 records (85 in our dataset after refining); (2) Mag-set
B, full and split-thickness skin (from 0.01 to 2 mm) set of 56 records (50 after refining); (3)
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Figure 3.2: Ranges of features and targets in animal datasets
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Mag-set C, including a pure liquid vehicle set of 34 records (27 after refining); (4) Mag-set
D, including an ionised solutes set of 54 records (45 records after refining); (5) Mag-set E,
PG vehicle set of 36 records (Kasting et al, 1987). Appendix B, section B.4 shows datasets
records (from Table S1 in Magnusson et al. (2004)).
3.4.1 Magnusson datasets features analysis
The datasets used for this research are obtained under experimental temperature ran-
ging from 22ºC to 39ºC. Ranges of molecular properties are: MW from 18 to 764.90,
logKow/logP from -5.60 to 8.70, Mpt from 147 to 573, HA from 0 to 13 and HD from 0 to
8. The other experimental conditions are not specified. All data features, their ranges along
with the logJmax values are demonstrated in Figure 3.3. The plots show that in general, sets
A and B cover larger ranges of numerical features and log Jmax values.
3.5 The enhanced ratio (ER) dataset
Various methods have been used to enhance percutaneous absorption. To do so, the enhan-
cers can be mixed with the chemical formulation. One way is to to add the enhancers such
as ethanol or propylene glycol to the formulation vehicle. The enhancement ratio (ER)
dataset is obtained from Pugh et al. (2005). It includes 73 enhancers of hydrocortisone per-
meation from propylene glycol across hairless mouse skin (we used 71 data records after
removing the repetitions and averaging the target for the same compounds). The molecu-
lar properties are chain lengths (CC) from 0 to 16 carbon atoms, H-bonding atoms (HB)
from 1 to 8, MW from 60 to 450, logP (calculated) 1.7 to 9.7 and logS (calculated) 7.8
to 0.7. These predictive properties were chosen because of their ready availability. ER is
defined as hydrocortisone transferred after 24 hours relative to control. Values of ER are
ranged from 0.2 to 25.3. The logER values are usually considered, because ER have a wide
range between 10 7 to 107. Using principal components analysis (PCA) (see Chapter 5 for
PCA), Pugh’s study showed that that good enhancers could be identified by a combination
of relevant descriptors: CC, HB and molecular weight. The ER dataset can be found in
Appendix B, sectionB.3.
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Figure 3.3: Ranges of features and targets in magnusson datasets
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3.6 Analysis of the same numerical features among all the
datasets
In this section, common features in all datasets are compared together and the ranges of
features can be seen in Figure 3.4. In this figure, the empty columns above some datasets
in each plot show that feature does not exist in the dataset. It can be seen that in general,
the range of each feature varies among datasets. However, the mean values over all datasets
are similar, except for MPt, where mean values of human sets are lower than those in the
Magnusson sets (Animal data do not have reportedMPt). MW range is largest in the Mouse
dataset and Mag-set B, however, the mean values are almost the same overall the datasets.
The MPt ranges are larger for datasets Human C, D and F and it is the smallest in Mag
set-C. The mean values of SP is almost the same for all datasets and the ranges are larger
in Human B and Human E datasets. However, both mean and ranges of log P/log Kow vary
over all the dataset. HA and HD have the similar average values in all the datasets and their
ranges are various among the datasets.
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Figure 3.4: Comparison of ranges of features in all datasets
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Chapter 4
Machine Learning Techniques
Machine Learning (ML) is a type of artificial intelligence method (AI); ML techniques ex-
plore the data and develop algorithms that can learn from data. It enables the algorithms to
make a prediction or decision on new data. ML is generally divided into two main types:
supervised learning and unsupervised learning, and which also considers reinforcement
learning which is a blend of these two types. Supervised learning models the relation-
ship from inputs to targets (or outputs). A large number of pharmaceutical and clinical
data analyses are performed using this method. Supervised learning is subdivided into two
primary tasks: classification and regression. In classification the outputs are discrete la-
bels, whereas in regression the outputs are continuous variables. In this thesis the focus is
predominately on regression, which is prediction of a continuous quantity and is dependent
on a set of continuous and sometimes nominal (categorical) inputs, from noisy measure-
ments. In other words, regression is the process of abstracting from functional data. In a
linear case, fitting a hyperplane to the data, or in the case of non-linear regression, fitting
an appropriate function to the data. An appropriate function is the one which with enable
predictions to be made for novel data effectively.
In this Chapter, all the ML and computational/statistics methods used in this thesis are
explained with details. The Gaussian Processes regression is the major method used in
this thesis. A detailed description of GP, kernels and optimisation methods can be used for
selecting hyper-parameters are given in Sections 4.2 and 4.3. To compare the linear QSAR
model that is used in this thesis, a trainable linear regression model (a Single Layer Network
37
method) is also described in section 4.4. Sections 4.5 and 4.6 discuss two more widely
used non-linear regression methods KNN and SVM, respectively. Moreover, a clustering
algorithm, Growing Neural Gas, is shown in Section 4.7. The advantage of this algorithm is
that the user does not need to initialise the number of clusters. In addition, the Monte Carlo
method is mentioned in section 4.8 which has been used to deal with data inconsistency.
Finally, section 4.9 discusses performance measurements applied in this thesis..
It should be noted that the visualisation methods used to discover the patterns and rela-
tionships in the datasets are discussed in Chapter 5.
4.1 The Prediction Problem
To do predictions, let us consider a dataset (D) with N number of data points (x1,...,xN).
Each data point has D number of descriptors and their corresponding continuous target
values yn(n = 1, ...,N). Our assumption is that the outputs are noisily observed from an
underlying functional mapping f (x). Our aim is to find a probability distribution over like-
lihood functions from the data D . There are several methods for performing regression.
Gaussian Process is the primary method I investigate with details in this thesis. GP defines
a probability distribution over functions p(f). This can be used as a Bayesian prior for the
regression. To make predictions from data then, Bayesian inference can be used as:
p( f |D) = p(D | f )p( f )
p(D)
(4.1)
This brief overview shows how GP solves the regression problem, as it provides prob-
abilistic predictions of possible interpolating functions f (Snelson (2007)). The complete
Gaussian Process usage for regression is explained with more details in the next sections.
It is notable that all the notations used in this and the next section, are from Rasmussen
(2006a) and Rasmussen (2004).
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4.2 Gaussian Process introduction
The Gaussian process (GP) is a simple and general class of probability distributions on
functions. GP is a non-parametric regression method, which means it does not assume a
particular functional form, but allows the form of the relationship between inputs and tar-
gets to be determined entirely by the data which may include infinitive number of functions.
It is assumed that the underlying function that produces the data will remain unknown but
that the predictions are generated from a set of functions with a Gaussian distribution in
the function space. Gaussian Process (GP) is an increasingly important area in machine
learning to find a nonlinear regression such as a function estimation from the training data.
It has been successfully used in various applications such as predicting skin permeability of
the chemicals (Sun et al. (2008); Moss et al. (2009); Sun et al. (2011)), transmission spec-
troscopy by Gibson et al. (2012) and prediction of ozone concentration in the air Petelin
et al. (2013). To be able to understand the posterior Gaussian Process to achieve the pre-
dictions for the unseen test set based on the training set, knowing the expressions, below,
is necessary:
Definition 1: Likelihood functions A likelihood function is a function of the parameters
of a statistical model such as GP. If the model involves a set of parameters q (for GP, they are
all hyper-parameters), then the likelihood of q , given outcomes y, is equal to the probability
of the data given the hyper-parameters,L (q |y) = p(y|x,q).
Definition 2: Inference methods Inference methods compute the posterior and the
negative log marginal likelihood and its partial derivations with respect to the hyper-
parameters. Depend on its usage for regression or classification, we may use different
inference methods such as Exact or Expectation Propagation (EP) inference method. The
Exact method approximates the function with Gaussian likelihood and it can be only used
for Gaussian likelihood. The EP is a method by Minka and Picard (1999), which is an
iterative method that approximates each data point likelihood term by a scaled Gaussian.
Therefor, it gives an overall Gaussian approximation the non-GP likelihood function. In
this thesis the Exact inference method is employed as the Gaussian likelihood function is
also used.
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4.3 Gaussian Process for regression
A simple regression method finds the weighted average of target of two points nearest
to the new point. The actual Gaussian Process uses a Gaussian function of distance as the
weight. To give a simple example, suppose we have two values of x, for which we know the
values of the dependent variable y, as (x1,y1) = (1,2),(x2,y2) = (3,4). We want to predict
the value of y for a new value of x, shown as x⇤ . This is achieved in the GP modelling
by using a weighted average of known values of y, with the weighting determined by the
closeness of x⇤ to each value for x in the data. For example, if x⇤ = 2, it is equally close
to the original x values (1 and 3). So each is given equal weight and the prediction is the
average of y, 3. If x⇤ = 2.5, which is 3 times as close to 3 as to 1, then a weighted average
of the known values of y would be [(0.75 × 4) + (0.25 × 2)], or 3.5. It should also be
noted that using the reciprocal of the distance between points is limited as (1 / distance)
approaches zero, yielding inconsistent results. In a GP model, the actual weighting is
not exactly proportional to the separation from the known values; rather, it is a Gaussian
function of that distance. To have a more insight into the basics of the GP, and see more
examples, Ashrafi et al. (2015) publication in the international journal of SAR and QSAR
in environmental research can be found in Appendix C.
A GP is a collection of random variables f (x) which have a joint Gaussian distribu-
tion for any set of inputs. As mentioned previously, it is a method to deal with nonlinear
regression problems. If we choose a particular finite subset of these random function vari-
ables such as f= {f1,f2,...,f N}, with corresponding inputs X = {x1,x2,...,xN}, then any set of
random function variables is distributed multivariate Gaussian:
f ⇠ GP(m,k), (4.2)
where GP(m,k) illustrates that the function f is distributed as a GP with mean function
m and covariance function k. The simplest mean function is usually considered to be zero.
Therefore, targets are predicted from a joint Gaussian distribution with zero mean and
a covariance matrix. The covariance function or kernel function k (xi, x j) is the expected
correlation between values of f (x) at the two points xi, xj. In other words, the kernel defines
the nearness or similarity between data points, and allows specifying a-priori information
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from training data for solving the regression problem. The kernel methods are standard
machine learning algorithms; they use kernel functions to embed the data into a high or
infinite dimension feature space. A kernel function computes the inner product of the
embedding of two data points under a certain mapping in the feature space. The feature
space that the data is embedded to, is expected to capture and enhance the patterns and
regularities in the data. Then using standard algorithms of classification or regression the
regularities of the data are investigated in the feature space.
For every input x there is an associated random variable f (x), which is the value of the
(stochastic) function f at the location. The Gaussian Process is over functions. However, to
be able to generalise the Gaussian Process wemaymove from the Process to the distribution
using a finite vector as m and a covariance matrix as k(x,x'v) to make the Gaussian Process
feasible.
4.3.1 Covariance functions for numerical data
A variety of kernels or covariance functions can be used in a GP model. In our initial
research, the Matérn, Polynomial and Gaussian covariance functions are applied to the
data.
The Matérn covariance functions has a positive parameter, n . This function becomes
especially simple when n is half-integer: n = p+ 1/2, where p is a non-negative integer.
TheMatérn covariance function can be defined as a product of an exponential and a polyno-
mial of order p. The most interesting cases for machine learning are n = 3/2 and n = 5/2
and they are defined as (Rasmussen (2006b)):
kn=3/2(r) =
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(4.4)
where r =|x x0 | and l (length scale) is a positive hyper-parameter. l defines the distance
can be moved in input space, before the function value is changed significantly. They are
called hyper-parameters since they are not set directly from the training set and studies have
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proved they can affect the model predictions sometimes with a great amount (Snoek et al.
(2012); Bergstra et al. (2011)). Note that as GP is a non-parametric method, there are not
any ordinary parameters set from the training set. The covariance function, should be then
multiplied by signal variance, s2f (noise in the data). More information can be found in
Abramowitz and Stegun (1964).
Polynomial covariance functions are defined as :
kPoly(x,x
0
) = (s2f +x·x0)p, (4.5)
where p is a positive integer and s2f is the signal variance. Dot product covariance functions
are invariant to a rotation of the coordinates about the origin, but not transitions. A simple
example is the covariance function k(x,x0) = s2f + x · x0 which can be obtained from linear
regression by puttingN (0, 1) priors on the coefficients of xd(d= 1, ...,D). D is determined
by the number of chemical compounds’ properties. Polynomial covariance functions are
usually not positive definite for all input dimensions but their validity is restricted up to
some maximum dimension D. Therefore, we should not chose the D values larger than
data dimension. Being positive definite is necessary for covariance functions in the GP
(otherwise, calculations generate error). A symmetric matrix like covariance function, is
positive definite if all its eigenvalues are non-negative.
In addition, the Squared Exponential covariance function is defined by the equation:
kSE(x,x0) = s2f exp(
 r2
2l2
), (4.6)
where l is the length scale, r =|x x0|, and s2f is signal variance. The squared exponential
covariance function corresponds to a Bayesian linear regression model with an infinite
number of basis functions (Rasmussen (2006b)).
As we shall see later (Chapter 6), the best prediction performances are obtained using
theMatérn covariance functions. To see the shape and smoothness of theMatérn covariance
function, it is plotted by changing the ranges of r and l values. Figure 4.1 represents the
3D plot of the Matérn covariance function with n = 3/2, changing the l values in a range
from 0.1 to 10 and r values from 0.1 to 10.
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Figure 4.1: Matérn covariance function n = 3/2 and changing the r and l values
4.3.2 Covariance function for categorical data
Some of the pharmaceutical data used for the purpose of this research involve the experi-
mental conditions and nominal data, such as body site, cell type and membrane (skin layer)
in which the chemical compounds applied through the skin. To investigate the probable
effect of this information, we need to calculate a categorical covariance matrix to be com-
bined with the numerical covariance matrix (such as Matérn). Having this data, a kernel
called categorical kernel by Couto (2005) is employed. It is then added to the Matérn kernel
used to get the GP predictions for numerical data (molecular features).
4.3.2.1 Hamming Distance Kernel Function
The kernel function employed for categorical data is based on Hamming distance, which
simply defines the number of positions at which the corresponding symbols are different
between two strings of equal length. This functions embeds the categorical data into an
inner product feature space. This kernel does not rely on a generative model or a priori
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information about the nature of the data. The kernel function KH(s, t) between two cat-
egorical inputs s and t is defined as (Couto (2005)):
KH(s, t) =
n
Â
i=1
fu(s)fu(t) = Â
u2Dc
c
’
i=1
ld (ui,si)ld (ui,ti), (4.7)
where fu(s) and fu(t) are the mapping of categorical objects s and t into the feature space
which is defined by the u coordinate. l 2 (0,1), d (x,y) is 0 when x = y and 1 otherwise.
c is the number of categorical features and Dc is the number of categories in each of the
categorical features. The kernel can be calculated recursively as follows:
K0(s, t) = 1
K j(s, t) = ((l 2(|Dj| 1 d (s j, t j))+(2l  1)d (s j, t j)+1)))K j 1(s, t), 1 j  c
KH(s, t) = Kn(s, t). (4.8)
|Dj| is the number of categories in each of the categorical features of the data. Therefore,
it can be different from feature to feature in each dataset.
The normalised kernel K˜ of a kernel function K is computed as follows:
K˜(x,y) =
K(x,y)p
K(x,x)K(y,y)
(4.9)
This kernel then can be combined (weighted multiplied/added) with the numerical ker-
nel to be used for the prediction of the unseen points target values. More information about
this kernel could be found in Couto (2005).
Test for Toy data
To understand the functionality of this method, a toy data with three nominal features
is introduced. Three features are gender, nationality and native English speaker (Y/N).
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Table 4.1: Toy data with nominal features
No Gender Nationality Native English Speaker
1 Female American Yes
2 Female Australian Yes
3 Male Egyptian No
The data is defined in Table 4.1. Here the values of Dj are 2, 3 and 2 for the mentioned
dimensions, respectively. Various values of l between (0,1) can be considered. In this
example it is defined as l=0.3. To obtain the d value between the features of two objects,
we compare the features one by one and according to the explained rules it is either 0 or 1
for each feature of the two objects. As an example, the d between the features of the first
and second object is (0, 1, 0). This means they have two similar features and their second
feature is different. The initial value of K is 1 and then it is calculated recursively for all the
features of these two objects using Equation 4.8. Using this equation, the K(1,2) = 0.58
between the first and second objects. Similarly the other K values between the objects can
be obtained. The values in the main diagonal of the K matrix is 1 as it defines the similarity
of each object with itself which is 1. The final K matrix is:
K =
2664 1 0.58 0.090.58 1 0.09
0.09 0.09 1
3775
This matrix shows that the similarity between the first and second data is more than the
similarity between the first and third or the second and third data (with no similarities!).
4.3.3 Posterior Gaussian process
Themost important aim of finding the posterior is to make predictions for the test data target
values. To make a prediction y⇤ at a new input x⇤, the conditional distribution p(y⇤|y1,...,yN)
on the observed data [y1, ...,yN ] should be assessed. Since our model is a Gaussian, this
distribution is also a Gaussian and is completely determined by its mean (prediction of new
inputs) and variance (predictive variance), which can be calculated using standard linear
algebra:
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E [y⇤] = kT⇤ .(K+s2n I) 1y (4.10)
var [y⇤] = k(x⇤,x⇤) kT⇤ (K+s2n I) 1k⇤, (4.11)
where k⇤ is the covariances between the test point and training data. K denotes the cov-
ariance matrix of the training data, I denotes identity matrix with 1’s on the diagonal and
zeros elsewhere, s2n denotes the variance of an independent identically distributed Gaussian
noise which means observations are noisy, and y denotes the vector of training targets.
In Equation (4.11), k(x⇤,x⇤) is the variance of x⇤. The predictions of a GP, are based on
the weighted average of the known values of y, with the weighting given by the proximity
of x⇤ to each x in the training data. The matrix (K+s2n I) 1 is completely independent
on a new point and is a linear transformation that forces the Gaussian weights to perform
interpolation, which results in zero value for all but one of the known data points. The
transformed weights are multiplied by y values and the prediction achieved. GP regression
is also able to provide the variance of the predictions, which reports the error of the predic-
tions. If the weights are high it means that the new data point should be near to some of the
original data and our prediction is precise. Based on the Equation (4.11), if the weights are
large then the variance should be low and vice-versa (Rasmussen (2006b)).
Considering the examples in Rasmussen (2004) and to make the process much clearer,
using 20 observed data, a sample from posterior process is drawn in Figure 4.3. In this
example, the mean and covariance functions arem(x) = 0, and k(x,x0) = exp( 12(x x
0
)2).
The prior GP is explained in the Appendix A.1. Comparing this figure with Figure 4.2
(obtained from prior GP, see A.1) one can see the uncertainty decreases close to the training
data (20 observed data). It could be inferred that the posterior variance is always smaller
than the prior variance, since the data has given us some additional information.
So far, we have seen how we can update the prior using the training data to obtain
the posterior. However, in this case we should have a prior information about a dataset
to specify its mean and covariance functions. Unfortunately, in ML problems we do not
usually have this detailed prior information about the data. In order to obtain the prior
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Figure 4.2: A random functions from GP. The shaded grey area shows the 95% confidence
intervals. The dots are the values generated from Equation (A.4).
information, we should use mechanisms to choose the mean and covariance functions or in
other words, we should train the GP model. this process is explained in the next section.
4.3.4 Functions and hyper-parameters selection
As mentioned earlier, various mean functions and covariance functions such as Matérn,
Polynomial and squared exponential can be used in GP regression. The best one for the
used data can be obtained by model selection methods such as bootstrap criteria, cross-
validation criteria and Bayesian methods. After choosing the proper mean value and co-
variance function, we may choose the appropriate parameters of these functions. hyper-
parameters control the mean and covariance functions and pre-setting the hyper-parameters
is an important task. In the following example Rasmussen (2004), the assumption is that
the mean function is considered to be zero and the covariance function is squared exponen-
tial. The aim is to find the best hyper-parameters of this model. A generalisation form of
this example is as follows:
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Figure 4.3: A random function from the posterior, given 20 training data points and a noise
level of sn= log (0.1). Comparing it with Figure 4.2 shows that the uncertainty decreases
close to the observations.
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f ⇠ GP(m,k), where m(x) = 0 (4.12)
and
k(x,x
0
) = s2f exp( 
(x x0)2
2l2
)+s2n dii0
The hyper-parameters are q = {s2f , s2n , l2}. Here, l is the characteristic length-scale,
s2f is the signal variance, s2n is the noise variance; and dii is the Kronecker delta. Our aim
is to make inferences about the hyper-parameters considering the data. In order to do this,
one way is to compute the probability of the data given the hyper-parameters. Fortunately,
considering the Gaussian distribution for the data, this calculation would not be difficult:
L= log p(y|x,q) = 1
2
log |S|  1
2
(y µ)>S 1(y µ)  n
2
log(2p). (4.13)
Quantity L is called the log marginal likelihood. The best hyper-parameter values are ob-
tained by maximising the marginal likelihood. For this purpose, we should set the initial
parameters and then the best hyper-parameters suitable for the data are observed. In Equa-
tion (4.13), the first term,  12 log |S| is a complexity penalty term, which measures and
penalises the complexity of the model. The second term is a negative quadratic, and plays
the role of a data-fit measure (it is the only term that depends on the training set output
values y). The third term is a log normalisation term, which is independent of the data
(Rasmussen (2004)).
Figure 4.4 shows the predictions obtained of a model trained by maximising the mar-
ginal likelihood. The best hyper-parameters obtained are l2=0.06 , s2f =0.25 , s2n =0.01.
In this particular example, the approach worked pretty well, even before optimising the
hyper-parameters of the model (Figure 4.3), but this is not true for all the applications.
4.3.4.1 hyper-parameter optimisation
The previous example is an example of how the hyper-parameters may be chosen. In
practice, there are different ways to choose the hyper-parameters. The cross validation
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Figure 4.4: Mean and 95% posterior confidence region with parameters learned by maxim-
ising marginal likelihood, for the same data as in Figure 4.3.
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method is explained in the ‘model selection’ section in work by Ashrafi et al. (2015) (see
Appendix C). Since GP is a probabilistic based model, the optimisation can be performed
bymaximising marginal liklehood (MML) as in the previous example. In this study, various
methods are used consideringMML and they are demonstrated in the following.
• Conjugate gradient
Essentially we are trying to find the minimum of a cost function (the cost function is neg-
ative log-likelihood) and the first order method is simply to follow the maximum gradient
downwards. Usually, however, second order methods are used such as Conjugate Gradient
(CG) which is an iterative method to solve the linear equation Shewchuk (1994)):
Ax= b, (4.14)
where x is an unknown vector, b is a known vector, and An⇥n is a known, square, symmetric
(A=AT ) and positive-definite (x>A
R
> 0 for every non-zero x) matrix. The unique solution
of this equation is x⇤. We can show that the solution x⇤ is also the unique minimiser of the
following quadratic function:
f (x) = 1
2
x>Ax b>x, (4.15)
A is a positive definite matrix, therefore, f (x) has a paraboloid bowl shape. At the bottom
of the paraboloid bowl the gradient is zero. To minimise the f (x), we can take the derivative
(gradient) of f (x), f 0(x), as the following:
f 0(x) = Ax b, (4.16)
A is positive-definite and symmetric. By setting the gradient of Equation 4.16 to zero, one
can obtain a mathematical expression of x in Equation (4.14).
in practice, we start at an initial random point x0 and slide down to the bottom of
the paraboloid. By taking some steps which at most is equal to n (the size of the mat-
rix A) we are getting closer to the solution until we are satisfied that the error is small
enough. The direction of a step in each iteration, should be chosen so that f decreases most
quickly, which is the direction opposite f 0(x). According to Equation (4.16), this direction
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is   f 0(x) = b Ax. For each iteration i, the residual ri = b Axi indicates how far we are
from the correct value of b or on the other hand, the error transformed by A into the same
space as b. More details on Conjugate definition can be seen in Appendix A.2.
• Grid search
To do this requires a grid search over all the the parameters (hyper-parameters in this
study) within specific steps (ideally equal sized steps). To keep this computationally tract-
able, one can search through limited number of steps. For example if 20 equal steps are
chosen in each parameter range and there are three parameters in the model, the total 8000
(20⇥20⇥20) different parameters combination sets are obtained . The best parameters are
from a parameters-set that resulted in the best prediction performance for the validation set.
The same parameters are then used to predict the test set targets.
• Random search
The idea of the random search is taken from the method defined in work by Bergstra and
Bengio (2012). They proved using random search over the same domain as used in the grid
search can find models that are as good or better as grid search within a small fraction of the
computation time. Granting random search the same computational budget, random search
finds better models by effectively searching a larger but less promising configuration space.
• Hyper-prior
Hierarchical model specification is commonly used to gain a joint regularisation for indi-
vidual models. The first level are parameters, which could be the parameters in linear or
non-linear models. At the second level hyper-parameters q , control the distribution of the
parameters of the first level. Finally, at the top level we may have a (discrete) set of possible
model structures which are called hyper-priors (H ) and are the prior distributions of the
hyper-parameters. The prior over models H is often taken to be flat, so that we do not
favour one model over another (Rasmussen (2006b)). The prior models that we used in
this research are Gaussian, Laplacian and non-linear Smoothbox prior methods. Univari-
ate smoothed box prior distributions defined with quadratic decay in the log domain and
it supports the whole real axis infinitely. It is built by cutting a Gaussian into two parts
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and inserting a uniform distribution from a (lower bound parameter) to b (upper bound
parameter), the parameters of the Smoothbox prior. There is also a parameter h , which
balances the probability mass between the constituents so that h /(h + 1) is used for the
box and 1/(h + 1) for the Gaussian sides. In this research, a and b are considered as the
minimum and maximum values of the hyper-parameters ranges. Larger values of h make
the distribution more box-like. Prior Smooth Box distribution is given as :
H (q) = 1
w · ( 1h+1)
·
8>><>>:
N(q | a,s2), t  a
1 t 2 [a,b]
N(q | b,s2) b t
(4.17)
w=| b a |, s= w
h
p
2p
, (4.18)
where a is the lower bound parameter, b is the upper bound parameter, h>0 is the slope
parameter, q(1⇤N) contains query hyper-parameters for prior evaluation, and t 2 q is first
initialised and optimised in each step. For sample a, b and h values, the hyperprior
smooth-box function is plotted, and shown in Figure 4.5 . To generate this plot a=2, b=10,
h(slope)=2, and t is considered in a range between 0.0001 and 12.
More information about the priors can be found in Rasmussen and Nickisch (2015).
The mean and variance parameters of the Gaussian and Laplacian priors should be
initialised based on the data. These values can be obtained using cross validation in each
of the datasets.
• Evolutionary Algorithm
These methods involve a subset of evolutionary computation, a genetic population-based
meta heuristic which tries to optimise the results in each generation. To evolute the popula-
tions, one of the methods of reproduction, mutation, recombination and selection or a mix
of them can be used. A fitness function is defined to determine the quality of the solution
each time. For instance, the fitness function in this research is the Negative Log Likelihood
function (NLL) (see section 4.9), in which we want to minimise using different combina-
tions of hyper-parameters. A notable point is that this fitness function results are static and
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Figure 4.5: Hyperprior smooth-box kernel shape, a (lower bound)=2, b (upper bound)=10,
h(slope)=2, t 2 [0.0001,12]
54
only depend on the current information. In order to improve the fitness function to vary
dynamically based on current and previous result states, a heuristic crossover function is
used. In this method, the population in the first generation is initialised randomly. Next
generation’s population can be obtained as follows:
• To make the reproduction possible, two parents from the previous generation resulted
in the best performance (according to the fitness function) are selected. Children of
parents can be obtained using crossover function (recombination function). We can
use various crossover functions; the one used for this study is heuristic function.
If parent1 has a better fitness value than parent2, the function returns the child as
follows (Houck et al. (1995)):
child = parent2+ ratio⇤ (parent1  parent2) (4.19)
The obtained child is closer to the parent with better fitness value and has more distant
from the other parent with worse fitness value. To specify the amount by which the
child is far from each parent, a ratio parameter is defined. The value of ratio can
be set between 0 to 1.2 and it should be chosen based on the data to accelerate the
convergence. This process continues till the required number of population in the
current generation is achieved.
• In each generation a number of children are obtained using mutation. In this case,
the variables (hyper-parameters) are chosen randomly from the variable ranges (min-
imum ta maximum defined ranges for hyper-parameters) from a gaussian or uniform
distribution. Performing mutation, population of a generation are not biased only on
the parents and can be chosen from the entire variables space.
• To keep the best results of the last generations, we can add a fixed number of best
children from last generation to the next generation. Adding Elite children, it is
guaranteed that the performance of the model is not fallen over generations.
As an example, if the Population size is 20, the Elite count is 2, and the Crossover fraction
is 0.8, the numbers of each type of children in the next generation are as follows:
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There are two elite children which are brought directly from the previous generation.
From the 18 individuals other than elite children, there are 14 crossover children (which
is obtained by 0.8*18 = 14.4 , the algorithms then rounds it to 14) . The remaining four
individuals, other than elite children, are mutation children which are chosen randomly
from the entire variables space (Mitchell (1998); Winter et al. (1996)). Genetic Algorithm
(GA) Matlab optimisation toolbox by Houck et al. (1995) is used to do the Evolutionary
Algorithm hyper-parameter optimisation.
A simple example of evolutionary algorithm
To understand the process, a simple example is given with the fitness function: f (x) =
100⇥ (x21 x2)2+(1 x3)2 that we aim to minimise. We consider 4 initial populations for
the first generation that initiated randomly for three parameters of the model.
Initial random population=
x1,2,3 (Parameters values) Fitness values
Populations
1.86 4.47 4.97 117.85
3.40 2.79 4.14 7701.15
1.87 4.49 4.03 107.81
2.67 3.57 3.11 1271.03
We choose two best scores (lowest) as parents for the second generation. Here, the
first and third populations have the lowest scores. The first child from these two parents is
obtained using Equation 4.19 and if we consider ratio to be 0.7 to be more similar to the
better parent (third one with lower score), the first child of the next generation is obtained
as Ch1=[1.86 4.48 4.31] with fitness value of 110.63. The obtained score is not better than
one of the parents. This child is stored and using the parents and the obtained child, we
will continue the same process to obtain the other children of the second generation. As
mentioned previously, to make sure we do not lose the best scores, in each generation we
may choose to keep the desired number of best populations from the last generation (elite
children). In addition, a number of children may be chosen by mutation (randomly, from
a gaussian or uniform distribution), to prevent the population of a generation only biased
on the parents. The process ends when we get to the termination condition, which in the
experiment in this thesis, is the number of generations.
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4.4 Single Layer Network
A Single Layer Network (SLN) is used to consider whether the relationship between the
data features and the target values are linear. An SLN can be considered as a simple gener-
alised linear model. SLNs are known as a statistical technique for linear regression. These
models have a linear combination of the input features, the coefficients are the parameters
of the model. They also include an activation function tailored to the data being modelled.
If we denote the input values to the network by xi where i = 1, ...,d then the network
will consist of c linear combinations of these inputs (c is the number of outputs). This gives
us a set of intermediate variables a j:
a j =
d
Â
i=1
wjixi+b j j = 1, ...,c. (4.20)
Each output unit has one variable a j. wji defines the weight matrix and b j are the bias
parameters. To obtain the output values y j, the a j variables should be transformed by the
activation functions of the output layer. For the regression case we use the linear function
of the form:
y j = a j (4.21)
We can also obtain the error function for the output values (Nabney (2002)).
4.5 K-nearest-neighbour
K-nearest-neighbours (KNN) is a simple algorithm that stores all the training and test fea-
tures and their corresponding targets, then predicts the numerical target based on a simil-
arity measure between the training and the test cases. It is a non-parametric method. The
simplest KNN regression algorithm calculates the average of the numerical target of the K
nearest neighbours. Another approach uses an inverse distance weighted average of the K
nearest neighbours.
In case of numerical variables distance algorithms such as Euclidean, Manhattan and
Minkowski can be used. But when it comes to the categorical variables hamming distance
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could be used, which calculates the number of instances in which corresponding symbols
are different in two strings of equal length.
Choosing the best K depends on the nature of the data. In general, we can trust more
on a large K value predictions as it reduces the overall noise; however, it may cause to
blurred distinct boundaries within the feature space. Another way to do this, is to use
cross-validation which determines a good way using an independent dataset to validate the
K value. The default and optimal K value is usually chosen from odd numbers (Hastie et al.
(2001)). As an example, the simplest Euclidean distance between one dimension p and q is
shown by the below equation:
d(p,q) = ||p q|| (4.22)
4.6 Support Vector Machine Regression
The e  SVM method has first introduced by Vapnik (1998). This method uses the max-
imum margin algorithm which is a non-linear function, learned by linear learning machine
mapping into high dimensional kernel induced feature space. The parameters involved in
the SVM do not depend on the dimensionality of feature space. Similar to the same as
classification, in regression problems, the generalisation bounds should also be optimise.
To do this, the loss function should be defined which is also called ‘epsilon intensive’ loss
function. Our goal is to find a function f (x) that has at most e deviation from the actually
obtained target points for all the training data, and at the same time is as flat as possible
(derivatives should vanish at those points). Here, we do not care about the errors as long
as they are less than e , but any deviation larger than this is not acceptable (Smola and
Schölkopf (2004)). In this method, the input x is first mapped onto a m-dimensional fea-
ture space using some fixed (nonlinear) mapping, and then a linear model is constructed in
this feature space. The linear f (x) function is given by the below mathematical notation:
f (x,w) =
m
Â
j=1
wjg j(x)+b, (4.23)
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where g j(x), j = 1, ..,m defines a set of nonlinear transformations, and b is the ’bias’ term.
As we usually consider the data to have zero mean, the bias term can be dropped.
The quality of this estimation is measured by the loss function L(y, f (x,w)) which is
called e-insensitive loss function proposed by Vapnik (1998):
Le(y, f (x,w)) =
(
0 i f y  f (x,w) e
|y  f (x,w)|  e Otherwise (4.24)
In order to reduce the complexity of the model, or keeping the function as flat as
possible we can minimise the ||w||2. To do this, one should introduce the non-negative
slack variables zi, z ⇤i , i = 1, ..n to measure the deviation of the training samples outside
e-insensitive zone. Therefore, the SVM regression is defined to minimise the following
function:
Minimise
1
2
||w||2+C
n
Â
i=1
(zi+z ⇤i ) (4.25)
Sub ject to
8>><>>:
yi  f (xi,w) e+z ⇤i
f (xi,w)  yi  e+zi
zi,z ⇤i   0, i= 1, ..n
the constant C>0 defines the trade off between the flatness of f (ideally to minimise the
w) and the maximum amount that the deviation larger than e can be tolerated. Figure 4.6
shows the situation graphically. Here the derivations are penalised in a linear fashion and
that is why only the points outside the shaded region causes the cost.
To solve this optimisation problem easier, we can transform it into the Lagrange dual
problem as the below:
f (x) =
nsv
Â
j=1
(ai a⇤i )K(xi,x),0 ai C,0 a⇤i C, (4.26)
where nsv is the number of support vectors (SVs) and the kernel function:
K(x,xi) =
m
Â
j=1
g j(x)g j(xi) (4.27)
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Figure 4.6: The soft margin loss setting for a linear SVM (Smola and Schölkopf (2004) )
The SVM prediction performance (estimation accuracy) depends on the parameters C,
e and the kernel function (with its parameters). Selecting the best model depends on the
distribution of the input values of the training data and the application the SVM regression
is used. Both of parameters C and e affect the model complexity in different ways. Para-
meter C controls the model flatness and the maximum threshold to which the derivations
can be tolerated. Parameter e determines the width of the e-intensive zone that used to fit
the training data. The number of support vectors are affected by the e value. The bigger
e values cause more flat estimates. The kernel functions for SVM regression are varied
from linear to non-linear for algorithms which can be expressed in terms of dot products.
Following kernel functions can be used for the SVM regression:
K(Xi,Xj) =
8>>>><>>>>:
Xi ·Xj linear
(gXi ·Xj+C)d Polynomial
exp( g|Xi Xj|2) RBF
tanh(gXi ·Xj+C) Sigmoid
,
where K(Xi,Xj) is the kernel function and it is a dot product of input data points mapped
into the higher dimensional feature space by transformation. Gamma (g) is an adjustable
parameter of certain kernel functions (Cherkassky and Mulier (2007); Cherkassky and Ma
(2002); Chapelle and Vapnik (1999); Smola and Schölkopf (2004)).
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By far, the RBF kernel has been proved to be the most popular choice of kernel types
used in SVM . This is due to the fact that unlike the other three kernel functions, the
variable of RBF kernel function can be considered as the Euclidean distance between two
points ||Xi Xj|| . However linear, polynomial and sigmoid kernel functions are based on
the inner products of the vectors ((Xi ·Xj) ) (Pedrycz and Chen (2013)).
4.7 Growing Neural Gas (GNG) for clustering
It is important from pharmaceutical point of view to see if the data can form clusters that
are classified based on specific physiochemical or experimental conditions. If we train the
model based on the data obtained in the new clusters and perform the predictions for the
unseen data, we may obtain better results. To do so, the Growing Neural Gas (GNG) by
Fritzke et al. (1995) is applied to cluster the complete dataset. GNG is an unsupervised
clustering algorithm which makes use of unlabelled data. It does not need to have any a
priori knowledge about the number of clusters. Clustering is performed based on the sim-
ilarity of the compounds’ features, which means similar compounds are clustered together.
This algorithm creates a graph structure of the data. It then generates sub-graphs in which
the number of sub-graphs shows the number of clusters. Graph structure and sub-graphs
are generated based on the following steps Fritzke et al. (1995) :
1. Two nodes a and b should be placed randomly in multi-dimensional space.
2. An input signal x from a probability density function (P(x )) should be generated.
3. The nearest node should be recognised and, w is assigned to this node as the winner
and the second nearest node is identified as s, the second winner.
4. All the edges emanating from w should be incremented and be kept as age.
5. The distance between the input signal x and w should be added to a variable, error.
6. The node w and its immediate neighbours should be moved towards x by multiplying
the error to the constant values a and b , respectively.
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7. If w and s are connected by an edge, the age should be reset to zero. If they are not
connected by an edge, an edge should be created and initialised to zero.
8. All edges with greater age than amax should be removed. All nodes with no emanating
edges should be removed.
9. If the number of generated input signals is an integer multiple of the parameter l ,
then a new node should be inserted based on the following rules:
• The node q with the greatest error value should be selected. A new node r
should be inserted between the nodes q and its neighbour f which have the
largest error value.
• The original edge that connecting q and f should be removed and edges should
be inserted between the new node r and the nodes q and f.
• The error variables of q and f should be decreased by a quantity called d . The
error variable of r should be initialised by the new error value which was ob-
tained for the node q.
10. All error variables should be decreased by constant d.
11. Steps 1-10 should be repeated until the maximum numbers of nodes are inserted.
4.8 Monte Carlo method
The Monte Carlo method is an application of the probability and statistics to the natural
sciences. It is mainly used in statistical analysis. In this algorithm, various distributions
of random numbers are generated. Each distribution shows a particular process of the
total processes that approximates the real data values (Anderson (1986)). Monte Carlo
techniques can be used for optimisation, sampling and estimation purposes. In general
this method involves random sampling from certain probability distributions (Kroese et al.
(2014)) . The following steps should be taken to generate the random distributions:
• A domain of possible input data should be defined.
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• Inputs are randomly generated from a probability distribution over the domain.
• Computational algorithms should be performed on the generated inputs.
• Based on the application the Monte Carlo algorithm is used, the results should be
aggregated.
4.9 Performance measures
The correlation coefficient (corrcoef), Negative Log Likelihood (NLL) and Improvement
Over Naïve (ION) are used to measure the model performance (Sun et al. (2012)). Probably
the simplest prediction (Naïve) always predicts the mean of the target value in the training
set independently of the input.
If we produce a predictive distribution at each test input x⇤, in the datasetD , the negative
log probability of the target under the model can be evaluated. If we consider µ as the
mean prediction, as GPR produces a Gaussian predictive density, one obtains (Rasmussen
(2006b)):
NLL= − log p(y⇤|D ,x⇤) = 12 log(2ps
2⇤ )+
(y⇤−µ)2
2s2⇤
, (4.28)
where the predictive variance s2⇤ for GPR is computed as s2⇤ = V( f ⇤) + s2n . V( f ⇤) is
the variance of the prediction. As we are predicting the noisy target y⇤, we must add the
noise variance s2n . To standardise this loss, we may subtract the loss from the obtained
NLL using the mentioned equation considering mean and variance of the training data. We
denote this the Standardised Log Loss (SLL). The mean SLL is denotedMSLL (Rasmussen
(2006b)). The MSLL will be approximately zero for simple methods and negative for better
methods.
In contrast, ION measures how much better a predictor is than the Naïve predictor. ION
is given by the below equation:
ION =
(MSEnaı¨ve MSEGP)
MSEnaı¨ve
, (4.29)
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where MSE denotes the Mean Squared Error and may varies between 0 and +•. ION
values may range from  • to 1. Large positive ION values represent better performance,
while smaller positive MSE values represent better model with low error.
Correlation coefficient (CorrCoef ) finds the statistical relationships between the targets
of the test set and predicted values for them, and it may vary from -1 to 1. In this study,
larger positive correlations defines good prediction performance (Sun et al. (2012)).
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Chapter 5
Data Visualisation
Visualising the datasets can reveal more details about the nature of the data and the relation-
ship between features and the data distribution. The datasets employed in this study contain
more than two numerical features. We need to use techniques to reduce the dimensionality
of the data. One way to do this is to apply Principal Component Analysis (PCA).
5.1 Principal Component Analysis (PCA)
5.1.1 PCA for numerical data
PCA is a well known technique for analysing numerical data. The Principal Components
(PC) of our data manifold, are a set of orthogonal vectors that progressively account for the
variance in the data. Figure 5.1 shows PC1 against PC2 for a sample data. Note that if the
data manifold is n-dimensional, then there will be exactly n principal components.
We can use as many principal components as we need to have an insight into the data.
We can consider the PCA as an n-dimensional ellipsoid that we want to fit to the data, each
of whose axis defines a principal component. A smaller unit value of the axis, represents the
small variance along that axis, and if we remove that axis and its corresponding principal
component from the data set presentation, we only miss a small amount of information.
The axes of the ellipse are obtained using the following process (Jolliffe (2002); Shlens
(2014)):
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Figure 5.1: PC1-PC2 for a sample dataset
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• First, for the d-dimensional data, we should calculate the d-dimensional mean vector
of the data features. Then to normalise the data, the mean data should be subtracted
from the dataset. We can also use Z-score method to normalise the data.
• Then, we should compute the covariance matrix of the data (or correlation matrix
if Z-score is applied first), and calculate the eigenvectors (e1,e2, ....,ed) and corres-
ponding eigenvalues (l1,l2, ...,ld).
• The eigenvectors should be sorted based on the decreasing eigenvalues rank. Then
the k eigenvectors with the largest eigenvalues can be chosen and d⇥ k dimensional
matrix W (each column of W defines an eigenvector).
• Each of the eigenvectors can be considered as an axis of the ellipsoid that fitted to
the data.
• The amount at which each eigenvector variance represents, can be calculated by di-
viding its corresponding eigenvalue by sum of all the eigenvalues.
The next step is to project the principal components to the real data, so that we can visu-
alise the projected data and be able to analyse the data. To do this, we can multiply the
d-dimensional data to the eigenvectors W, that we selected as the most important ones
(eigenvectors with the largest eigenvalues) and obtain the projected data P, considering
only the important features. This projected data can be plotted and analysed. One of the
main uses of PCA is the dimensionality reduction. For example, if the first two principal
components stand for 90% of the variance of the data, the plotting of the data manifold
in the PC1-PC2 space will give a very precise two dimensional representation of the data
manifold.
Figure 5.2 represents eigenvectors corresponding variance of the data. From this figure
we can see that the fifth and sixth PCs variance is close to zero. So, if we remove them, we
do not miss much information.
To see the relationship between the most important principal components of dataset
human D (see Chapter 3 for dataset details), PC1-PC2 is plotted and can be seen in Figure
5.3. In this figure, the first and second principal components account for 50% and 26%
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Figure 5.2: Variance of the Principal components
variances of the data, respectively. From this figure, we can see the area that data points are
gathered together and a few outliers can also be seen. These outliers are explained later.
5.1.2 PCA for nominal data
In addition to the numerical data that is mentioned in the previous section, we also need to
visualise the nominal data which are items that differentiated by a naming system. Numbers
may be assigned to nominal data, to simplify capturing and referencing, but it does not
mean they can be considered as numerical or ordinal data. An example of a nominal data
can be the countries people were born or different colours of a particular object. Nominal
items are usually categorical. To visualise the nominal data, initially we need to find a
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Figure 5.3: The PCA plot of human dataset D (numerical data)
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way to calculate the covariance/correlation matrix of the features. Three various methods
are used to plot the PCA for dataset human D nominal data and they are illustrated in the
following sections.
5.1.2.1 Using correlation matrix between the nominal features
The first method byWakelam et al. (2016), finds the correlation between the nominal fea-
tures. As an instance, if we have three objects with two dimensions or features, as:
A=
D
at
a
ob
je
ct
s
(D
)
data features/dimensions (d)
a b
a b
c b
,
the correlation matrix K(2⇥2) is symmetric with 1 in the main diagonal (correlation
between each feature by itself). The other values of the matrix can be calculated based on
the following instruction:
• First, we should consider all the ways data objects can be compared together. In our
example we can compare D1 with D2, D2 with D3 and D1 with D3. Number of com-
parisons is stored in comp variable, which is 3 in this example, and the comparison
pairs P= (D1 D2,D1 D3,D2 D3).
• To find the values of the matrix K, we will compare the features of all pair of objects
in P. The ‘count’ always starts at 0.
– If values of the first feature d1, are the same, then we look at the second feature
d2. If both of their d2 are also the same we will add 1, if not we deduct 1 from
count.
– If values of the first feature d1, are not the same, we look at the second feature
d2. If both of their d2 are also not the same we will add 1, if they are equal, we
will deduct 1 from count.
– This process is continued till we add/deduct count for all the P pairs objects.
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• The obtained values from the previous steps then are divided by comp and we locate
them in the covariance matrix based on their relation.
For example, the matrix K for the data A is K=
 
1  0.33
 0.33 1
!
which in this case,
-0.33 shows there is not a strong correlation between features 1 and 2 of the data. The
reason is that although we have 2 data points with the same features, the last data point
has the same second feature but not the same first feature as the other two, and it therefore
made the correlation as weak as -0.33. This highlights the issue of dealing with variable
data of a biological origin.
Having the covariance/correlation matrix for nominal data can perform the same pro-
cess as numerical data to obtain the principal components of the human dataset D. To see
the PCA plot for the same dataset in the previous section, we plotted the nominal data (we
have only 3 features in this dataset) PC1 against PC2 in Figure 5.4. PC1 and PC2 repres-
ent %58 and 42% of the data features, respectively which cover all the data variance. The
figure shows a linear relationship between the PC1 and PC2 with some outlier points.
The method described above on computing correlation on nominal features has ad-
vantage to be learned and used easily, as it does not involve complicated mathematical
calculations. In addition, it does not take a long time to be executed. On the other hand, its
weak point is that it is not appropriate to be used for ordinal and interval variables.
Relationship between the numerical and nominal data: To investigate the probable
relationship between the chemical features (numerical data) and of experimental conditions
(nominal features) on the predictions, their PCA plots are compared together. The first
thing to be noticed from Figure 5.3 is the four outliers in the left and right side of the
figure. These points are shown in green in Figure 5.5(a). The same data points’ projections
in categorical data are also shown in plot (b) of the same figure with red stars. One can see
that 4 outliers of PC1 and PC2 projected numerical data are 3 points in the categorical PC
data projection (there is one repetition). At least 2 of these points seem to be outliers in
Figure 5.5 (b) as well.
To do more analysis, the linear relationship formed in the nominal data PC plot is also
investigated to see whether the same data points in the numerical data PC plot represent
71
Figure 5.4: The PCA plot of human dataset D (nominal data), using the method byWakelam
et al. (2016)
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any specific relationship between these two. Figure 5.6 (a) and (b) shows this scenario.
The red stars in plot (a) represent the liner relationship in the nominal data and the same
points are shown in plot (b) by green. As it is expected, we could not find any specific re-
lationship between the numerical and nominal data. To examine the other methods of PCA
visualisation for nominal data, two other methods are discussed in the following sections.
5.1.2.2 Using Hamming distance covariance function
In chapter 4 of this thesis, a kernel function is introduced by Couto (2005) which is calcu-
lated based on the Hamming distance. In this section, using this technique, the covariance
matrix between the nominal features are calculated and plotted in Figure 5.7. PC1 and
PC2 represent %65 and 20% of the data features, respectively which covers 85% the data
variance. This figure is different from Figure 5.4, but it also shows a linear relationship
between the PC1 and PC2 with some outlier points. To investigate the linear relationship in
this figure and their corresponding data in the numerical PCA plot, Figure 5.8 is generated.
Similar to the result in the previous section and as expected, the green points in plot (a)
of this figure do not yield a specific relationship with the green points (the corresponding
points in numerical data) in the same figure plot (b).
To visualise the nominal data, another method based on multiple correspondence ana-
lysis (MCA) is used (Linting and van der Kooij (2012)), and the PCA plot is shown in
Figure A.1. The details of applying this method can be found in section A.3. Similar to
the previous techniques used for nominal data visualisation, no correlation can be found
between the numerical and nominal data.
5.2 Conclusion
In this chapter, I have shown how PCA can be used to analyse both numerical and nominal
data. As expected, we could not find any correlation between numerical and nominal data.
Although the number of nominal features is small in the studied datasets, the possibility of
using different methods to set up the covariance/correlation matrix for nominal data, was
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Figure 5.7: The PCA plot of human dataset D (nominal data), using Hamming distance
method Couto (2005)
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investigated. This can be useful when dealing with a dataset involving a large number of
nominal features.
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Chapter 6
Experimental Results
In this Chapter, the major experiments that have been performed throughout this research
are defined and the results are discussed. Various Machine Learning (ML) methods are
applied to the human and animal datasets described in Chapter 3. It should be noted that in
all of experiments, the training data is normalised as Z-score. The test set is also normalised
with the training set mean and standard deviation.
These experiments include:
• Experiment 1: Various regression methods, kernels and hyper-parameters settings
are applied to human datasets with 7 and 5 numerical features (Section 6.1).
• Experiment 2: The Gaussian Process and SVM methods are used to examine the
effect of using human and non-human models to predict the performance of each
other (Section 6.2).
• Experiment 3:The efficiency of considering experimental conditions on permeability
predictions is investigated (Section 6.3).
• Experiment 4: A kernel containing a mix of of numerical and nominal data is used
in the GP regression model (Section 6.4 ).
• Experiment 5: A clustering method, Growing Neural Gas, is applied to the complete
human dataset. The prediction performances within their original sets and the new
GNG clusters are then compared (Section 6.5).
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• Experiment 6: The last experiment is using Monte Carlo method to deal with incon-
sistent data (Section 6.6).
6.1 Experiment 1: on Human Data (Applying GP, SLN,
QSAR, KNN and SVM methods)
The main aim of this section is to investigate the chemical descriptors, different regression
methods, their performances and the suitable parameters (and hyper-parameters) to be used
for the defined datasets in this study.
First of all, I examine the effect of using all the descriptors compared with using some
of the descriptors on the performance. GP is applied (see section 4.3.1 of Chapter 4) to
the six human datasets considering 7 and 5 features, separately. The 5 features used in
the experiments are widely used descriptors in skin permeability laboratory experiments
(MW,SP, logP,HA and HD). As mentioned in Section 3.2.1, the reason these particular
features are selected is missing or zero values that are assigned to a number of chemicals
for their MR and MPt features. This might cause issues with predictions. All covariance
functions’s hyper-parameters are optimised using conjugate gradient method.
Furthermore, different covariance functions have been applied in order to find the best
performance of the GP. Polynomial, Squared Exponential andMatérn covariance functions
using leave-one-out method and different parameters setting are employed and their per-
formance are compared together.
Linear methods including the traditional QSAR technique that is commonly used in
physical and biological sciences areas, including drug delivery and environmental sciences,
and the SLN algorithm (see Chapter 4 section 4.4) are used to see whether linear equations
can be fitted well to the data to estimate the permeability of the unseen data. The datasets
are quite small and it may raise the over-fitting and under-fitting problems. Therefore, I
use KNN (see section 4.5 of Chapter 4) that is known to cope with small datasets. Due to
the problems of data similarity and inconsistency with GP (see 6.1.1), the SVM regression
method (see Chapter 4, section 4.6) has also been applied to the datasets. The Leave-one-
out technique is used in all the experiments of this section.
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6.1.1 Gaussian Process
The experiments in this section are performed using GP as described in section 4.3
(Rasmussen and Nickisch (2015)). The nature of the data in datasets illustrates that there
are many similar or the same feature vectors in each of the datasets with different target val-
ues corresponding to them that cause problem in GP predictions. To perform the regression
in the GP, the Cholesky Decomposition1 of the covariance matrix of training vectors (K)
should be calculated and and it should be positive definite, otherwise it generates an error.
Similar or same vectors tend to result in not positive definite covariance matrix. In order
to omit this effect on the predictions, the same feature vectors (of chemical descriptors) are
removed and only one of them is kept. The target value is obtained by averaging values of
the target (e.g. logKp) for those with same features.
In addition, using a threshold, the very similar vectors are also removed and one of
them is kept using the average value of their targets. The threshold of 0.01 is considered
between the features vectors in training set. If the distance between the points become less
than the threshold, then GP does not work well on the data. To solve this issue, the similar
points should be replaced with only one point with the same features and target that is the
average of different target values. The similarity is defined as the following:
Distance=
di, j
max(| fi|, | f j|)  0.01, (6.1)
where di, j is the Euclidean distance between two vectors i and j, and | fi|, | f j| are the mag-
nitudes of vectors i and j respectively. As an example if we have two vectors with three
features each, as i=[1.5 5 3.5] and j=[2 5.5 3], the similarity between them is calculated as
the following:
di, j = 0.87, | fi| = 6.28, | f j| = 6.58
Distance= 0.876.58 = 0.13
In this example the distance is more than the threshold and we can keep both points
without causing any problem. As another example, if i is the same vector and j=[1.5 5 3.4],
then the distance between i and j is calculated as following:
1In linear algebra the CholeskyDecomposition is the product of a lower triangular matrix and its conjugate
transpose.
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di, j = 0.10, | fi| = 6.28, | f j| = 6.23
Distance= 0.106.28 = 0.01
In this case, as the distance is 0.01, we should remove one of the two vectors randomly.
As in the skin datasets, there is a target value (e.g. permeability) assigned to each features
vector. The average value of the targets might be calculated and assigned to the vector that
is remained in the dataset.
6.1.1.1 Considering 7 chemical compound descriptors
In this experiment, Matérn covariance function with n = 3/2 is employed. 6 datasets with
7 molecular features of MW,MR,MPt,SP, logP,HA and HD are examined. Details on the
datasets can be found in Chapter 3. The aim is to predict the permeability coefficient.
The mean values of ION and MSE (the mean value is obtained from all the ION and MSE
values for all the predicted points) and Correlation coefficient (CorrCoef) performance
measures can be seen in the first result row of Tables 6.1, 6.2 , and 6.3. Result for each
performance measure method (e.g. ION) are collated and represented in a single table to
make the comparisons convenient. Each row in these tables represents the performance
of a regression method (with various numerical features and parameter settings) for the
datasets used in this study. To have a better visualisation on the overall ION and MSE
performance of various methods, the best methods’ performances for each dataset (in each
column) are coloured by blue and the second best values are coloured by green in Tables
6.1 and6.2. Correlation coefficient results are important in pharmaceutical field; therefore,
the Corrcoef results are added for the main experiments. Other kernel methods with their
details are defined in the next sections.
6.1.1.2 Considering 5 chemical compound descriptors
In this experiment, 5 features, which areMW,SP, logP,HA and HD, are used and the model
performance is shown in the second result row of Tables 6.1, 6.2 , and 6.3. As explained,
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Table 6.1: ION performance of the GP, larger positive ION demonstrate better results.
Experiment/Data Dataset A Dataset B Dataset C Dataset D Dataset E Dataset F
GP, 7 features, Matérn cov, n = 3/2 -0.03 0.00 0.12 0.31 -0.10 0.52
GP , 5 features, Matérn cov, n = 3/2 0.19 -0.02 0.35 0.50 0.01 0.37
GP, 5 features, Polynomial Cov, D=5 0.02 0.00 0.00 -0.04 -0.01 -5.85
GP, 5 features, SE cov 0.18 -0.02 0.35 0.55 0.01 0.28
GP, 5 features, Matérn cov, n = 1/2 0.17 -0.01 0.30 0.45 0.00 0.42
GP, 5 features, Matérn cov, n = 5/2 0.19 -0.03 0.35 0.52 0.01 0.35
QSAR (Potts and Guy) -7.31 -3.49 -0.06 -0.30 -2.69 -0.62
SLN , 2 features (MW and logP) -1.28 -0.1 -0.14 0.11 -0.03 0.12
SLN, 5 features -6.86 -0.46 0.2 0.01 0.04 0.06
KNN, 5 features -0.22 -0.48 0.45 -0.09 -0.4 -0.02
Table 6.2: MSE performance of the GP, smaller MSE demonstrate better results with less
error between predictions and real target values.
Experiment/Data Dataset A Dataset B Dataset C Dataset D Dataset E Dataset F
GP, 7 features, Matérn cov, n = 3/2 1.15 1.64 1.62 1.17 1.23 0.97
GP , 5 features, Matérn cov, n = 3/2 0.81 1.68 1.19 0.84 1.11 1.27
GP, 5 features, Polynomial Cov, D=5 0.97 1.64 1.84 1.75 1.14 13.76
GP, 5 features, SE cov 0.82 1.68 1.14 0.76 1.11 1.44
GP, 5 features, Matérn cov, n = 1/2 0.81 1.66 1.28 0.92 1.12 1.16
GP, 5 features, Matérn cov, n = 5/2 0.81 1.69 1.19 0.81 1.11 1.30
QSAR (Potts and Guy) 9.37 7.38 1.95 2.20 4.15 3.26
KNN, 5 features 1.21 2.04 0.78 1.45 1.3 1.68
Table 6.3: Corrcoef performance of the GP, positive Corrcoef values closer to 1, demon-
strate higher correlation between predictions and real target values.
Experiment/Data Dataset A Dataset B Dataset C Dataset D Dataset E Dataset F
GP, 7 features, Matérn cov, n = 3/2 -0.94 -0.21 0.40 0.54 -0.01 0.72
GP , 5 features, Matérn cov, n = 3/2 0.19 -0.23 0.52 0.69 0.11 0.62
QSAR (Potts and Guy) -0.96 -0.99 0.04 0.20 -0.81 0.18
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MR and MPt features are removed, since there they contain a number of zero or missing
values. Comparing these results with those obtained in the previous experiment (first row
in all tables) shows that except from dataset B with a slightly decrease in performance and
dataset F that the performance is also dropped, in general using 5 features, more precise
estimation of the target values are obtained. Considering these results, the 5 mentioned
physicochemical features are used for the next experiments.
6.1.1.3 Various covariance functions
In this section, the results are obtained using different covariance functions. Polynomial
covariance function with parameter D (order)= 5, is employed and the ION andMSE results
are demonstrated in row three of Tables 6.1 and 6.2, respectively.
It is clear that Polynomial Covariance function does not demonstrate a good perform-
ance compared to theMatérn function in all the datasets. Further investigation shows thatK
and K⇤ which are related to the weighting factor of the predictions, are very small (almost
zero) . Therefore, this covariance function is not suitable to be used on our datasets.
The Squared Exponential (SE) covariance function is also applied to the datasets. The
results are also shown in Tables 6.1 and 6.2. Comparing the performance of using this
method with the others, SE gives better performance than Polynomial covariance function
(in 5 out of 6 datasets in both ION andMSE). SE also shows better ION andMSE perform-
ance thanMatérnCovariance function in only one dataset (dataset D), andMatérn performs
better or the same in the other datasets. Additional investigation about this method shows
small weighting factors and the large distance values between test point and training points
(r values) are obtained which might make the model unreliable
In addition, Matérn function’s performance is also examined with parameters n = 1/2
and n = 5/2 , and the ION and MSE results are shown in Tables 6.1 and 6.2, respectively.
As one can see from these tables, regardless of the performance measure method, the results
are quite similar for all three values of n . As the average performance of the Matérn
kernel with n = 3/2 is slightly better for the datasets used in this study,Matérn covariance
function with n = 3/2 is chosen as the bench mark method in GP to apply regression in the
next experiments.
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6.1.2 Linear methods
In order to investigate the performance of linear methods in estimating the permeability
values, traditional QSAR and SLN methods are applied to the datasets.
6.1.2.1 Traditional QSAR method
Potts and Guy (1995) QSAR method (see Equation 2.7) is used to estimate the permeab-
ility of the chemicals. The ION, MSE and corrcoef are shown in Tables 6.1, 6.2, and 6.3,
respectively. The main outcome from these results considering all performance measure-
ment approaches, show that in all 6 datasets, GP works extremely better than linear QSAR
method. This has been also previously shown in studies by Moss et al. (2011; 2002; 2009),
and Sun et al. (2010, 2012) in this field. To make this visually clear, an example of compar-
ison between real target values (permeability coefficients), with the predicted values using
GP (Matérn covariance function,n = 3/2 ), and linear QSAR methods, for all the chem-
icals in one of this study’s datasets ( human C ) is shown in Figure 6.1. In this figure, it
is demonstrated that except from three chemicals (Chemicals number 1, 3 and 11), all the
other GP predicted values are closer to the target values than QSAR estimated permeability
values.
6.1.2.2 SLN
In addition to the previous method, using the linear SLN method (Nabney (2002)), model is
trained and tested. The results are presented in Tables 6.1 and 6.2. The results are presen-
ted for using two features and five chemical features. Due to the reason that QSAR uses
two features (logP and MW ) to estimate the skin permeability values, the same molecular
features are also used in linear model. The first thing to be noticed is that in both datasets
A and B, the linear model works worse than the Naïve model and in particular on dataset
A with 5 features the SLN works very poorly. This is almost certainly due to the fact that
these datasets are very small with few vectors. It is also apparent that using SLN on the
other datasets brings little if any benefit.
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Figure 6.1: Comparison between real target values (permeability coefficients), with the
ones predicted with GP (Matérn covariance function,n = 3/2 and leave-one-out method ),
and linear QSAR methods, for all the chemicals in the dataset human C.
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6.1.3 KNN application
The performances of applying KNN are shown in Tables 6.1 and 6.2. From both ION and
MSE results, it is clear that KNN does not work properly on most of the datasets (worse
than Naïve predictor in 5 out of 6 datasets). KNN performance illustrates that the model
tends to have over-fitting due to the complexity of the data. The simple Euclidean Distance
is implemented to measure the distances in KNN technique.
6.1.4 SVM application
As mentioned earlier, similar feature vectors in training set are problematic in the GP,
while they are not an issue in a Support Vector Machine (SVM) regressor. In this method,
similarity between the same chemicals with different permeability do not cause any math-
ematical problems in calculations. Therefore, all the data in the datasets are used to do
the experiment. Using a few SVR types with different parameter settings, the one with the
best performance for the skin datasets is epsilon-SVR (e-SVR) with RBF (Radial Basis
Function) kernel (Chang and Lin (2011)). The optimised values of parameters g and C are
obtained by grid search. The ION results are demonstrated in Table 6.4, respectively .
It should be noted that these results are not comparable with the ones in Table 6.1(the
test sets of the models are not the same as all the chemicals’s features including inconsistent
data are used in this dataset). The SVM performance confirms that inconsistent data are not
mathematically problematic in this technique, and it can provide a comparable prediction
performance with the ones obtained from GP. Studies by Obrezanova and Segall (2010)
and Cortes-Ciriano et al. (2015) show that both GP and SVM with relevant parameter
settings, result in better performance (classification/regression) than the other methods. In
addition, a research by Shah et al. (2016) illustrates that a global approach to modelling
a biological process may not necessarily be the best method. The authors suggest that
a‘mixed-methods’ approach (using GP and SVM) to different parts of the chemical space
can improve the model performance.
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Table 6.4: SVM applying to the data-Considering 5 and 7 data features. The results can be
compared to the GP performance in the same table.
Performance/Data Dataset A Dataset B Dataset C Dataset D Dataset E Dataset F
ION SVM-5 features (mean) -0.07 -0.15 0.28 0.35 0 0.42
ION SVM-7 features (mean) -0.3 -0.07 0.18 0.37 -0.04 0.52
6.1.5 Conclusion
The aim of the experiments in this section was to evaluate the performance of different
regression methods, with proper parameter settings on the skin permeability estimation
problem. Blue and green coloured values in Tables 6.1 and6.2 show the best and second
best performance obtained for each dataset, using various methods and parameters. There-
fore, methods (rows) with more blue and green values demonstrate better models. The first
conclusion from these tables is that QSAR method works worse than all the other methods
in all the datasets. Additionally, it can be seen that GP with Matérn covariance function
(with all three values n= 1/2, 3/2, 5/2) perform similar, using 5 chemical features; however,
the average of performance of this function with n = 3/2 in all datasets, outperforms the
GP withMatérn covariance function with n = 1/2,5/2 . Using GP method with SE kernel
shows comparable performance with Matérn kernel, however, as discussed, small weight-
ing factors and large distance values between test point and training data might make this
model unreliable.
In addition, the result represent that SVM performs reasonably good and comparable
to GP with the Matérn covariance function (n = 3/2) to predict the permeability values.
A mix of these methods may be used for best quality predictions. Since this study’s main
focus is on GP, this approach is employed (using 5 features) as the fundamental technique
to perform further experiments in this thesis.
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6.2 Experiment 2: Comparing human, mouse, rat and pig
models
In this section, four datasets (complete human, mouse, rat and pig) are used to perform the
experiments. The GP is applied to one of the datasets each time to obtain a GP model.
The model of that dataset then is used to predict the permeability of the other datasets. As
an example, the model is first trained, using the human data and then predict the mouse
data permeability using human GP model. This is especially an important question in
pharmaceutical field that which of the mammalian skins may perform as a better model to
be trained to result in better permeability estimation for the other types. Animal membranes
can be used as they are economical in both time and financially, and for safety reasons, so
humans do not get exposed to problems with chemicals. However, the relevance of rodents
in particular has been questioned with most researchers now agreeing that rodent skin has
little correlation to human skin in terms of permeability.
From pharmaceutical point of view, this experiment is important from two aspects.
First, if we can make models work better (than animals), we do not need to use animal
models as it might be unethical. Second, we need to consider whether the outputs (from
animal data) match human in both predictions and mechanistic understanding, and this
would allow us to conclude as to the good or bad use of animal tissues to replace human
studies.
6.2.1 Datasets
The details about the nature and the size of the four datasets employed in this study are ex-
plained in Chapter 3. Each dataset includes measurements of both the chemical properties
(5 descriptors are used) and the absorption rate of the variety of compounds. As mentioned
previously, the average value of the permeability for inconsistent chemicals is used to deal
with the inconsistency problem. There is also a degree of overlap between datasets after
removing the inconsistency which are also shown in Table 6.5.
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Table 6.5: Overlap among the complete human, rat and mouse datasets
Datasets Complete human Rat Mouse Pig
Complete human *(121) 17 23 4
Rat 17 (26) 5 4
Mouse 23 5 (46) 2
Pig 4 4 2 (14)
* As only five chemical descriptors are used in this study (temperature is not considered),
the size is less than the the complete human dataset in Table 3.1(with temperature the
size=145)
6.2.2 Experiments and results
Two major experiments have been performed in this section.
1. The first one is to measure the performance of the model for each dataset separately.
2. The second experiment investigates the performance of employing one dataset model
to predict the skin permeability of the other types of the mammalian skins.
3. Finally, the last experiment is performed the same as the second experiment but SVM
is used to train the model.
6.2.2.1 The performance of each model using GP model
The Leave-One-Out technique is used for each of the datasets, and the ION values are
shown in Table 6.6. The results show that the best prediction performance is obtained
for pig and that the prediction performance of rat and human data are better than mouse
data. Comparing the ranges of chemical features and permeability values of pig and other
datasets (can be seen in Figures 3.2 and 3.4) illustrates that the comprehensive performance
of Pig dataset (with only 14 data) may be caused by having the largest range of permeability
values (targets) among the others.
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Table 6.6: GP prediction performances using leave-one-out in each dataset
Dataset ION (mean) CorrCoef
Complete human 0.40 0.63
Mouse 0.32 0.55
Rat 0.42 0.65
Pig 0.77 0.88
6.2.2.2 Effect of using one mammalian model to predict the skin permeability of the
others
Having repetitions in training and test datasets: In this experiment, I examine how
using one of the human, mouse and rat datasets to train the model hypothetically may help
to predict the other groups permeability coefficients. In this method, one dataset is used
to train the model and the other dataset is used as the test set at which the permeability
values are predicted. The same chemicals exist in both test and training sets are kept. The
following stages are taken to do this experiment:
1. The training and test datasets are first normalised as discussed earlier. The GP model
is trained with human dataset and then each time one of the mouse, rat and pig data-
sets is used as the test set to estimate their targets based on the model which has been
had trained. The prediction performances (ION) are then calculated.
2. This process is repeated for mouse, rat and pig datasets as well and then the model is
used to get the performance of the other datasets and the prediction performances are
reported as ION in Table 6.7. The datasets shown in red are the training sets and the
blue datasets are the test sets and the prediction performances are reported for them.
The best ION (0.57) is achieved for the Rat dataset where the model is trained with Mouse
data. However, the best Correlation coefficient (0.80) is related to the Rat dataset as well,
but the model is trained with Human data. Comparing these results with those in Table 6.6
shows that rat dataset permeability values can be predicted better when the model is trained
with either human or mouse dataset, However, the vice versa is not correct as the datasets
sizes are not the same. The important finding is that the best permeability predictions for
human data are obtained when the model is trained by mouse data. Training the model
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with Pig dataset for predicting the other datasets target values is not beneficial on any of
the datasets.
Table 6.7: GP prediction performances training the models and test on the other datasets.
Comparing these results with the ones in Table 6.6 shows rat dataset permeability values
can be predicted better when the model is trained with either human or mouse dataset.
To be tested on
ION CorrCoef
The training set The training set
Complete human Mouse Rat Pig Complete human Mouse Rat Pig
Complete human —— 0.36 0.21 0.12 —— 0.64 0.43 0.36
Mouse 0.22 —— 0.10 0.11 0.64 —— 0.26 0.34
Rat 0.52 0.57 —— 0.07 0.80 0.65 —— 0.15
Pig 0.19 0.10 0.03 —— 0.34 0.30 0.10 ——
Removing repetitions from training or test datasets: The second part of this analysis
considers removing the repetitions between training and test data and investigates its effect
on predictions performances. The steps have been taken to conduct the experiment are as
follows:
1. The repeated vectors of chemical features are removed from the training set where
the number of data is more than the number of data in the test set, otherwise, the
repeated data is removed from the test set.
2. All the process in the previous experiment is then followed for each of the datasets
and the results are reported in Table 6.8. The same as the previous experiment, the
datasets with red colour are the training sets and the blue datasets performance are
reported in the results table.
As expected, due to removing the repetitions between training and test sets, there is a
decrease in the prediction performances. However, interestingly the best performances are
obtained for the same training and test sets of the previous experiment (0.50 and 0.64 for
ION and Correlation coefficient, respectively). The results illustrate that human and mouse
data result in better performances when they are used to train the model and then the model
is used for the rat data permeability estimation, compared to the model which is trained with
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rat data (Table 6.6). Similar poor performance is obtained when the models are trained with
Pig data.
Table 6.8: GP prediction performances training the models and test on the other datasets,
after removing the repetitions Comparing these results with the ones in Table 6.6 shows rat
dataset permeability values can be predicted better when the model is trained with mouse
dataset.
To be tested on
ION CorrCoef
The training set The training set
Complete human Mouse Rat Pig Complete human Mouse Rat Pig
Complete human —— 0.32 0.11 0.09 —— 0.56 0.31 0.31
Mouse 0.18 —— 0.11 0.07 0.51 —— 0.32 0.28
Rat 0.45 0.50 —— 0.06 0.64 0.61 —— 0.12
Pig 0.15 0.7 0.02 —— 0.26 0.24 0.06 ——
6.2.2.3 Effect of using one mammalian model to predict the skin permeability of the
other groups (using SVM)
Considering all the experiments in this section, I also apply SVM to the datasets (included
all the inconsistent data) to investigate whether better performance can be obtained. The
outcome shows that SVM did not change the performance by a great amount. Therefore, I
do not report the results in this section.
6.2.3 Conclusion
To summarise this section, the best results were obtained using the mouse and human data
to train the model and then using the obtained models to predict the permeability of the rat
data. The pig dataset shows to have a thorough performance (using leave-one-out) com-
paring to the other ones (ION=0.77 and CorrCoef=0.88); however, training the model with
Pig dataset to predict the other datasets’ permeability values result in poor performance.
The other interesting finding is that training the model with mouse data to obtain the
human data permeability values, could result in better performance than training the model
with rat data. It should be noted that, all models work better than the Naive models.
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6.3 Experiment 3 : The effects of experimental conditions
(environment temperature and diffusion cells type ) on
permeability predictions
A closer look at the datasets and their prediction performances raised an interesting ques-
tion about the effect of experimental conditions on the permeability predictions. The ques-
tion is, whether the experimental conditions such as temperature and various diffusion cells
can affect the performance of the model. In this section the effect of temperature change
and using the static or flow-through cells on the prediction performances are investigated.
6.3.1 Temperature effect on the model performance
To examine the effect of temperature on chemical’s permeability across the skin, this nu-
merical feature is added to the training data. Temperature values that used for this study
includes 37oC ( all 32oC skin surface temperature are considered to be 37oC as it shows the
temperature of the diffusion cell during the experiment), in addition to 30oC, 27oC, 26oC,
25oC, 23oC. For the ‘not given’ values the corresponding chemical features are removed.
then omitted. The temperature ranges in the datasets are demonstrated in Chapter 3, Figure
3.1. Temperature values are added with other numerical molecular features and the ION
performance of the experiments are shown in Table 6.9. To make the comparison easier, the
ION performance of the datasets before adding the temperature is also shown in the table.
Since among datasets A-D, the temperature is constant, the experiment is performed only
on the datasets E and F. The results yield much better performance in the dataset F (about
73% increase). This is due to the fact that dataset F has the largest range of temperature
values.
6.3.2 Conclusion
This shows that adding temperature as a numerical feature to the data can be helpful to
increase the prediction performance, and it is especially effective when the temperature
range in the dataset is large.
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More exploration is also performed employing 7 features together with the temperature
values (using GP) results do not change by great amount.
Table 6.9: ION performances with and without temperature added to the 5 features
Using 5 features Dataset E Dataset F
ION-without temp 0.00 0.37
ION-adding temp 0.01 0.64
6.3.3 Using only flow-through or static diffusion cells
In this experiment, the static and flow-through cell data are separated and the performance
of each of these groups is calculated separately. There are in total 93 static and 53 flow-
through data in the complete human dataset. In the first experiment, the model is trained
based on the flow-through data and the predictions are obtained for flow-through data only
(leave-one-out is used). The results of the experiment have been shown in Table 6.10. Then
similarly, the model is trained only based on the static data and the predictions are achieved
only for static data and the results are shown in Table 6.11. The results show that using
flow-through data to train the model results in poor prediction performance for the flow-
through cell data(almost the same as Naive predictor); However, training the model with
static data to predict the static data permeability values, yield so much better performance.
Table 6.10: GP prediction performances considering only flow-through cell data to train the
model and predict the flow-through cells data permeabilities (leave-one-out). The results
compared to the ones in Table 6.11 show that static data results in much better prediction
performance than the flow-through data.
Flow-through only for Training Mean
MSE_GP_flow-through 0.84
ION_GP_flow-through 0.04
MSE_Naive_GP_flow-through 0.87
CorrCoef_GP_flow-through 0.20
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Table 6.11: GP prediction performances considering only static cell data to train the model
and predict the static cells data permeabilities (leave-one-out). The results compared to the
ones in Table 6.10 show that static data results in much better prediction performance than
the flow-through data.
Static only for training Mean
MSE_GP_static 0.98
ION_GP_static 0.42
MSE_Naive_GP_static 1.68
CorrCoef_GP_static 0.66
Since, static data resulted in better prediction performances, in the following experi-
ment I train the model based on the static data and estimate the flow-through data permeab-
ility values. In addition, I investigate on training the model with flow-through data and
obtaining predictions for static data. The results of these experiments are shown in Tables
6.12 and 6.13. One can see that this approach does not work well on any of the static or
flow-through data and the prediction performance for both data types are dropped.
Table 6.12: GP prediction performances Considering only static cell data to train the model
and predict the flow-through cells data permeabilities. The results compared to the ones in
Table 6.10 show that this training model does not results in better performance for flow-
through data.
Static only for Training Mean
MSE_GP_flow-through 1.17
ION_GP_flow-through -0.35
MSE_Naive_flow-through 0.86
CorrCoef_GP_flow-through 0.07
Table 6.13: GP prediction performances Considering only flow-through cell data to train
the model predict the static cells data permeabilities. The results compared to the ones in
Table 6.11 show that this training model does not results in better performance for static
data.
Flow-through only for Training Mean
MSE_GP_static 1.64
ION_GP_static 0.05
MSE_Naive_static 1.73
CorrCoef_GP_static 0.19
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6.3.4 Mixing static and flow-through data
In this experiment, the static and flow-through cell data are collated together (in total 143
data). Subsequently, 10 different training and test sets from the mixed static and flow-
through cell data are randomly selected based the following process:
1. As mentioned, the number of flow-through and static cell data are different in the
complete data (size=93 for static data and size=53 for flow-through data in the com-
plete data). Therefore, the same number of static and flow-through data are selected
and included in each training set (36 data are selected randomly from each of static
and flow-through data). The rest of the data that remained in the complete datasets is
used as the test set. The test set contains unequal mixed static and flow-through cell
data. This process is done for 10 times to obtain 10 random training and test sets.
2. The 10 sets are trained separately and the predictions obtained for their corresponding
test sets.
3. As the experiment have been performed 10 times to obtain the predictions on 10 test
sets, the mean and standard deviation (STD) of the 10 experiments performances are
reported in Table 6.14.
Although the results are not comparable with the ones in Tables 6.12 and 6.13 (as their
test sets are different), it can bee seen from Table 6.14, that using both datasets to train the
model does not bring much benefit and the prediction performance for flow-through data is
still very poor.
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Table 6.14: GP prediction performances mixing static and flow-through cell data. The res-
ults show that mixing the data do not bring much benefit to predict the static and especially
flow-through data (with very low performance) permeability values.
Mixed_static_flow-through Mean (over 10 experiments) STD (over 10 experiments)
MSE_GP_flow-through 0.93 0.23
MSE_GP_static 0.96 0.09
ION_GP_flow-through -0.07 0.09
ION_GP_static 0.43 0.05
CorrCoef_GP_flow-through 0.19 0.16
CorrCoef_GP_static 0.67 0.05
MSE_GP_Naive_flow-through 0.86 0.14
MSE_GP_Naive_static 1.70 0.09
6.3.5 Conclusion
To conclude, the experimental condition features such as temperature and cell type can af-
fect the model prediction. As for temperature, with large range of temperature values in
the data, the performance of the model can be improved by a great amount. Furthermore,
separating the data based on the different cell types show that the best predictive models
are always obtained when static diffusion cell data permeability is predicted compared to
models constructed from flow-through cell experiments. These results are obtained regard-
less of whether data from static or flow-through cells, or mixtures of both, are used to train
models. Further, training models based on flow-through cell data only, and predicting the
permeability of ‘unseen’ test data resulted in poor models.
It is apparent that the quality of the model is directly affected by the nature of the in-
put data, and that the inclusion of data from flow-through experiments may reduce overall
model quality and predictive power, while models based solely on such data offer poor pre-
dictions of skin permeability. This is in significant contrast to models developed from static
diffusion cell experiments, which resulted in highly predictive models. It may therefore be
suggested that, in order to optimise the model quality, data from only static, franz-type,
experiments should be used to construct computation models. It is also interesting to in-
vestigate using different chemical features when flow-through cell type is used.
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6.4 Experiment 4: Mixing numerical and nominal Data
The aim of this experiment is to consider the nominal experimental features and investigate
their probable effect on the predictions. To do this, 6 numerical data features including
the temperature and three nominal features as the experimental conditions are considered.
The numerical and nominal features of the datasets are illustrated in Chapter 3 (see 3.2.2).
To obtain the covariance function of the numerical data,Matérn function (n = 3/2) is used
and a categorical kernel function based on hamming distance by Couto (2005) (see Chapter
4, section 4.3.2.1) is employed to calculate the categorical kernel function.
Finally, the covariance matrices are added together considering different weighting
factors multiplied by them. The weights are chosen to be µ and 1-µ for categorical and
Matérn covariance/correlation matrices, respectively; these weighted kernels are then ad-
ded together. The µ values are considered to be 0.4 and 0.8. So, the weight of categorical
and Matérn covariance/correlation matrices are first set to 0.4 and 0.6 and the experiment
is performed. For the second experiment, the weights are considered to be 0.8 and 0.2,
respectively.
The results are reported for different values of l = 0.01, 0.5, 0.8 and 0.99 in Tables
6.16 and 6.17. For conveniency, the ION results for numerical data including temperature,
are added in Table 6.15. Comparing the obtained ION values using both numerical and
categorical data to the ones using only numerical data, it can be seen performance of the
model is so poor when (l=0.01). Considering the other parameter values for l and µ ,
except from dataset E, all other datasets can have a slightly improvement by varying these
parameters.
Table 6.15: ION performances only numerical data with temperature. This is the bench-
mark results as the best prediction performances are obtained using GP (with 6 numerical
data, Matérn function (n = 3/2)). These should be compared to the ones in Table 6.16.
Using 5 features Dataset A Dataset B Dataset C Dataset D Dataset E Dataset F
ION-adding temp (mean) 0.19 -0.03 0.38 0.33 0.01 0.64
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Table 6.16: Adding categorical features to the 6 numerical data features (Higher ION
better) µ = 0.4. These results should be compared to the ones in Tables 6.15 and 6.17to
examine which l parameter setting performs better among all.
Performance/dataset Dataset A Dataset B Dataset C Dataset D Dataset E Dataset F
ION-mean (l=0.01) -0.5 -19.09 -1.85 -70.84 -13.98 -48.45
ION-mean(l=0.5) 0.21 0.02 0.35 0.3 -0.01 0.66
ION-mean(l=0.8) 0.21 -0.05 0.38 0.33 -0.01 0.66
ION-mean(l=0.99) 0.21 -0.05 0.38 0.33 -0.01 0.66
Table 6.17: Adding categorical features to the 5 numerical data features (Higher ION
better) µ = 0.8. These results should be compared to the ones in Tables6.15 and 6.16 to
examine which l parameter setting performs better among all.
Performance/dataset Dataset A Dataset B Dataset C Dataset D Dataset E Dataset F
ION-mean(l=0.01) -0.7 -28.59 -4.42 -159.25 -27.44 -80.53
ION-mean(l=0.5) 0.2 0.05 0.31 0.29 -0.02 0.65
ION-mean(l=0.8) 0.21 -0.05 0.37 0.32 -0.02 0.66
ION-mean(l=0.99) 0.21 -0.08 0.38 0.32 -0.01 0.66
6.4.1 Conclusion
The small improvement in this experiment’s performance compared to the ones in Table
6.15 may be caused by involving cell type in the features, as can be seen in 6.3, it can
decrease the performance with flow-through cell data. More investigation needs to be done
in future to consider this case or to combine the categorical kernel with the numerical
kernel using the other weighting factors and combining methods (e.g. by multiplying them
together with different weights).
100
Table 6.18: Number of points in each cluster obtained from applying GNG
Clusters DS 1 DS 2 DS 3 DS 4
Number of points 41 79 13 12
6.5 Experiment 5: Data clustering (using Growing Neural
Gas algorithm)
This experiment has been performed on the complete human dataset by gathering all the
human datasets and removing the repetitions. The average value of the permeabilities con-
sidered for the inconsistent data. The GNG by Fritzke et al. (1995) (see section 4.7 on
Chapter 4) is applied to the complete dataset to investigate the nature of the generated
clusters. The maximum nodes is set to 100 and the default values are selected for the other
parameters of the GNG (Loos and Fritzke (1998)). Employing GNG on the complete data-
set with 145 data points with 6 chemical features including temperature, 14 natural clusters
are obtained. Some of the obtained clusters include only 2 or 3 data which cause problem
in GP (the training set can not have only 1 or 2 data). To solve this issue, the centre of
the clusters are calculated and the closer clusters are combined together. As a result, 4
clusters are obtained from GNG. PCA is used to show the clusters in two dimensions. Fig-
ure 6.2 shows the PC1 against PC2 of the data points and the obtained clusters from GNG,
are shown in different colours. The number of data points in each of the clusters are also
shown in Table 6.18.
To predict the permeability of the chemicals in the new clusters, and compare them with
the the previous permeability estimations in their original clusters (datasets), the following
steps have been taken:
• In each cluster, for the same chemicals with different permeability values (targets),
one of them (with its all chemical features) is kept and the average value of the
various permeability values is considered as that chemical’s target value.
• GP is applied separately to each of the GNG clusters and using leave-one-out tech-
nique, the predictions for each of the chemicals in their new clusters are obtained.
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Table 6.19: Comparing the MSE of predictions in the original datasets and the new GNG
clusters and the overall MSE of the predictions
Original human datasets Dataset A Dataset B Dataset C Dataset D Dataset E Dataset F Overall datasets
MSE 0.96 1.68 1.19 0.84 1.11 1.27 1.62
GNG clusters DS 1 DS 2 DS 3 DS4 NA NA Overall clusters
MSE 1.16 0.80 0.90 0.59 —– —— 0.89
• GP is applied to the original datasets (6 human datasets) and the predictions also
obtained for each of the chemicals in the their original datasets (using leave-one-
out).
• The obtained permeability values for the chemicals in each of the new clusters (from
GNG) then are compared to the predictions achieved for the chemicals in their ori-
ginal datasets.
• Finally, the MSE of the predictions are calculated for all the chemical in both their
previous datasets and new GNG clusters. It is interesting that for 107 chemicals out
of 145, the error of the predictions in the GNG clusters is less than the average value
of the errors in the previous datasets.
Table 6.19 shows the MSE in each of the predictions in the original datasets and the GNG
clusters. The overall MSE of all compounds are also shown in the same table. From
these results, one can see that GNG clusters decrease the prediction errors by 45% and
clustering the large data using GNG is suggested to be used in future experiments for target
(permeability) estimation.
6.5.1 Conclusion
In summary, GNG clustering works better in predicting 107 chemical’s permeability (out
of 145) which are the majority of the compounds. In addition, the absolute error box-plot
(Figure 6.3) shows that GNG clustering result in better predictions overall the compounds.
The MSE over all the compounds improved 45% (from 1.62 in the previous datasets to the
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Figure 6.2: PC1-PC2 application of GNG and the natural clusters
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Figure 6.3: Comparing Absolute error of predictions between the chemicals in their previ-
ous datasets and new GNG clusters
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0.89 in the GNG clusters). However, predictions in the original datasets still work better
for 42 chemicals. In the next section, I examine applying the Monte Carlo method to deal
with inconsistency in the data.
6.6 Experiment 6: Using Monte Carlo method to deal
with inconsistent data
As mentioned earlier, the datasets used for this study may include the same chemicals
with various target (e.g. permeability) values. This ‘inconsistent data’ may cause problem
for predictions. To deal with this issue, the mean of all target values corresponding to a
single chemical in each of the datasets is considered in all the previous experiments. In this
section, application ofMonte Carlomethod (see 4.8) is investigated to see whether a better
solution for the average of target values can be found. To do so, the following steps should
be taken:
• The human datasets are gathered in a set ’complete human dataset’ (Table 3.1)
• 2/3 of the data is considered as training set and 1/3 is considered as test set.
• For the compounds with more than one target value (e.g. permeability rate), one of
the values is randomly chosen and placed in the training set.
• Model is trained with GP and predictions are obtained for the test sets using 3-fold
cross validation. The mean ION (for three test sets) and correlation coefficients are
obtained.
• In order to establish which values worked best, this whole process is repeated with
10000 different training sets and10000 different random choices.
• The best ION (mean) and CorrCoef among all 10000 repetitions of the experiment is
then found and the best selection for each compound target values can be obtained.
This dataset can be used as a proper training set for further experiments and target
estimations.
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Table 6.20: Complete human dataset, the performance of using Monte Carlo method is
compared with the ones in which average of targets are used for inconsistent data.
Performance measures
ION (with mean of targets) 0.34
ION (with Monte Carlo the best) 0.41
CorrCoef (with mean of targets) 0.55
CorrCoef ( with Monte Carlo the best) 0.64
Figure 6.4: Comparison of estimates with targets (Monte Carlo method).
The performance of this method are compared with the original dataset that mean values are
used for each inconsistent compound. The same test sets with 3-fold cross validation are
used to do the experiment on the original datasets (mean of target values for inconsistent
data). The comparison of results between these two methods performances is shown in
Table 6.20. Figures 6.4 and 6.5 show a summary of the total results – they highlight the
estimates for 35 chemicals taken from the “best” Monte Carlo data set. From these results it
is apparent that, in most cases, the application of the Monte Carlo method works better than
using a data set containing mean values of chemicals in that it produces better estimates.
This analysis also yields an ‘optimal’ data set; starting with the complete data set repetitive
data points are removed and the best target values of the statistical metrics are produced.
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Figure 6.5: Comparison of estimates with targets (conventional GP methods).
6.6.1 Conclusion
The ION and correlation coefficient for the non-optimised (using the mean value for each
inconsistent compound) model are 0.34 and 0.55, respectively; these increased in the op-
timised model to 0.41 and 0.64, respectively. This experiment shows that following the
application of the random sampling approach of the Monte Carlo simulation, results in a
measurably improved model. Therefore the Monte Carlo method provides a clear oppor-
tunity to optimise a dataset with inconsistent data points.
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Chapter 7
Hyper-parameter Optimisation Methods
In the previous chapters, it is shown that machine learning techniques, specifically Gaussian
Process (GP) methods have better prediction performance compared to the QSAR tradi-
tional models (Moss et al. (2009); Obrezanova et al. (2007); Burden (2001); Cortes-Ciriano
et al. (2015)). In this chapter, the problem of finding optimised hyper-parameters involved
in GP kernel functions is addressed. In particular, finding suitable hyper-parameters with
the small datasets used for this study is addressed. Ii is shown that the choice of hyper-
parameters can play an important role in obtaining good model. Matérn kernel is used as
the covariance function of the model as it shows promising results in my previous work. It
is also demonstrated that a §particular method for finding good hyper-parameters namely
smooth-box hyper-prior method finds good parameters with all the datasets. Therefore, this
method is recommended to be used with small datasets. This is one of the major findings
of my thesis.
7.1 Introduction
Obrezanova et al. (2007) show that the Gaussian Processes method is comparable to and
sometimes exceeds artificial neural networks in performance. There are hyper-parameters
such as length scale (l), signal variance s2f and noise variance s2n involved in the GP re-
gression.
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An important feature of the data used in this study is that the datasets are relatively
small (the sizes of the datasets vary between n=9 to n=85). The study performed by Steyer-
berg et al. (2000), investigates the logistic regression method with small datasets (61 small
containing on average 336 objects). To obtain the small subsets, the data (size=20512) was
split into a training and test part. The regression estimation methods in their study included
standard maximum likelihood, the use of linear linkage factor, penalised maximum likeli-
hood and the Lasso on univariable regression coefficient. The research indicates that using
shrinkage methods in full models including predefined predictors and external information
resulted in the best prediction performance in the small datasets. In addition, the work
done by Dreiseitl and Ohno-Machado (2002) investigates the logistic regression and arti-
ficial neural network models as predictive models. They show that the problem of lacking
data can be addressed by applying cross-validation or bootstrapping methods to make the
best possible use of the limited amount of data.
Several studies have investigated hyper-parameter optimisation, such as the work by
Bergstra et al. (2011) and Bergstra and Bengio (2012) on random search through hyper-
parameters space which is also used in my study. Bardenet and Kégl (2010) showed that
using Evolutionary Algorithms (EA) to optimise the hyper-parameters can outperform the
other methods. Similarly, MacKay (1997) demonstrated that the hyper-parameter optim-
isation landscape is a multi- modal. This suggests that a slower but more robust global
optimiser, such as an EA, may yield better results. Using a variety of EA methods in-
cluding the advanced ones such as CMA (Covariance Matrix Adaptation) and CMA-ES
(Covariance Matrix Adaptation Evolution Strategy) by Hansen and Ostermeier (2001) and
accelerating EA as in Büche et al. (2005) showed the usefulness of evolutionary methods
in optimisation specifically for GP hyper-parameters. In the hyper-prior technique, a prior
distribution is assigned to the hyper-parameters and the distribution is then modified to
improve the fit to the actual data.
In this chapter, the performances of different hyper-parameters optimisation strategies
in the GP are investigated. In addition to EA and the hyper-prior optimisation method,
the results of applying the Conjugate gradient (marginal likelihood maximisation (MLM)
techniques), manual grid search and random search (Bergstra and Bengio (2012)) through
the hyper-parameters space are discussed.
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7.2 Datasets
In this work, 11 small datasets are investigated. Thay are collated from different sources.
The datasets and their features specifications are shown in Chapter 3 with more details.
The number of data records in each dataset after refining are shown in Table 7.1. The
small size is due to the fact that gathering pharmaceutical data is difficult, time consuming,
and expensive. In these circumstances obtaining good predictions from small data sets is
very important.
Table 7.1: Number of data-points in each dataset. The first 5 datasets are related to the
same group of the data with the same number of features (5 chemical features which are
MW,SP, logP,HA and HD). ER is the enhanced ratio data with 6 features and the last
5 datasets are from Magnusson et al. (2004) with 6 features. All the datasets and their
features are introduced in Chapter 3 of this thesis.
Dataset Human C Human F Rat Mouse Pig ER
# Data points 21 84 26 46 14 71
# Used molecular features 5 5 5 5 5 5
Dataset Mag-set A Mag-set B Mag-set C Mag set-D Mag-set E -
# Data points 85 50 27 45 36 -
# Used molecular features 6 6 6 6 5 -
7.2.1 Experimental set up
7.2.1.1 Software
The software used for this study is Gaussian Process modelling for non-linear regression
(Rasmussen (2006b,c)) and the latest version of toolbox defined in Rasmussen and Nick-
isch (2015), is used for the hyper-prior optimisation method. The Genetic Algorithm (GA)
Matlab optimisation toolbox is used for Evolutionary Algorithm hyper-parameter optim-
isation.
7.2.1.2 Cross validation
A 5 fold cross-validation has been applied in this chapter’s experiments. Each time one
of the folds is considered as the test set and the rest are considered as the training set
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plus the validation set. The mentioned hyper-parameter optimisation methods are applied
to the training set and the prediction performances are gained for the validation set. The
best hyper-parameters are the ones minimise the average values of negative log likelihood
(NLL) over validation sets. Furthermore, the best set of hyper-parameters is used to predict
the permeability values of the test sets. Therefore, the results are the mean of 5 prediction
performance values together with their standard deviations.
7.2.1.3 Experimental Initialisations
In this section, all initialisations set up for the experiments are explained as the following:
• Grid search: To do the manual search through the hyper-parameters space, the
hyper-parameters ranges are considered in [ 10 3, 103] with 20 equal distance steps.
Using 5-fold cross validation, the model is trained with all the 8000 (20⇥20⇥20)
different sets of the hyper-parameters and obtained the predictions for the test sets.
The average values and their standard deviation among 5 folds are then reported.
Looking at the prediction performances, a finer search for better values of the hyper-
parameters is performed and the searching range is limited to [0.01 10] with 20 steps,
as no better results are obtained using the hyper-parameters out of this range. The
model is trained with the new hyper-parameters and the best performance are repor-
ted.
• Random search: For random search, 20 values for each hyper-parameters are ob-
tained randomly between the same range [0.01 10] which is also considered in the
grid search. Using a 5-fold cross validation, the model is then trained and the predic-
tions are obtained. Since, in each run of this experiment, the hyper-parameters are
selected randomly, this experiment is run for 5 times and the results are the average
of 5 mean and standard deviation values obtained from each 5-fold cross validation.
• Conjugate Gradient: The hyper-parameters were initialised to log(0.5). The num-
ber of function evaluations is set to 100.
• Hyper-prior methods:
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– Gaussian prior and Laplacian prior: The mean and variance parameters of
the Gaussian and Laplacian priors are set to constant values of 0.1 and 0.01
respectively. The mentioned values are obtained as the best prediction perform-
ances using cross validation in each of the datasets.
– Smooth-box prior: Based on the Equation 4.17 in Chapter 4, in these experi-
ments the a, b and h are set to 10 3, 10 and 2, respectively. Different values of
h are tried and 2 is the best value obtained for my datasets.
• Evolutionary Algorithm: In this research, heuristic fitness function is employed
with ratio=0.7 to accelerate convergence. Various ratio values (in a range from 0.1
to 1.2) are tried and it turns out, ratio=0.7 works better for the datasets used in this
study. In each of the 50 generations, there are 50 populations and the optimised
hyper-parameters are obtained in the last generation. Elite children is set to 4 and
the mutation function is uniform, means the children are randomly selected from a
uniform distribution within the range of hyper-parameters. Crossover fraction is 0.8,
meaning the rest of children in a population, are 4 Elite children and also reproduced
from mutation. The first generation’s population is initialised randomly, therefore,
similar to the random search, this experiment is also repeated for 5 times. Genetic
Algorithm toolbox in Matlab used for this experiment Houck et al. (1995).
7.3 Results and discussion
7.3.1 Results analysis
To see the effect of size of the dataset on the prediction performance, the datasets in the
Tables 7.2 and 7.3 are sorted based on the number of data points from the largest (Mag-
set A dataset) to the smallest (Pig dataset). The best and worst results for each dataset
in the tables are shown in blue and red, respectively. As it can be seen from the MSLL
results (Table 7.2), smooth box hyper-prior kernel works better than the other methods for
8 out of 11 datasets. In general, it shows a good performance for all-size datasets. In
addition ION results (Table 7.3) also confirms that hyper-prior smooth-box results in better
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prediction performances for majority of the datasets (6 out of 11 datasets). The results
show that this algorithm produces good results independently of the performance measure.
The inconsistency between the MSLL and ION results may be related to the small size of
the datasets, because more investigation shows that the predictive variance which is part of
MSLL (but not ION), could be so much variable in small datasets.
A notable thing from Table 7.3 is that using Evolutionary Algorithm (EA) to optimise
the hyper-parameters works well for the larger datasets (human F, Mag-set A and ER sets)
as they have the best performance among the other methods. However, as the size of
the datasets decreases, the performance of EA measured by ION also decreases as it can
be noted in Table 7.3. The worst ION performance predictions are obtained using the
EA method in the 3 smallest datasets (pig, human C and mouse datasets). We have also
initialised the population with the best hyper-parameters obtained from the grid search and
unfortunately it did not change the results noticeably.
Second thing to be noted in the results is that the grid search and random search hyper-
parameter optimisation methods have similar performance which confirms the results ob-
tained from the research by Bergstra and Bengio (2012). Interestingly, these two methods
are not the best methods to optimise the hyper-parameters. Most probably it is due to the
limitation of these methods in searching three hyper-parameter spaces withO(m3) which is
expensive and limited to the certain number of hyper-parameters (in our case 20 values for
each hyper-parameters which makes the 20⇥20⇥20=8000 times). It seems that, changing
a bit in the hyper-parameter values can lead to better results which is not always possible
with grid / random search.
As we can see from the obtained results, using the hyper-prior optimisation method
outperforms the Conjugate Gradient method. Figure 7.1 shows a comparison of these two
techniques prediction performances (MSLL results used for this purpose). From this figure
we can see that except from human C and pig datasets, for all the other datasets using
hyper-prior smooth-box, a better or same prediction performance was obtained compared
to conjugate gradient hyper-parameter selection method. A smaller standard deviation of
MSLL is obtained when hyper-prior method was applied.
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It it important to emphasise that the natures of the permeability measurements in data-
sets human C, B, mouse, rat and pig are different from the Magnusson datasets. So compar-
isons between performance of the models constructed from Kp and Jmax might be limited
especially from pharmaceutical point of view.
All the experiments have been performed with a windows system processor 3.6 GHz
and 8 GB Ram and the time each experiment took was short for all the methods and data-
sets. It took between 2 to 7 seconds to run the experiments for the Conjugate gradient
and all hyper-prior methods depending on the size of datasets. In addition the time taken
to run the Evolutionary algorithm was between 60 to 100 seconds for different datasets
and between 200 to 350 seconds for the grid/random search through the hyper-parameters
space. The hyper-parameter values ranges obtained for each of the methods on each dataset
show that almost all hyper-parameters are in the same range from 0.001 to 5 for the data-
sets human C, human F, mouse, rat, pig and ER datasets. Larger ranges from 5 to 15 are
obtained for signal variance s2f of Magnusson datasets (Mag- sets A to E).
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Figure 7.1: Comparing the MSLL performance using conjugate gradient and hyper-prior
smooth-box optimisation methods (lower MSLL values show better performance of the
models)
7.3.2 Data features analysis
To have a better visualisation on the features and their ranges in each dataset, the first 5
datasets with the same features (human C, human F, rat, mouse and pig sets) plus their log
Kp ranges are plotted in box-plot separately in Figure 7.2. Similarly, the same features
of the Magnusson datasets (Mag-sets A-E) and each dataset log Jmax ranges are plotted
together in Figure 7.3. Figure 7.4 shows all the features plus their target (ERQ) value
ranges in the ER dataset. From Tables 7.2 and 7.3, the best prediction performance among
the first 5 datasets is for Pig which has the smallest number of data points (size=14). From
the Figure 7.2, one can see that the Pig dataset covers a larger range of the target values
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compared to the other datasets. Comparing Mag-set B and Mag-set D in Figure 7.3 also
confirms the same relationship; as we can see with almost the same number of data points,
Mag-set B covers a larger target range and its prediction performance is so much better
than Mag-set D datasets. My hypothesis is that if the datasets that are used for training
the model, cover a large range of target values, one can expect to obtain good prediction
performance.
To investigate the effect of size and molecular feature ranges on the performance, an-
other examination is performed in the following section.
7.3.3 Effect of size and chemical feature ranges on predictions
This experiment explores the effect of training data size and molecular feature ranges on
prediction performances. In this investigation, Mag-set A is investigated as the largest
datasets. It also performs better than the other datasets (using the hyper-prior smooth-box
optimisation method). The aim of this experiment is observing the performance of the
model by reducing the size of the dataset, while the range of molecular features are kept
maximised.
To do this, in separate experiments the ranges of one important molecular feature (MW
or logKow) each time is kept as same as the Mag set-A (by keeping both minimum and
maximum values for that feature). Then four different sized subsets are generated. The
subsets sizes are varied from size=44 to size=9 based on the following steps:
• First experiment:
– I use Mag-set A data and the aim is to choose different size data by keeping the
MW range as maximum as possible. 4 different subsets are chosen randomly
(sizes are 44, 33, 17 and 9). So theMW are selected in all ranges fromminimum
to maximum values.
– The GP models are trained with the 4 datasets and the 5-fold cross validation
is used to measure the prediction performance of the models. The hyper-prior-
smoothbox optimisation method is used to set the best hyper-parameters of the
model.
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Table 7.4: ION and MSLL performance using 4 different size subsets from Mag-Set A,
MW ranges are maximum
Performance/Subsets Mag-set A Subset 1 Subset 2 Subset 3 Subset 4
Size 85 44 33 17 9
ION 0.93 0.92 0.91 0.88 0.89
MSLL -1.35 -1.20 -1.06 -0.88 -0.99
Table 7.5: ION and MSLL performance using 4 different size subsets from Mag-Set A,
logKow ranges are maximum
Performance/Subsets Mag-set A Subset 1 Subset 2 Subset 3 Subset 4
Size 85 44 33 17 9
ION 0.93 0.90 0.93 0.94 0.72
MSLL -1.35 -1.04 -1.1 -1.02 -0.98
• Second experiment:
– The same as first experiment, but this time by considering maximum value
ranges for logKow and 4 different size datasets (sized from 9 to 44) are ob-
tained and the experiments are performed on the datasets similar to the first
experiment.
The results are shown in Table 7.4 for the first experiment and Table 7.5 for the second
experiment. Interestingly, the results from Table 7.4 show that decreasing the dataset Mag-
Set A size, considering to keep the maximum range forMW do not affect the good perform-
ance of the model, especially in subsets 1 and 2 (with a slightly decrease in ION andMSLL
performances). In the subsets 3 and 4 with sizes 17 and 9, respectively, the performances
are more fallen (e.g. ION from 0.93 to 0.88 and 0.89 for subsets 3 and 4, respectively).
Similarly, the results in Table 7.5 confirm that reducing the dataset Mag-Set A size by
keeping the maximum range for logKow do not affect the good performance of the model
and it seems that there is even a small increase in the ION performance in the subset 3
(from 0.93 to 0.94). However, the model performance is declined with a larger proportion
in subset 4 (ION form 0.93 to 0.72). Further investigation shows that the major difference
between this subset and the subset 4 in the first experiment is the range of MW which is
larger in subset 4 of the first experiment (maximised MW range). This shows that range of
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the important features such as MWmay affect the model’s performance and they should be
as large as possible in training sets.
7.4 Conclusion
The main finding of this study is that using hyper-prior smooth-box method to optimise the
GPR hyper-parameters works good independently of the data and the performance measure
method. Therefore, this approach is recommended to be used in this field.
In addition, investigation in the datasets features reveal that the range of the target
values in the dataset can affect the model so that the larger the range of the target values in
a dataset, the better prediction performance is obtained for the unseen data.
It is also important to consider the effect of size of the datasets on the model prediction
performance. This study shows that decreasing the size of the datasets by keeping the
chemical features maximum ranges, does not highly affect the performance of the model. In
other words, to choose the training set for the model prediction, it is more important to pay
attention choosing the wide ranges for important chemical features rather than gathering
very large datasets which is difficult as discussed previously.
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Figure 7.2: Range of features and targets in the human C, human F, Mouse, Rat and Pig
datasets
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Figure 7.3: Range of features and targets in the Magnusson datasets
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Figure 7.4: Range of features and targets in the ER dataset
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Chapter 8
Conclusion and Future Work
This chapter discusses the major findings and contribution of all the work in this thesis. In
addition, it demonstrates the future work. It is worth mentioning that the presented work
is an interdisciplinary research between the Computer Science and Pharmacy. Bringing
these two domains together and performing research on both sides has been a challenging
experience.
8.1 Chapter summary
Chapter 2 of the thesis gives an overview of the skin structure and its functionalities. In
addition, it specifies that human and animal skins consist of three main layers called the
epidermis, the dermis and the subcutaneous layers from outside to inside. The outermost
part of the epidermis is called the stratum corneum which works as the main barrier for
the external chemicals to enter the skin (Williams (2003); Moss and Cronin (2002)). There
are a number of pathways for passing the chemicals through the skin. It also discusses
the importance of predicting the permeability of the chemicals through the skin in pharma-
ceutical and cosmetic industries. The permeability values are usually estimated based on
the physicochemical properties of the compounds applied to the skin and the experimental
conditions (e.g. temperature) under which the experiments have been performed in the
labs. The most important pharmaceutical QSAR/QSPR approaches used for this purpose
are explained and their performance are compared and evaluated (Flynn (1990); El Tayar
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et al. (1991); Potts and Guy (1992); Moss and Cronin (2002)). Most of these models define
a linear relationship between the permeability values and the chemical descriptors. The
first reason for this is that physical scientists do not usually use computational models to
obtain and evaluate the efficiency of non-linear methods and second, that linear equations
are so easy to be used. However, visualising the datasets reveals that there is not a lin-
ear relationship between the permeability factors and the chemical features. Consequently,
computational models and specifically machine learning algorithms are used and they out-
perform the QSAR/QSPR models which have been used in this domain (Sun et al. (2011);
Moss et al. (2009)).
In Chapter 3 all the datasets employed for the experiments in this thesis are illustrated.
These datasets consist of different sized human and animal datasets collated from various
sources (Prapopoulou (2012); Moss and Cronin (2002); Flynn (1990)). There are 8 numer-
ical features for each chemical including molecular descriptors and the temperature of the
skin/environment at the time of the experiment. In addition, categorical features including
the experimental conditions (nominal data) for each dataset are also explained.
In Chapter 4, all the computational methodologies applied to the datasets are explained.
It includes Gaussian Processes, SVM, linear regression methods, KNN for regression,
GNG clustering algorithm and performance measurement methods used in this thesis.
Chapter 5 explains the PCA visualisation method for both numerical and nominal data.
In this chapter using PCA, the first and second principal components of both numerical and
nominal features of dataset ‘human D’ are visualised and compared together. Three various
methods are used to plot the PCA plot for categorical data. The first one is a novel method
used by Wakelam et al. (2016), the second one uses Hamming distance Couto (2005) to
generate the kernel and the last one employs the MCA method to obtain the principal
components (Linting and van der Kooij (2012)). None of the PCA plots for nominal data
shows any clear relationship with numerical data PCA plot and it is most probably because
the number of categorical features are only limited to three.
Chapter 6 illustrates the major experiments (all the methods from Chapter 4) performed
for this research. The major findings are listed as the following:
• It starts with Gaussian Process as the major regression model in this thesis. The GP is
applied to the 6 human datasets using 5 and 7 numerical features. The results shows
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that employing 5 molecular features (MW, SP, logP, HA and HD) performed better
than 7 features in predicting the permeability rate of compounds through skin.
• In addition, using various covariance functions in GP with various parameters set-
tings, the results confirm that GP with Matérn covariance function, n = 3/2 outper-
forms the other methods in most of the human datasets.
• Comparing the GP prediction performances with the linear regression methods in
including the QSAR and SLN techniques and KNN as a non linear regression al-
gorithms illustrates that GP performs better than these methods in estimation the
target values. However, SVM technique shows comparable performance to the GP
and a mix of these two methods may be result in very good quality predictions (Shah
et al. (2016)).
• In the next experiment of Chapter 6 the models are trained with one of the human, rat
and mouse data and the targets are predicted for the other two datasets. The finding
is that training the model with mouse data to estimate the human data permeability
values, could result in better performance than training the model with rat data but it
still does not perform better than using human datasets.
• Furthermore, the effect of experimental conditions such as temperature and cell types
were examined. The results show that including temperature in the features improves
the performance specially if the dataset contains a large range of temperature values.
Additionally, the experiments show that the best predictive models are always ob-
tained when static diffusion cell data permeability is predicted compared to models
constructed from flow-through cell experiments.
• Continuing the visualisation of numerical and categorical data and to apply a novel
covariance function in GP, a kernel is constructed based on both numerical (using
Matérn covariance function) and categorical data (using Hamming distance by Couto
(2005)) and it could enhance the performance of the model slightly for a few datasets.
As discussed in Chapter 5, using more categorical features (more than three that used
for this experiment) may improve the performance of the model.
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• Some of the datasets contain more than one target value (e.g. permeability coef-
ficient) assigned to a single chemical and it is referred as data inconsistency. It is
normal in biological systems like skin to take multiple readings and it is common to
have variability on these measurements. This needs to be addressed in a way that
not only suits the model but also to consider the requirements of both parties in a
collaborative piece of work. Therefore, the final experiment in this Chapter, deals
with the inevitable inconsistent data in the biological systems. To do so, the Monte
Carlo method is applied to the complete human dataset and the prediction perform-
ance from the data states that this method can be used to generate a better training
set. It can be applied to the datasets with inconsistency before the regression model
is trained.
In Chapter 7 various hyper-parameter optmisation methods are applied to the 11 datasets to
obtain the best setting for GP hyper-parameters. The results show that hyper-prior smooth-
box method works well for most of the datasets independently of the data and the perform-
ance measure method and it can be used in further studies in this domain. The other finding
of this chapter is that to choose the training set for the model, we should pay attention to
use a dataset with a large ranges of important chemical features regardless the size of the
data.
8.2 Contribution to knowledge
This thesis can be used as a source that compares various computational methods to es-
timate the target values (e.g. permeability) of compounds with chemical and experimental
descriptors. It seeks to find the best technique to enhance the prediction performances with
small datasets. The significant contribution that this thesis made to knowledge are:
• To predict the permeability of the compounds and similar applications, GP method
using the hyper-prior smooth-box algorithm for selecting the suitable hyper-
parameters shows so much better performance than the traditional linear QSARmod-
els which are currently used in the pharmacy domain. GP models can be an outstand-
ing replacement for QSAR/QSPR methods.
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• In estimating the chemical’s permeability including the experimental conditions such
as temperature and diffusion cells as the model features shows to improve the effi-
ciency of the model and they should be considered when the models are trained for
regression purpose.
• The datasets that include inconsistent data, may cause problem in predicting the tar-
get values. This study confirms that Monte Carlo algorithm can generate better train-
ing set and can be used in similar studies with data inconsistency issue.
• Local non-linear models are obtained by clustering which can further improve the
predictions.
• A new model including both numerical and categorical features is investigated and
evaluated.
• Better experimental designs are obtained which allow the biological and physical
scientists to work with computational models to build better models that more accur-
ately reflect the aim of the models. This could result in producing better predictions
and a better mechanistic understanding of the biological process.
• The efficiency of ML methods to predict the unseen chemical’s permeation, show the
faults and flaws in previous models.
• This work can be extended to other biological and environmental systems.
8.3 Future work
The future work to be performed after this research include:
• Using more datasets (e.g. the eye, environmental and language datasets) to eval-
uate the performance of the hyper-prior smooth-box hyper-parameter optimisation
method.
• To include more categorical features and evaluate the performance of the model using
the novel kernel function (considering both numerical and categorical kernels) in the
GP.
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• Using Monte Carlo algorithm suggested in Chapter 6 on more datasets and evaluate
their prediction performances.
• In GNG clustering, more investigations may be performed on the compounds in each
new cluster to be used in future studies in this domain.
• To apply the other methods rather than Hamming distance technique to obtain the
categorical kernel. The other methods of combining the numerical and categorical
kernels apart from weighted additive such as weighted multiplying can be also used
to evaluate the model.
• The ML methods usually provide models as black box with ‘lack of an equation’.
Therefore, these techniques are mainly difficult to be employed by pharmaceutical
and biological scientists. This issue is to be addressed in the further studies in this
domain (e.g. by generating local effective polynomial equations/models).
• This study might have a very large impact on the pharmaceutical industry. However,
applying statistical and computational methods to perform the regression (predic-
tion), may be difficult to be employed by pharmacists and chemists. In order to
use the methods suggested in this thesis, designing and implementing a web applic-
ation for prediction purpose, could bring a large benefit in these domains. In the
application, various skin data such as human and non-human datasets along with
their known experimental conditions may be stored to be used to train the model to
predict the required chemical’s permeability through the skin. GP and SVM with op-
timised parameter settings can be employed to automatically predict the permeability
for non-computer scientists.
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Appendix A
Mathematical Concepts
A.1 Gaussian Process prior
In this section, I explain an example that helps to understand the GP prior. The below
Gaussian Process is given with its mean and covariance function (inspired by an example
in Rasmussen (2004) ):
f ⇠ GP(m,k), where m(x) = 0, and k(x,x0) = exp( 1
2
(x x0)2) (A.1)
Drawing samples of function f could be helpful to understand the process. To be able to
work with the finite number of quantities, the values of f should be obtained at a distinct fi-
nite number n of locations. Having the known x values, the vector of means and covariance
function values could be evaluated and a regular Gaussian distribution is obtained:
µi = m(xi) = 0, f or all xi, i= 1...,n (A.2)
Â
i, j
= k(xi,xj) = exp( 12(xi x j)
2), i,j=1,...,n (A.3)
µ and Â are chosen to show the Gaussian distribution. Consequently, a random vector
could be generated from this distribution and the function values f (x) for corresponding
x’s are defined by :
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f ⇠N (µ,S) (A.4)
As mentioned earlier, f is a generalisation of a probability Gaussian Process obtained
from stochastic process. In this case it denotes the finite-dimensional random variable
to functions. The plot of this distribution obtained by considering the values of f as the
function of x and could be seen in Chapter 4 Figure 4.2. Here we have only used random
functions and did not make inference about functions with given training examples. This
example showed us how to use GP to define distributions over functions. The GP obtained
here, can be used as a prior for Bayesian inference. As it is noted, the prior does not need
to know anything about the training data. It only specifies some properties of the functions
such as smoothness and the shape. The next step is to update this prior considering the
training data (Rasmussen (2004)).
A.2 Conjugate definition
If A is a positive definite matrix, two non-zero vectors u and v are conjugate (with respect
to A) if uTAv = 0, which means that conjugate vectors are orthogonal with respect to this
inner product (hu,viA). Being conjugate is a symmetric relation: if u is conjugate to v, then
v is conjugate to u.
If we have P = {p1, ..., pn} as a set of n mutually conjugate vectors, then we may
express the solution x0 of Ax= b on this basis:
x⇤ =
n
Â
i=1
aipi
Multiplying A and pTk (for k = i+1) to both sides of this equation we obtain:
Ax⇤ =
n
Â
i=1
aiApi
pTk Ax⇤ =
n
Â
i=1
aipTk Api
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pTk b=
n
Â
i=1
ai hpk,piiA
hpk,bi= ak hpk,piiA
Then we obtain each step a as:
ak =
hpk,bi
hpk,piiA
. (A.5)
As it explained, the directions pi are defined to be conjugate to each other. The next
search direction should also be built out of the current residue and all previous search
directions.
The following expression acquired from this assumption and also the conjugation con-
straint and Gram-Schmidt orthonormalisation (Shewchuk (1994)):
pk = rk 
n
Â
i=1
pTi Ark
pTi Api
pi (A.6)
Following this direction, the next optimal location is given by
xk+1 = xk+ak pk, (A.7)
ak =
pTk b
pTk Apk
=
pTk (rk 1+Axk 1)
pTk Apk
=
pTk rk 1
pTk Apk
, (A.8)
where holds the last equality, due to the reason that pk and xk 1 are conjugate.
To calculate the iterations, we may initialise the input vector x0 = 0 and p0 = r0 and
continue to calculate the directions and steps values in each iteration (Shewchuk (1994)).
A.3 Using nonlinear PCA (in SPSS)
Nonlinear principal component analysis (NLPCA) (Linting and van der Kooij (2012)) is a
method to explore the possible patterns and nonlinear relationships in the datasets. This
technique can be used for all kind of the data and it is particularly useful for categorical
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data. Similar to the PCA method, the main purpose of using NLPCA is to reduce the
dimensionality of the data to a smaller number of uncorrelated variables (Principal com-
ponents) which show the most information of the data. This is possible if a small number
of linear combinations can be found that illustrate as much as possible of the variance in the
data. Therefore, visualising the possible relational structures among the observed variables
becomes possible.
The difference between PCA and NLPCA is that PCA can only recognises the lin-
ear relationships; however, NLPCA can define both linear and nonlinear relationships by
quantifying nonlinearity related variables to be optimal for the PCA aim. To do so, PCA is
applied to variables with numerical features and multiple correspondence analysis (MCA)
to nominal variables. In order to perform this method, two models can be used called the
vector model and centroid model, respectively. The vector model shows a variable as a
straight line (vector), thus representing a variable as a direction in the component space,
whereas the centroid model depicts a variable as a set of category points (centroids).
For dimension reduction of nominal data, MCA, first transforms the nominal variables
to numeric values. To do this, optimal scaling technique is used. In this method, the
centroid model is useful when one wants to find the location of the separate categories
in the principal components space. Alternatively, one may be interested to examine the
variable as a whole. That is when the vector model can be employed. Details of this
method can be found in Linting and van der Kooij (2012). To perform this experiment,
CATPCA in SPSS is used and the PCA plot is shown in Figure A.1. It can be seen that,
similar to the other approaches, this technique does not also reveal a specific relationship
between the numerical and nominal data.
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Figure A.1: The PCA plot of human dataset D (nominal data) , using NLPCA in CATPCA
(Linting and van der Kooij (2012)).
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Appendix B
All Datasets
B.1 Human datasets
B.1.1 Dataset human A
B.1.1.1 Experimental conditions
• Skin Thickness: 0.2-0.5 mm
• Site: Abdominal Cell
• type: Flow through cells
• Temperature: 32ºC at the surface of the skin
• Time: of 24 – 48 h
• Vehicle: Water, physiological buffer, propylene glycol, ethanol, methanol
• Receptor Fluid: Normal saline
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B.1.1.2 Data
Name Mwt MR Mpt SP logP Ha HD logKp Temp membrane Site Cell type
caffeine 194.2 49.2834 238 32.83 0.16 4 0 -3.68 32 (skin) dermatomed 0.35 mm abdomen flow-through
caffeine 194.2 49.2834 238 32.83 0.16 4 0 -3.68 33 (skin) dermatomed 0.35 mm abdomen flow-through
cannabinol 310.46 95.4483 76 10.9 7.23 2 1 -3.82 32 (skin) dermatom. 0.2 mm abdomen flow-through
cannabidiol 314.46 97.9573 67 11.11 8.01 2 2 -3.62 32 (skin) dermatom. 0.2 mm abdomen flow-through
Diazinon 304.35 25.9609 88 14.98 3.86 2 1 -2.02 37 dermatomed 0.5 mm abdomen flow-through
DDT 354.49 85.3157 108.50 9.45 6.79 0 %0 -2.23 37 dermatomed 0.5 mm abdomen flow-through
mannitol 182.17 38.4036 138.97 18.63 -3.01 6 6 -4.60 32 isol.epidermis abdomen flow-through
N-N-Diethyl m-toluamide 191.28 58.9692 -45 10.70 2.26 1 0 -2.65 37 dermatomed 0.5 mm abdomen flow-through
testosterone 288.4 84.5453 155 10.66 3.27 2 1 -3.74 32 (skin) dermatom. 0.35 mm abdomen flow-through
testosterone 288.4 84.5453 155 10.66 3.27 2 1 -2.17 32 (skin) dermatom. 0.35 mm abdomen flow-through
D-Tetrahydrocannabinol (THC) 314.46 96.4453 304.5 9.75 7.6 2 1 -4.55 32 (skin) dermatom. 0.2 mm abdomen flow-through
B.1.2 Dataset human B
B.1.2.1 Experimental conditions
• Skin Thickness: All types of thickness
• Site: All types
• type: Flow through cells
• Temperature: 32ºC at the surface of the skin
• Time: of 24 – 72 h
• Vehicle: Water, physiological buffer, propylene glycol, ethanol, methanol
• Receptor Fluid: Normal saline
B.1.2.2 Data
Name Mwt MR Mpt SP logP Ha HD logKp Temp membrane Site Cell type
136
caffeine 194.2 49.2834 238 32.83 0.16 4 0 -3.68 32 (skin) dermatomed
0,35 mm
abdomen flow-through
caffeine 194.2 49.2834 238 32.83 0.16 4 0 -3.29 32 (skin) dermatomed
0,35 mm
abdomen flow-through
cannabinol 310.46 95.4483 76 10.9 7.23 2 1 -3.82 32 (skin) dermatom.
0,2 mm
abdomen flow-through
cannabidiol 314.46 97.9573 67 11.11 8.01 2 2 -3.62 32 (skin) dermatom.
0,2 mm
abdomen flow-through
Diazinon 304.35 25.9609 88 14.98 3.86 2 1 -2.02 37 dermatomed
0,5 mm
abdomen flow-through
DDT 354.49 85.3157 108.50 9.45 6.79 0 0 -2.23 37 dermatomed
0,5 mm
abdomen flow-through
N-N-
Diethyl
m-
toluamide
191.28 58.9692 -45 10.70 2.26 1 0 -2.65 37 dermatomed
0,5 mm
abdomen flow-through
testosterone 288.4 84.5453 155 10.66 3.27 2 1 -1.92 37 full-
thickness
abdomen flow-through
testosterone 288.4 84.5453 155 10.66 3.27 2 1 -1.93 37 full-
thickness
abdomen flow-through
testosterone 288.4 84.5453 155 10.66 3.27 2 1 -2.04 37 full-
thickness
abdomen flow-through
testosterone 288.4 84.5453 155 10.66 3.27 2 1 -1.92 37 full-
thickness
abdomen flow-through
testosterone 288.4 84.5453 155 10.66 3.27 2 1 -1.40 37 full-
thickness
abdomen flow-through
testosterone 288.4 84.5453 155 10.66 3.27 2 1 -3.74 32 (skin) dermatom.
0,35 mm
abdomen flow-through
testosterone 288.4 84.5453 155 10.66 3.27 2 1 -2.17 32 (skin) dermatom.
0,35 mm
abdomen flow-through
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D-
Tetrahydrocannabinol
(THC)
314.46 96.4453 304.5 9.75 7.6 2 1 -4.55 32 (skin) dermatom.
0,2 mm
abdomen flow-through
isosorbide
dinitrate
(ISDN)
236.14 0 70 10.36 0.76 4 0 -2.35 37 SCE abdomen flow-through
nicorandil 211.18 0 92.5 14.40 0.43 3 1 -4.30 37 SCE abdomen flow-through
Bisphenol
A
diglycidyl
ether
(BADGE)
340.8 95.2347 10 10.38 3.84 4 0 -6.32 32(skin) dermatomed
skin
breast flow-through
chlorpyrifos 350.59 0 42 10.10 4.66 1 0 -3.96 32(skin) full-
thickness
breast flow-through
o-cresyl
glycidyl
ether
(oCGE)
164.2 46.3071 30.25 10.38 2.16 2 0 -4.03 32 (skin) dermatommed breast flow-through
dodecyl
glycidyl
ether
(C12GE)
242.2 72.4384 58 8.41 5.01 2 0 -5.48 32 (skin) dermatomed
skin
breast flow-through
1,6-
hexanediol
diglycidyl
ether
(HDDGE)
230.2 60.2566 84.83 9.36 0.84 4 0 -3.87 32(skin) dermatomed
skin
breast flow-through
methiocarb 225.31 63.7027 119 10.92 2.87 1 1 -2.96 32 (skin) dermatom.
0,6-0,9 mm
breast flow-through
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pirimicarb 238.29 66.9037 254.6 11.05 1.4 4 0 -2.57 32 (skin) dermatom.
0,6-0,9 mm
breast flow-through
prochloraz 376.7 91.2691 48 10.69 4.13 3 0 -3.15 32 (skin) dermatom.
0,6-0,9 mm
breast flow-through
benzoic
acid
122.1 32.8164 122.4 11.94 1.87 1 1 -2.88 37 dermatomed
0,6 mm
not given flow-through
boric acid 61.83 0 171 44.06 -0.22 3 3 -3.54 32(skin) dermatomed
0,5 mm
thigh flow-through
boric acid 61.83 0 171 44.06 -0.22 3 3 -5.85 32(skin) dermatomed
0,5 mm
thigh flow-through
boric acid 61.83 0 171 44.06 -0.22 3 3 -3.92 32(skin) dermatomed
0,5 mm
thigh flow-through
boric acid 61.83 0 171 44.06 -0.22 3 3 -3.30 32(skin) dermatomed
0,5 mm
thigh flow-through
coumarin 146.15 41.5486 70.6 11.91 1.51 1 0 -3.42 32 (skin) full-
thickness
breast flow-through
coumarin 146.15 41.5486 70.6 11.91 1.51 1 0 -3.14 32 (skin) full-
thickness
breast flow-through
glyphosate 169.10 0 230 12.73 -4.47 3 4 -3.34 37 dermatom.
1mm
not given flow-through
malathion 330.36 0 2.85 10.61 2.29 2 0 -0.69 37 dermat.
1mm
not given flow-through
methyl-4-
hydroxy
benzoate
152.14 39.2796 131 12.50 2 2 1 -4.60 37 dermatom.
0,45 mm
dorsal flow-through
methyl-4-
hydroxy
benzoate
152.14 39.2796 131 12.50 2 2 1 -3.49 37 dermatom.
0,45 mm
dorsal flow-through
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methyl-4-
hydroxy
benzoate
152.14 39.2796 131 12.50 2 2 1 -3.54 37 dermatom.
0,45 mm
dorsal flow-through
methyl-4-
hydroxy
benzoate
152.14 39.2796 131 12.50 2 2 1 -3.27 37 dermatom.
0,45 mm
dorsal flow-through
methyl-4-
hydroxy
benzoate
152.14 39.2796 131 12.50 2 2 1 -2.53 37 dermatom.
0,45 mm
dorsal flow-through
methyl-4-
hydroxy
benzoate
152.14 39.2796 131 12.50 2 2 1 -2.38 37 dermatom.
0,45 mm
dorsal flow-through
methyl-4-
hydroxy
benzoate
152.14 39.2796 131 12.50 2 2 1 -2.32 37 dermatom.
0,32 mm
dorsal flow-through
theophylline 180.17 44.3867 273 14.05 -0.39 4 1 -3.36 37 dermatomed
0,2 mm
dorsal flow-through
B.1.3 Dataset human C
B.1.3.1 Experimental conditions
• Skin Thickness: All types of thickness
• Site: All types
• Cell type: static
• Temperature: 32ºC at the surface of the skin
• Time: of 24 – 72 h
• Vehicle: Water, physiological buffer, propylene glycol, ethanol, methanol
• Receptor Fluid: Normal saline
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B.1.3.2 Data
Name Mwt MR Mpt SP logP Ha HD logKp Temp membrane Site Cell type
benzoic
acid
122.1 32.8164 122.4 11.94 1.87 1 1 -1.60 37 full-
thickness
abdomen static
caffeine 194.2 49.2834 238 32.83 0.16 4 0 -3.59 37 is.epidermis upper leg static
codeine 299.4 84.6037 155 12.09 1.28 4 1 -4.31 37 isol.epidermis abdomen static
coumarin 146.15 41.5486 70.6 11.91 1.51 1 0 -2.04 37 full-
thickness
abdomen static
coumarin 146.15 41.5486 70.6 11.91 1.51 1 0 -1.90 37 full-
thickness
scalp static
dichlofenac 296.16 75.4614 337.5 11.13 4.02 2 2 -3.00 37 full-
thickness
abdomen static
doxycycline
HCL
444.44 113.7208 866 16.55 -1.36 9 6 -5.32 37 full-
thickness
not given static
doxycycline
HCL
444.44 113.7208 866 16.55 -1.36 9 6 -3.68 37 full-
thickness
not given static
doxycycline
HCL
444.44 113.7208 866 16.55 -1.36 9 6 -3.58 37 full-
thickness
not given static
doxycycline
HCL
444.44 113.7208 866 16.55 -1.36 9 6 -2.6 37 epidermis not given static
doxycycline
HCL
444.44 113.7208 866 16.55 -1.36 9 6 -2.6 37 epidermis not given static
etorphine 411.55 116.2256 215 11.76 3.02 5 2 -2.44 37 full-
thickness
abdominal static
griseofulvin 352.77 87.9616 220 10.44 1.92 6 0 -2.89 37 full-
thickness
abdomen static
griseofulvin 352.77 87.9616 220 10.44 1.92 6 0 -2.71 37 full-
thickness
abdomen static
hydromorphone 285.34 78.0905 266 10.96 1.6 4 1 -4.82 37 isol.epidermis abdomen static
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ibuprofen 206.3 0 76 10.21 3.97 1 1 -1.44 37 full-
thickness
abdomen static
lindane 290.83 54.081 112.5 8.54 4.26 0 0 -5.23 32 (skin) dermat.
0,23 mm
breast/abdomen static
methyl
nicotinate
137.14 35.4286 42.5 11.80 0.64 2 0 -2.41 37 full-
thickness
abdomen static
methyl
parathion
263.21 2.75 35.5 10.45 2.75 1 0 -4.87 32(skin) full-
thickness
abdomen static
morphine 285.3 79.8346 255 13.68 0.72 4 2 -5.03 37 isol.epidermis abdomen static
N-N-
Diethyl
m-
toluamide
191.28 58.9692 -45 10.70 2.26 1 0 -3.24 37 full-
thickness
not given static
N-N-
Diethyl
m-
toluamide
191.28 58.9692 -45 10.70 2.26 1 0 -3.22 37 full-
thickness
not given static
N-N-
Diethyl
m-
toluamide
191.28 58.9692 -45 10.70 2.26 1 0 -4.00 37 full-
thickness
not given static
N-N-
Diethyl
m-
toluamide
191.28 58.9692 -45 10.70 2.26 1 0 -4.20 37 full-
thickness
not given static
N-N-
Diethyl
m-
toluamide
191.28 58.9692 -45 10.70 2.26 1 0 -3.92 37 full-
thickness
not given static
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N-N-
Diethyl
m-
toluamide
191.28 58.9692 -45 10.70 2.26 1 0 -3.98 37 full-
thickness
not given static
N-N-
Diethyl
m-
toluamide
191.28 58.9692 -45 10.70 2.26 1 0 -2.92 37 full-
thickness
not given static
N-N-
Diethyl
m-
toluamide
191.28 58.9692 -45 10.70 2.26 1 0 -3.40 37 full-
thickness
not given static
N-N-
Diethyl
m-
toluamide
191.28 58.9692 -45 10.70 2.26 1 0 -4.80 37 full-
thickness
not given static
naproxene 230.3 64.8535 153 11.42 3.1 2 1 -2.54 37 full-
thickness
abdomen static
nicorandil 211.18 0 92.5 14.40 0.43 3 1 -3.58 37 full-
thickness
breast static
nicotine 162.3 49.6542 -7.9 11.25 1 2 0 -1.99 32 (skin) dermatom.
0,408 mm
abdomen/breast static
nicotine 162.3 49.6542 -7.9 11.25 1 2 0 -2.48 37 full-
thickness
abdomen static
propoxur 209.25 56.3432 87 10.31 1.9 2 1 -4.54 37 full-
thickness
abdomen static
propoxur 209.25 56.3432 87 10.31 1.9 2 1 -1.39 37 full-
thickness
abdomen static
salicylic
acid
138.1 34.5105 158 14.39 2.24 2 2 -1.89 32 (skin) dermatom.
0,408 mm
abdomen/breast static
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salicylic
acid
138.1 34.5105 158 14.39 2.24 2 2 -1.86 37 full-
thickness
abdomen static
testosterone 288.4 84.5453 155 10.66 3.27 2 1 -2.30 32 (skin) dermatom.
0,408 mm
abdomen/breast static
B.1.4 Dataset human D
B.1.4.1 Experimental conditions
• Skin Thickness: All types
• Site: All types
• Cell type: Flow through/Static
• Temperature: 37ºC
• Time: Not specified
• Vehicle: Any
• Receptor Fluid: Any
B.1.4.2 Data
Name Mwt MR Mpt SP logP Ha HD logKp Temp membrane Site Cell type
2-
ethoxyethanol
90 24.0528 -90 10.33 -0.42 2 1 -3.05 37 full-
thickness
abdomen flow-through
2-
phenoxyethanol
138.17 38.8135 14 11.49 1.1 2 1 -2.87 37 dermat.0,33 breast/abdomen/legflow-through
2-
phenylethanol
122.2 37.6285 -27 11.38 1.57 1 1 -1.51 37 epidermis abdomen static
2,4
dimethy-
lamine
266.13 0 86 9.52 0.84 3 2 -3.02 37 dermatom.0,3
mm
abdomen flow-through
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2,4
dimethy-
lamine
266.13 0 86 9.52 0.84 3 2 -3.09 37 dermatom.0,3
mm
abdomen flow-through
4-n-
butylaniline
149.24 49.6026 -14 9.51 3.1 1 1 -0.39 37 epidermis abdomen static
4-
phenylbutanol
150 46.8305 16.20 10.8 2.55 1 1 -1.06 37 epidermis abdomen static
5-
Fluorouracil
130.01 26.1222 281 13.46 -0.81 3 2 -3.22 37 epidermis abdomen static
Aniline 93.1 30.7584 -6.2 10.83 1.08 1 1 -1.21 37 epidermis abdomen static
b-estradiol 272.4 79.6175 173 11.9 3.94 2 2 -2.39 37 isol.epidermis various static
benzoic
acid
122.1 32.8164 122.4 11.94 1.87 1 1 -1.60 37 full-
thickness
abdomen static
benzoic
acid
122.1 32.8164 122.4 11.94 1.87 1 1 -2.88 37 dermatomed
0,6 mm
not given flow-through
benzyl
nicotinate
213.24 60.0412 24 11.55 2.35 2 0 -1.80 37 isol.epidermis abdomen/breast static
benzyl
nicotinate
213.24 60.0412 24.00 11.55 2.35 2 0 -4.69 37 isol.epidermis static
butyl
paraben
194.23 53.1528 68.5 11.45 3.47 2 1 -1 37 epidermis abdomen static
caffeine 194.2 49.2834 238 32.83 0.16 4 0 -3.59 37 is.epidermis upper leg static
codeine 299.4 84.6037 155 12.09 1.28 4 1 -4.31 37 isol.epidermis abdomen static
coumarin 146.15 41.5486 70.6 11.91 1.51 1 0 -2.04 37 full-
thickness
abdomen static
coumarin 146.15 41.5486 70.6 11.91 1.51 1 0 -1.9 37 full-
thickness
scalp static
DDT 354.49 85.3157 108.5 9.45 6.79 0 0 -2.23 37 dermatomed
0,5 mm
abdomen flow-through
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Diazinon 304.35 25.9609 88 14.98 3.86 2 1 -2.02 37 dermatomed
0,5 mm
abdomen flow-through
dichlofenac 296.16 75.4614 337.5 11.13 4.02 2 2 -3 37 full-
thickness
abdomen static
dimethylformamide73.1 19.6669 -61 10.63 -0.93 1 0 -2.02 37 full-
thickness
abdomen flow-through
doxycycline
HCL
444.44 113.7208 866 16.55 -1.36 9 6 -5.32 37 full-
thickness
not given static
doxycycline
HCL
444.44 113.7208 866 16.55 -1.36 9 6 -3.68 37 full-
thickness
not given static
doxycycline
HCL
444.44 113.7208 866 16.55 -1.36 9 6 -3.58 37 full-
thickness
not given static
doxycycline
HCL
444.44 113.7208 866 16.55 -1.36 9 6 -2.6 37 epidermis not given static
doxycycline
HCL
444.44 113.7208 866 16.55 -1.36 9 6 -2.6 37 epidermis not given static
ethylaniline 121.2 40.9998 -64 9.73 2.11 1 1 -0.54 37 epidermis abdomen static
etodolac 287.26 81.1565 146.5 10.86 3.93 3 2 -2.13 37 full-
thickness
abdomen static
etorphine 411.55 116.2256 215 11.76 3.02 5 2 -2.44 37 full-
thickness
abdominal static
famotidine 337.43 0 163.5 16.08 -0.64 5 4 -4.79 37 full-
thickness
abdomen franz
fentanyl 336.50 0.00 84 10.3 4.05 2 0 -2.25 37 isol.epidermis abdomen static
glyphosate 169.1 0 230 12.73 -4.47 3 4 -3.34 37 dermatom.
1mm
not given flow-through
griseofulvin 352.77 87.9616 220 10.44 1.92 6 0 -2.89 37 full-
thickness
abdomen static
griseofulvin 352.77 87.9616 220 10.44 1.92 6 0 -2.71 37 full-
thickness
abdomen static
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hydrocortisone 362.5 97.6308 220 12.75 1.61 5 3 -3.8 37 full-
thickness
abdomen flow-through
hydrocortisone 362.5 97.6308 220 12.75 1.61 5 3 -4.12 37 full-
thickness
abdomen flow-through
hydrocortisone 362.5 97.6308 220 12.75 1.61 5 3 -4.02 37 full-
thickness
abdomen flow-through
hydromorphone 285.34 78.0905 266 10.96 1.6 4 1 -4.82 37 isol.epidermis abdomen static
ibuprofen 206.3 0 76.00 10.21 3.97 1 1 -1.44 37 full-
thickness
abdomen static
isosorbide
dinitrate
236.14 0 70 10.36 0.76 4 0 -2.35 37 SCE abdomen flow-through
ITF 296 238.00 0 55.5 12.91 1.85 3 0 -2.45 37 SCE abdomen flow-through
ketoprofen 254.29 0 94 11.75 3.12 2 1 -3.21 37 full-
thickness
abdomen static
lidocaine 234.34 72.1476 67 8.78 1.66 2 1 -3.46 37 dermat.
0,15 mm
leg flow-through
lidocaine 234.34 72.1476 67 8.78 1.66 2 1 -3.41 37 dermat.
0,15 mm
leg flow-through
lidocaine 234.34 72.1476 67 8.78 1.66 2 1 -1.97 37 dermat.
0,15 mm
leg flow-through
linoleic acid 289.45 88.5188 -5 9.05 7.51 1 1 -4.97 37 full-
thickness
abdomen static
malathion 330.36 0 2.85 10.61 2.29 2 0 -0.69 37 dermat.
1mm
not given flow-through
meperidine 247.4 72.4823 270 9.82 3.03 2 0 -2.43 37 isol.epidermis abdomen static
methotrexate 454.45 0 195 15.05 -1.28 10 5 -3.50 37 full-
thickness
abdomen static
methotrexate 454.45 0 195 15.05 -1.28 10 5 -3.95 37 full-
thickness
abdomen static
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methotrexate 454.45 0 195 15.05 -1.28 10 5 -3.25 37 full-
thickness
abdomen static
methotrexate 454.45 0 195 15.05 -1.28 10 5 -2.95 37 full-
thickness
abdomen static
methotrexate 454.45 0 195 15.05 -1.28 10 5 -3.28 37 full-
thickness
abdomen static
methyl
nicotinate
137.14 35.4286 42.5 11.80 0.64 2 0 -2.41 37 full-
thickness
abdomen static
methyl
nicotinate
137.14 35.4286 42.5 11.80 0.64 2 0 -2.51 37 isol.epidermis abdomen/breast static
methyl
nicotinate
137.14 35.4286 42.5 11.80 0.64 2 0 -2.47 37 isol.epidermis abdomen/breast static
methyl
paraben
152.15 39.2796 131 12.50 2 2 1 -1.67 37 epidermis abdomen static
methyl-4-
hydroxy
benzoate
152.14 39.2796 131 12.50 2 2 1 -4.6 37 dermatom.
0,45 mm
dorsal flow-through
methyl-4-
hydroxy
benzoate
152.14 39.2796 131 12.50 2 2 1 -3.49 37 dermatom.
0,45 mm
dorsal flow-through
methyl-4-
hydroxy
benzoate
152.14 39.2796 131 12.50 2 2 1 -3.54 37 dermatom.
0,45 mm
dorsal flow-through
methyl-4-
hydroxy
benzoate
152.14 39.2796 131 12.50 2 2 1 -3.27 37 dermatom.
0,45 mm
dorsal flow-through
methyl-4-
hydroxy
benzoate
152.14 39.2796 131 12.50 2 2 1 -2.53 37 dermatom.
0,45 mm
dorsal flow-through
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methyl-4-
hydroxy
benzoate
152.14 39.2796 131 12.50 2 2 1 -2.38 37 dermatom.
0,45 mm
dorsal flow-through
methyl-4-
hydroxy
benzoate
152.14 39.2796 131 12.5 2 2 1 -2.32 37 dermatom.
0,32 mm
dorsal flow-through
morphine 285.3 79.8346 255 13.68 0.72 4 2 -5.03 37 isol.epidermis abdomen static
N-N-
Diethyl
m-
toluamide
191.28 58.9692 -45 10.70 2.26 1 0 -2.65 37 dermatomed
0,5 mm
abdomen flow-through
N-N-
Diethyl
m-
toluamide
191.28 58.9692 -45 10.70 2.26 1 0 -3.24 37 full-
thickness
not given static
N-N-
Diethyl
m-
toluamide
191.28 58.9692 -45 10.70 2.26 1 0 -3.22 37 full-
thickness
not given static
N-N-
Diethyl
m-
toluamide
191.28 58.9692 -45 10.70 2.26 1 0 -4.00 37 full-
thickness
not given static
N-N-
Diethyl
m-
toluamide
191.28 58.9692 -45 10.70 2.26 1 0 -4.20 37 full-
thickness
not given static
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N-N-
Diethyl
m-
toluamide
191.28 58.9692 -45 10.70 2.26 1 0 -3.92 37 full-
thickness
not given static
N-N-
Diethyl
m-
toluamide
191.28 58.9692 -45 10.70 2.26 1 0 -3.98 37 full-
thickness
not given static
N-N-
Diethyl
m-
toluamide
191.28 58.9692 -45 10.70 2.26 1 0 -2.92 37 full-
thickness
not given static
N-N-
Diethyl
m-
toluamide
191.28 58.9692 -45 10.70 2.26 1 0 -3.40 37 full-
thickness
not given static
N-N-
Diethyl
m-
toluamide
191.28 58.9692 -45 10.70 2.26 1 0 -4.80 37 full-
thickness
not given static
naproxene 230.3 64.8535 153 11.42 3.1 2 1 -2.54 37 full-
thickness
abdomen static
nicorandil 211.18 0 92.5 14.40 0.43 3 1 -3.58 37 full-
thickness
breast static
nicorandil 211.18 0 92.5 14.40 0.43 3 1 -4.30 37 SCE abdomen flow-through
nicotine 162.3 49.6542 -7.9 11.25 1 2 0 -2.48 37 full-
thickness
abdomen static
nicotinic
acid
123.11 30.6595 236.6 13.23 0.69 2 1 -4.62 37 isol.epidermis abdomen/breast static
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nimesulide 308.31 0 143 15.25 2.22 3 2 -2.995 37 full-
thickness
abdomen static
nizatidine 331.45 0 130 12.36 -0.43 5 2 -4.43 37 full-
thickness
abdomen static
parathion 291.26 0 6.1 10.76 3.73 1 0 -3.72 37 dermatom.
0,5 mm
back flow-through
propoxur 209.25 56.3432 87 10.31 1.9 2 1 -4.54 37 full-
thickness
abdomen static
propoxur 209.25 56.3432 87 10.31 1.9 2 1 -1.39 37 full-
thickness
abdomen static
ranitidine 314.1 0 133 11.41 0.29 5 2 -4.05 37 full-
thickness
abdomen static
salicylic
acid
138.1 34.5105 158 14.39 2.24 2 2 -2.88 37 dermatom.
0,5 mm
breast static
salicylic
acid
138.1 34.5105 158 14.39 2.24 2 2 -2.88 37 dermat. 0,5
mm
abdomen static
salicylic
acid
138.1 34.5105 158 14.39 2.24 2 2 -1.86 37 full-
thickness
abdomen static
sufentanil 386.6 113.3917 97 10.47 3.62 3 0 -1.92 37 isol.epidermis abdomen static
testosterone 288.4 84.5453 155 10.66 3.27 2 1 -1.92 37 full-
thickness
abdomen flow-through
testosterone 288.4 84.5453 155 10.66 3.27 2 1 -1.93 37 full-
thickness
abdomen flow-through
testosterone 288.4 84.5453 155 10.66 3.27 2 1 -2.04 37 full-
thickness
abdomen flow-through
testosterone 288.4 84.5453 155 10.66 3.27 2 1 -1.92 37 full-
thickness
abdomen flow-through
testosterone 288.4 84.5453 155 10.66 3.27 2 1 -1.4 37 full-
thickness
abdomen flow-through
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theophylline 180.17 44.3867 273 14.05 -0.39 4 1 -3.36 37 dermatomed
0,2 mm
dorsal flow-through
triclosan 289.55 68.4073 265.6 10.02 2.47 2 1 -4.47 37 isol.epidermis breast and
abdomen
static
B.1.5 Dataset human E
B.1.5.1 Experimental conditions
• Skin Thickness: All types
• Site: All types
• Cell type: Flow through
• Temperature: Not specified
• Time: Not specified
• Vehicle: Any
• Receptor Fluid: Any
B.1.5.2 Data
Name Mwt MR Mpt SP logP Ha HD logKp Temp membrane Site Cell type
atenolol 266.3 73.50 147 12.49 -0.03 4 3 -4.30 32 dermatomed
1,2 mm
abdominal flow-
through
benzoic
acid
122.1 32.82 122.4 11.94 1.87 1 1 -2.88 37 dermatomed
0,6 mm
not given flow-
through
bisoprolol 325.5 92.15 100 10.01 1.84 5 2 -3.57 32 dermatom.
1,2 mm
abdominal flow-
through
Bisphenol
A dig
340.8 95.23 10 10.38 3.84 4 0 -6.32 32 (skin) dermatomed
skin
breast flow-
through
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boric acid 61.83 0.00 171 44.06 -0.22 3 3 -3.54 32 (skin) dermatomed
0,5 mm
thigh flow-
through
boric acid 61.83 0.00 171 44.06 -0.22 3 3 -5.85 32 (skin) dermatomed
0,5 mm
thigh flow-
through
boric acid 61.83 0.00 171 44.06 -0.22 3 3 -3.92 32 (skin) dermatomed
0,5 mm
thigh flow-
through
boric acid 61.83 0.00 171 44.06 -0.22 3 3 -3.30 32 (skin) dermatomed
0,5 mm
thigh flow-
through
caffeine 194.2 49.28 238 32.83 0.16 4 0 -3.14 32 (skin) dermatomed
0,35 mm
abdomen flow-
through
caffeine 194.2 49.28 238 32.83 0.16 4 0 -7.39 32 (skin) dermatomed
0,35 mm
abdomen flow-
through
caffeine 194.2 49.28 238 32.83 0.16 4 0 -3.68 32 (skin) dermatomed
0,35 mm
abdomen flow-
through
caffeine 194.2 49.28 238 32.83 0.16 4 0 -3.29 32 (skin) dermatomed
0,35 mm
abdomen flow-
through
cannabinol 310.46 95.45 76 10.9 7.23 2 1 -3.82 32 (skin) dermatom.
0,2 mm
abdomen flow-
through
cannabidiol 314.46 97.96 67 11.11 8.01 2 2 -3.62 32 (skin) dermatom.
0,2 mm
abdomen flow-
through
celiprolol 379.5 106.41 111 11.51 1.93 5 3 -3.23 32 dermatom.
1,2 mm
abdominal flow-
through
chlorpyrifos 350.59 0.00 42 10.10 4.66 1 0 -3.60 32 (skin) full-
thickness
breast flow-
through
chlorpyrifos 350.59 0.00 42 10.10 4.66 1 0 -3.96 32 (skin) full-
thickness
breast flow-
through
coumarin 146.15 41.55 70.6 11.91 1.51 1 0 -3.42 32 (skin) full-
thickness
breast flow-
through
coumarin 146.15 41.55 70.6 11.91 1.51 1 0 -3.14 32 (skin) full-
thickness
breast flow-
through
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o-cresyl
glycidyl
164.2 46.31 30.25 10.38 2.16 2 0 -4.03 32 (skin) dermatommed breast flow-
through
Diazinon 304.35 25.96 88 14.98 3.86 2 1 -2.02 37 dermatomed
0,5 mm
abdomen flow-
through
DDT 354.49 85.32 108.50 9.45 6.79 0 0 -2.23 37 dermatomed
0,5 mm
abdomen flow-
through
dimethylformamide73.1 19.67 -61 10.63 -0.93 1 0 -2.02 37 full-
thickness
abdomen flow-
through
2,4
dimethy-
lamine
266.13 0.00 86 9.52 0.84 3 2 -3.02 37 dermatom.0,3
mm
abdomen flow-
through
2,4
dimethy-
lamine
266.13 0.00 86 9.52 0.84 3 2 -3.09 37 dermatom.0,3
mm
abdomen flow-
through
dodecyl
glycidyl
242.2 72.44 58 8.41 5.01 2 0 -5.48 32 (skin) dermatomed
skin
breast flow-
through
2-
ethoxyethanol
90.12 24.05 -90 10.33 -0.42 2 1 -3.05 37 full-
thickness
abdomen flow-
through
2-
ethoxyethanol
90.12 24.05 -90 10.33 -0.42 2 1 -4.23 32 dermat.
0,28 mm
breast flow-
through
2-
ethoxyethanol
90.12 24.05 -90 10.33 -0.42 2 1 -4.13 32 dermat.
0,28 mm
breast flow-
through
flufenamic
acid
281.2 0.00 133 10.96 4.88 5 2 -3.28 32 sc 0,012
mm
abdomen flow-
through
flufenamic
acid
281.2 0.00 133 10.96 4.88 5 2 -3.27 32 sc 0,012
mm
abdomen flow-
through
flufenamic
acid
281.2 0.00 133 10.96 4.88 5 2 -3.41 32 sc 0,012
mm
abdomen flow-
through
flufenamic
acid
281.2 0.00 133 10.96 4.88 5 2 -3.26 32 dermatom.
0,075 mm
abdomen flow-
through
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flufenamic
acid
281.2 0.00 133 10.96 4.88 5 2 -3.29 32 dermatom.
0,075 mm
abdomen flow-
through
flufenamic
acid
281.2 0.00 133 10.96 4.88 5 2 -3.42 32 dermatom.
0,075 mm
abdomen flow-
through
flufenamic
acid
281.2 0.00 133 10.96 4.88 5 2 -4.40 32 full-
thickness
abdomen flow-
through
flufenamic
acid
281.2 0.00 133 10.96 4.88 5 2 -4.03 32 full-
thickness
abdomen flow-
through
flufenamic
acid
281.2 0.00 133 10.96 4.88 5 2 -4.43 32 full-
thickness
abdomen flow-
through
5-
Fluorouracil
130.01 26.12 281 13.46 -0.81 3 2 -4.78 31 dermatomed
0,42 mm
abdomen flow-
through
glyphosate 169.10 0.00 230 12.73 -4.47 3 4 -3.34 37 dermatom.
1mm
not given flow-
through
1,6-
hexanediol
dig
230.2 60.26 84.83 9.36 0.84 4 0 -3.87 32 (skin) dermatomed
skin
breast flow-
through
hydrocortisone 362.5 97.63 220 12.75 1.61 5 3 -3.80 37 full-
thickness
abdomen flow-
through
hydrocortisone 362.5 97.63 220 12.75 1.61 5 3 -4.12 37 full-
thickness
abdomen flow-
through
hydrocortisone 362.5 97.63 220 12.75 1.61 5 3 -4.02 37 full-
thickness
abdomen flow-
through
ITF 296 238 0.00 55.5 12.91 1.61 3 0 -2.45 37 SCE abdomen flow-
through
isosorbide
dinitrate
236.14 0.00 70 10.36 0.76 4 0 -2.35 37 SCE abdomen flow-
through
lidocaine 234.34 72.15 67 8.78 1.66 2 1 -3.46 37 dermat.
0,15 mm
leg flow-
through
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lidocaine 234.34 72.15 67 8.78 1.66 2 1 -3.41 37 dermat.
0,15 mm
leg flow-
through
lidocaine 234.34 72.15 67 8.78 1.66 2 1 -1.97 37 dermat.
0,15 mm
leg flow-
through
malathion 330.36 0.00 2.85 10.61 2.29 2 0 -0.69 37 dermat.
1mm
not given flow-
through
mannitol 182.17 38.40 138.97 18.63 -3.01 6 6 -4.60 32 isol.epidermis abdomen flow-
through
mannitol 182.17 38.40 138.97 18.63 -3.01 6 6 -4.60 not given dermat.0,13
mm
abdomen flow-
through
methiocarb 225.31 63.70 119 10.92 2.87 1 1 -2.96 32 (skin) dermatom.
0,6-0,9 mm
breast flow-
through
methyl-4-
hydroxy
152.14 39.28 131 12.50 2 2 1 -4.60 37 dermatom.
0,45 mm
dorsal flow-
through
methyl-4-
hydroxy
152.14 39.28 131 12.50 2 2 1 -3.49 37 dermatom.
0,45 mm
dorsal flow-
through
methyl-4-
hydroxy
152.14 39.28 131 12.50 2 2 1 -3.54 37 dermatom.
0,45 mm
dorsal flow-
through
methyl-4-
hydroxy
152.14 39.28 131 12.50 2 2 1 -3.27 37 dermatom.
0,45 mm
dorsal flow-
through
methyl-4-
hydroxy
152.14 39.28 131 12.50 2 2 1 -2.53 37 dermatom.
0,45 mm
dorsal flow-
through
methyl-4-
hydroxy
152.14 39.28 131 12.50 2 2 1 -2.38 37 dermatom.
0,45 mm
dorsal flow-
through
methyl-4-
hydroxy
152.14 39.28 131 12.50 2 2 1 -2.32 37 dermatom.
0,32 mm
dorsal flow-
through
1-
methoxylpropan-
2
90.123 23.72 -142 10.16 -0.49 2 1 -2.84 32 dermatom.
0,5 mm
breast flow-
through
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1-
methoxylpropan-
2
90.123 23.72 -142 10.16 -0.49 2 1 -4.19 32 dermatom.
0,5 mm
breast flow-
through
1-
methoxylpropan-
2
90.123 23.72 -142 10.16 -0.49 2 1 -3.19 32 dermatom.
0,5 mm
breast flow-
through
metoprolol 267.4 76.70 124 10.39 1.69 4 2 -3.08 32 dermatomed
1,2 mm
abdominal flow-
through
N-N-
Diethyl
m-tolua
191.28 58.97 -45 10.70 2.26 1 0 -2.65 37 dermatomed
0,5 mm
abdomen flow-
through
Naltrexone
(NTX)
341 91.33 166 13.75 1.39 5 2 -2.02 32 dermatomed
0,2 mm
abdominal flow-
through
NTX-3-
acetate
383 100.77 114.00 12.96 1.47 5 1 -2.11 32 dermatomed
0,2 mm
abdominal flow-
through
NTX-3-
propionate
397 105.39 147.00 12.06 1.96 5 1 -2.6 32 dermatomed
0,2 mm
abdominal flow-
through
NTX-3-
butyrate
411 110.00 106.00 11.88 2.45 5 1 -2.89 32 dermatomed
0,2 mm
abdominal flow-
through
NTX-3-
valerate
425 110.00 83.00 11.72 2.45 5 1 -3.15 32 dermatomed
0,2 mm
abdominal flow-
through
NTX-3-
hexanoate
439 114.60 62.00 11.57 2.94 5 1 -2.92 32 dermatomed
0,2 mm
abdominal flow-
through
NTX-3
heptanoate
453 123.80 58.00 11.44 3.92 5 1 -3.05 32 dermatomed
0,2 mm
abdominal flow-
through
nicorandil 211.18 0.00 92.5 14.40 0.43 3 1 -4.30 37 SCE abdomen flow-
through
oxprenolol 265.4 76.00 110 10.52 1.83 4 2 -2.81 32 dermatomed
1,2 mm
abdominal flow-
through
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parathion 291.26 0.00 6.1 10.76 3.73 1 0 -3.72 37 dermatom.
0,5 mm
back flow-
through
2-
phenoxyethanol
138.17 38.81 14 11.49 1.1 2 1 -2.87 37 dermat.0,33 breast/abdomen/leg flow-
through
pirimicarb 238.29 66.90 254.6 11.05 1.4 4 0 -2.57 32 (skin) dermatom.
0,6-0,9 mm
breast flow-
through
prochloraz 376.7 91.27 48 10.69 4.13 3 0 -3.15 32 (skin) dermatom.
0,6-0,9 mm
breast flow-
through
propranolol 295.3 76.82 166 11.13 2.6 3 2 -2.75 32 dermatomed
1,2 mm
abdominal flow-
through
testosterone 288.4 84.55 155 10.66 3.27 2 1 -1.92 37 full-
thickness
abdomen flow-
through
testosterone 288.4 84.55 155 10.66 3.27 2 1 -1.93 37 full-
thickness
abdomen flow-
through
testosterone 288.4 84.55 155 10.66 3.27 2 1 -2.04 37 full-
thickness
abdomen flow-
through
testosterone 288.4 84.55 155 10.66 3.27 2 1 -1.92 37 full-
thickness
abdomen flow-
through
testosterone 288.4 84.55 155 10.66 3.27 2 1 -1.40 37 full-
thickness
abdomen flow-
through
testosterone 288.4 84.55 155 10.66 3.27 2 1 -4.57 32 (not given) dermatom.
0,28 mm
breast flow-
through
testosterone 288.4 84.55 155 10.66 3.27 2 1 -3.55 32 (skin) dermatom.
0,35 mm
abdomen flow-
through
testosterone 288.4 84.55 155 10.66 3.27 2 1 -3.74 32 (skin) dermatom.
0,35 mm
abdomen flow-
through
testosterone 288.4 84.55 155 10.66 3.27 2 1 -2.17 32 (skin) dermatom.
0,35 mm
abdomen flow-
through
testosterone 288.4 84.55 155 10.66 3.27 2 1 -3.62 27 dermatom.
0,6 mm
not given flow-
through
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D-
Tetrahydrocann
314.46 96.45 304.5 9.75 7.6 2 1 -4.55 32 (skin) dermatom.
0,2 mm
abdomen flow-
through
theophylline 180.17 44.39 273 14.05 -0.39 4 1 -3.36 37 dermatomed
0,2 mm
dorsal flow-
through
water 18.02 0.00 0 26.68 -1.38 1 1 -2.89 31 (skin) dermatomed
0,42 mm
abdomen flow-
through
B.1.6 Dataset human F
B.1.6.1 Experimental conditions
• Skin Thickness: All types
• Site: All types
• Cell type: Static
• Temperature: Not specified
• Time: Not specified
• Vehicle: Any
• Receptor Fluid: Any
B.1.6.2 Data
Name Mwt MR Mpt SP logP Ha HD logKp Temp C membrane Site Cell type
water 18.02 0 0 26.68 -1.38 1 1 -3.12 Not given full-
thickness
abdomen static
water 18.02 0 0 26.68 -1.38 1 1 -3.16 Not given isol.epidermis abdomen static
water 18.02 0 0 26.68 -1.38 1 1 -3.04 Not given isol.epidermis abdomen static
water 18.02 0 0 26.68 -1.38 1 1 -2.93 Not given dermatomed
0,13 mm
abdomen static
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water 18.02 0 0 26.68 -1.38 1 1 -3.15 Not given dermatomed
0,13 mm
abdomen static
water 18.02 0 0 26.68 -1.38 1 1 -2.77 30 (not
given)
dermatomed
skin
abdomen static
ethanol 46.07 13.0093 -114.1 10.92 -0.14 1 1 -3.5 30 full-
thickness
abdomen static
2-
methoxyethanol
76.096 19.3048 -85.1 10.67 -0.91 2 1 -2.54 30(not
given)
is.epidermis abdomen static
benzene 78.115 26.058 5.5 9.19 1.99 0 0 -0.95 31 (skin) isol.epidermis abdomen static
benzene 78.115 26.058 5.5 9.19 1.99 0 0 -3.03 31 (skin) isol.epidermis abdomen static
benzene 78.115 26.058 5.5 9.19 1.99 0 0 -0.78 31 (skin) isol.epidermis abdomen static
benzene 78.115 26.058 5.5 9.19 1.99 0 0 -2.62 31 (skin) isol.epidermis abdomen static
benzene 78.115 26.058 5.5 9.19 1.99 0 0 -3.96 31 (skin) isol.epidermis abdomen static
2-
ethoxyethanol
90.12 24.0528 -90 10.33 -0.42 2 1 -3.07 30 (not
given)
full-
thickness
abdomen static
1-
methoxylpropan-
2-ol
90.123 23.723 -142 10.16 -0.49 2 1 -2.9 30 (not
given)
isol.epidermis abdomen static
Aniline 93.1 30.7584 -6.2 10.83 1.08 1 1 -1.21 37 epidermis abdomen static
phenol 94.11 27.7521 40.9 12.33 1.51 1 1 -2.09 25 (not
given)
is.epidermis abdominal static
phenol 94.11 27.7521 40.9 12.33 1.51 1 1 -3.83 22 (not
given)
stratum
corneum
abdomen static
2-cresol
(o-cresol)
108.1 32.7933 30.9 11.89 2.06 1 1 -1.8 25 (not
given)
isolated
epidermis
abdominal static
4-cresol
(p-cresol)
108.1 32.7933 33.00 11.89 2.06 1 1 -1.76 25 (not
given)
isolated
epidermis
abdominal static
3-cresol
(m-cresol)
108.14 32.7933 11.50 11.89 2.06 1 1 -1.82 25 (not
given)
isolated
epidermis
abdominal static
hydroquinone 110.11 29.4462 170 15.18 1.03 2 2 -5.03 30 isol.epidermis abdomen static
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resorcinol 110.11 29.4462 110 15.18 1.03 2 2 -3.62 25 is.epidermis abdominal static
squaric acid 114.06 25.027 293 20.47 -0.44 4 2 -5.12 not given dermatom. thigh static
2-
butoxyethanol
118.18 33.178 -70 9.88 0.57 2 1 -3.67 30 (not
given)
is.epidermis abdomen static
2-(2-
methoxyethoxy)ethanol
120.15 30.3483 -70 10.25 -1.18 3 1 -3.69 30(not
given)
isol.epidermis abdomen static
ethylaniline 121.2 40.9998 -64 9.73 2.11 1 1 -0.54 37 epidermis abdomen static
benzoic
acid
122.1 32.8164 122.4 11.94 1.87 1 1 -1.6 37 full-
thickness
abdomen static
2-
phenylethanol
122.2 37.6285 -27 11.38 1.57 1 1 -1.51 37 epidermis abdomen static
nicotinic
acid
123.11 30.6595 236.6 13.23 0.69 2 1 -4.62 37 isol.epidermis abdomen/breast static
nonane 128.3 43.2112 -53.5 7.51 4.76 0 0 -4.38 32 (skin) dermatom.0,56
mm
back static
5-
Fluorouracil
130.01 26.1222 281 13.46 -0.81 3 2 -3.22 37 epidermis abdomen static
n-octanol 130.23 40.5385 -15.5 9.45 2.81 1 1 -1.21 22 (not
given)
strarum
corneum
abdomen static
2-
ethoxyethyl
acetate
132.16 33.2043 -61.7 9.22 0.59 2 0 -3.09 30 (not
given)
isol.epidermis abdomen static
n-
nitrosodiethanolamine
134.13 32.6351 81.52 15.67 -1.28 4 2 -2.39 32 (skin) isol.epidermis abdomen static
2-(2-
ethoxyethoxy)ethanol
134 35.0963 -76 10.04 -0.69 3 1 -3.88 30 (not
given)
isol.epidermis abdomen static
methyl
nicotinate
137.14 35.4286 42.5 11.8 0.64 2 0 -2.41 37 full-
thickness
abdomen static
methyl
nicotinate
137.14 35.4286 42.5 11.8 0.64 2 0 -2.51 37 isol.epidermis abdomen/breast static
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methyl
nicotinate
137.14 35.4286 42.5 11.8 0.64 2 0 -2.47 37 isol.epidermis abdomen/breast static
salicylic
acid
138.1 34.5105 158 14.39 2.24 2 2 0.34 32 dermatom.
0,6 mm
abdomen static
salicylic
acid
138.1 34.5105 158 14.39 2.24 2 2 -1.89 32 (skin) dermatom.
0,408 mm
abdomen/breast static
salicylic
acid
138.1 34.5105 158 14.39 2.24 2 2 -2.88 37 dermatom.
0,5 mm
breast static
salicylic
acid
138.1 34.5105 158 14.39 2.24 2 2 -1.92 25 full-
thickness
breast static
salicylic
acid
138.1 34.5105 158 14.39 2.24 2 2 -3.13 25 full-
thickness
breast static
salicylic
acid
138.1 34.5105 158 14.39 2.24 2 2 -2.88 37 dermat. 0,5
mm
abdomen static
salicylic
acid
138.1 34.5105 158 14.39 2.24 2 2 -1.86 37 full-
thickness
abdomen static
3-
nitrophenol
139.1 0 98.00 13.02 1.91 2 1 -2.25 25 (not
given)
isol.epidermis abdomen static
2-naphthol 144.16 0 123 12.69 2.69 1 1 -1.55 25 (not
given)
isol.epidermis abdomen static
coumarin 146.15 41.5486 70.6 11.91 1.51 1 0 -2.04 37 full-
thickness
abdomen static
coumarin 146.15 41.5486 70.6 11.91 1.51 1 0 -1.90 37 full-
thickness
scalp static
4-n-
butylaniline
149.24 49.6026 -14 9.51 3.1 1 1 -0.39 37 epidermis abdomen static
4-
phenylbutanol
150 46.8305 16.2 10.8 2.55 1 1 -1.06 37 epidermis abdomen static
thymol 150.2 46.9841 49 10.81 3.52 1 1 -1.28 25 (not
given)
is.epidermis abdominal static
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ethyl
nicotinate
151.17 40.1766 -8.5 11.06 1.13 2 2 -2.22 37(not
given)
isol.epidermis abdomen/breast static
ethyl
nicotinate
151.17 40.1766 -8.5 11.06 1.13 2 2 -2.18 37(not
given)
isol.epidermis abdomen/breast static
ethyl
nicotinate
151.17 40.1766 -8.5 11.06 1.13 2 2 -3.65 37(not
given)
isol.epidermis abdomen/breast static
methyl
paraben
152.15 39.2796 131 12.50 2 2 1 -2.38 23 epidermis abdomen static
methyl
paraben
152.15 39.2796 131 12.50 2 2 1 -2.03 30 epidermis abdomen static
methyl
paraben
152.15 39.2796 131 12.50 2 2 1 -1.67 37 epidermis abdomen static
methyl
paraben
152.15 39.2796 131 12.50 2 2 1 -1.49 45 epidermis abdomen static
chloroxylenol 156.6 42.6393 115 11.20 3.25 1 1 -1.23 25 isol.epidermis abdominal static
2-(2-
butoxyethoxy)ethanol
162.23 44.2215 -68 9.74 0.29 3 1 -4.45 30 (not
given)
is.epidermis abdomen static
nicotine 162.3 49.6542 -7.9 11.25 1 2 0 -1.99 32 (skin) dermatom.
0,408 mm
abdomen/breast static
nicotine 162.3 49.6542 -7.9 11.25 1 2 0 -2.48 37 full-
thickness
abdomen static
diethyl
squarate
170.16 44.0254 131.55 11.5 4.07 4 0 -3.92 not given dermatomed
skin
thigh static
2-
phenylphenol
170.21 52.8883 116.1 12.24 3.28 1 1 -1.58 32 is.epidermis dorsal/flank static
2-
phenylphenol
170.21 52.8883 116.1 12.24 3.28 1 1 -2.8 32 full-
thickness
abdomen static
2-
phenylphenol
170.21 52.8883 116.10 12.24 3.28 1 1 -1.74 32 is.epidermis abdomen static
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4-
bromophenol
173.01 35.3749 66.40 11.48 2.4 1 1 -1.44 25 (not
given)
is.epidermis abdominal static
butyl
nicotinate
179.22 49.3018 69.59 10.57 2.11 2 0 -1.78 37 (not
given)
is.epidermis abdomen/breast static
butyl
nicotinate
179.22 49.3018 69.59 10.57 2.11 2 0 -4.1 37 (not
given)
is.epidermis abdomen/breast static
mannitol 182.17 38.4036 138.97 18.63 -3.01 6 6 -4.96 not given full-
thickness
abdomen static
mannitol 182.17 38.4036 138.97 18.63 -3.01 6 6 -4.96 not given isol.epidermis abdomen static
mannitol 182.17 38.4036 138.97 18.63 -3.01 6 6 -4.21 30 full-
thickness
abdomen static
N-N-
Diethyl
m-
toluamide
191.28 58.9692 -45 10.70 2.26 1 0 -3.24 37 full-
thickness
not given static
N-N-
Diethyl
m-
toluamide
191.28 58.9692 -45 10.70 2.26 1 0 -3.22 37 full-
thickness
not given static
N-N-
Diethyl
m-
toluamide
191.28 58.9692 -45 10.7 2.26 1 0 -4 37 full-
thickness
not given static
N-N-
Diethyl
m-
toluamide
191.28 58.9692 -45 10.7 2.26 1 0 -4.2 37 full-
thickness
not given static
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N-N-
Diethyl
m-
toluamide
191.28 58.9692 -45 10.70 2.26 1 0 -3.92 37 full-
thickness
not given static
N-N-
Diethyl
m-
toluamide
191.28 58.9692 -45 10.7 2.26 1 0 -3.98 37 full-
thickness
not given static
N-N-
Diethyl
m-
toluamide
191.28 58.9692 -45 10.7 2.26 1 0 -2.92 37 full-
thickness
not given static
N-N-
Diethyl
m-
toluamide
191.28 58.9692 -45 10.7 2.26 1 0 -3.4 37 full-
thickness
not given static
N-N-
Diethyl
m-
toluamide
191.28 58.9692 -45 10.7 2.26 1 0 -4.8 37 full-
thickness
not given static
caffeine 194.20 49.2834 238 32.83 0.16 4 0 -3.59 37 is.epidermis upper leg static
butyl
paraben
194.23 53.1528 68.5 11.45 3.47 2 1 -1.56 23 epidermis abdomen static
butyl
paraben
194.23 53.1528 68.5 11.45 3.47 2 1 -1.25 30 epidermis abdomen static
butyl
paraben
194.23 53.1528 68.5 11.45 3.47 2 1 -1 37 epidermis abdomen static
butyl
paraben
194.23 53.1528 68.5 11.45 3.47 2 1 -0.56 45 epidermis abdomen static
3,4 xylenol 202.55 37.8345 62.50 11.54 2.61 1 1 -1.44 25 isol.epidermis abdominal static
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propoxur 209.25 56.3432 87 10.31 1.9 2 1 -4.54 37 full-
thickness
abdomen static
propoxur 209.25 56.3432 87 10.31 1.9 2 1 -1.39 37 full-
thickness
abdomen static
propoxur 209.25 56.3432 87 10.31 1.9 2 1 -3.05 32 full-
thickness
abdomen static
nicorandil 211.18 0 92.5 14.4 0.43 3 1 -3.58 37 full-
thickness
breast static
benzyl
nicotinate
213.24 60.0412 24 11.55 2.35 2 0 -1.8 37 isol.epidermis abdomen/breast static
benzyl
nicotinate
213.24 60.0412 24 11.55 2.35 2 0 -4.69 37 isol.epidermis not given static
DEP 222.24 58.609 -3 10.51 2.65 2 0 -4.94 30 (not
given)
isol.epidermis abdomen static
dibutyl
squarate
226.27 62.2758 176.71 10.58 2.45 4 0 -4.70 not given dermatomed
skin
thigh static
naproxene 230.3 64.8535 153 11.42 3.1 2 1 -2.54 37 full-
thickness
abdomen static
meperidine 247.4 72.4823 270 9.82 3.03 2 0 -2.43 37 isol.epidermis abdomen static
paraquat 257.16 0 300 10.45 -2.71 0 0 -5.06 30 full-
thickness
abdomen static
methyl
parathion
263.21 2.75 35.5 10.45 2.75 1 0 -4.87 32 (skin) full-
thickness
abdomen static
methyl
parathion
263.21 2.75 35.5 10.45 2.75 1 0 -4.42 32 (skin) full-
thickness
abdomen static
estrone 270.4 78.7956 254.5 11.55 3.43 2 1 -2.44 26 (not
given)
isol.epidermis not given static
b-estradiol 272.4 79.6175 173 11.9 3.94 2 2 -3.52 26 (not
given)
isol.epidermis not given static
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b-estradiol 272.4 79.6175 173 11.9 3.94 2 2 -3 32 dermatomed
0,5 mm
abdomen static
b-estradiol 272.4 79.6175 173 11.9 3.94 2 2 -2.00 32 dermatomed
0,5 mm
abdomen static
b-estradiol 272.4 79.6175 173 11.9 3.94 2 2 -2.39 37 isol.epidermis various static
dibutylphthalate 278.35 0 -35 10.86 5.11 2 0 -5.64 30 (not
given)
isol.epidermis abdomen static
morphine 285.3 79.8346 255 13.68 0.72 4 2 -5.03 37 isol.epidermis abdomen static
hydromorphone 285.34 78.0905 266 10.96 1.6 4 1 -4.82 37 isol.epidermis abdomen static
etodolac 287.26 81.1565 146.5 10.86 3.93 3 2 -2.13 37 full-
thickness
abdomen static
estriol 288.4 80.979 282 12.95 2.81 3 3 -4.4 26 (not
given)
isol.epidermis not given static
testosterone 288.4 84.5453 155 10.66 3.27 2 1 -3.92 32 full-
thickness
abdomen static
testosterone 288.4 84.5453 155 10.66 3.27 2 1 -2.30 32 (skin) dermatom.
0,408 mm
abdomen/breast static
testosterone 288.4 84.5453 155 10.66 3.27 2 1 -3.4 26 (not
given)
is.epidermis not given static
linoleic acid 289.45 88.5188 -5 9.05 7.51 1 1 -4.97 37 full-
thickness
abdomen static
triclosan 289.55 68.4073 265.6 10.02 2.47 2 1 -4.47 37 isol.epidermis breast and
abdomen
static
lindane 290.83 54.081 112.5 8.54 4.26 0 0 -5.23 32 (skin) dermat.
0,23 mm
breast/abdomen static
lindane 290.83 54.081 112.5 8.54 4.26 0 0 -5.23 32 (skin) dermat.
0,23 mm
breast/abdomen static
dichlofenac 296.16 75.4614 337.5 11.13 4.02 2 2 -3 37 full-
thickness
abdomen static
codeine 299.4 84.6037 155 12.09 1.28 4 1 -4.31 37 isol.epidermis abdomen static
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nimesulide 308.31 0 143 15.25 2.22 3 2 -2.995 37 full-
thickness
abdomen static
ranitidine 314.1 0 133 11.41 0.29 5 2 -4.05 37 full-
thickness
abdomen static
progesterone 314.5 92.8212 121 10.05 3.67 2 0 -2.82 26 (not
given)
is.epidermis not given static
progesterone 314.5 92.8212 121 10.05 3.67 2 0 -1.52 37 (not
given)
is.epidermis various static
pregnenolone 316.5 93.7559 192 10.36 3.89 2 1 -2.82 26 (not
given)
is.epidermis not given static
nizatidine 331.45 0 130 12.36 -0.43 5 2 -4.43 37 full-
thickness
abdomen static
clotrimazole 344.85 102.1434 148 11.17 6.26 2 0 -2.70 32 dermatom.
0,6 mm
abdomen static
cortexolone 346.47 96.0389 208 11.91 3.15 4 2 -4.12 26 (not
given)
isol.epidermis not given static
corticosterone 346.5 96.2312 183 11.91 1.99 4 2 -4.22 26 (not
given)
isol.epidermis not given static
griseofulvin 352.77 87.9616 220 10.44 1.92 6 0 -2.89 37 full-
thickness
abdomen static
griseofulvin 352.77 87.9616 220 10.44 1.92 6 0 -2.71 37 full-
thickness
abdomen static
Aldosterone 360.45 96.4918 164 12.31 1.63 4 2 -5.52 26 (not
given)
isol.epidermis not given static
Aldosterone 360.45 96.4918 164 12.31 1.63 4 2 -4.24 26 (not
given)
isol.epidermis various static
cortisone 360.5 96.7062 220 12.1 1.81 5 2 -5 26 (not
given)
isol.epidermis not given static
sufentanil 386.6 113.3917 97 10.47 3.62 3 0 -1.92 37 isol.epidermis abdomen static
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DEHP 390.57 113.409 -50 9.39 8.39 2 0 -5.24 30 (not
given)
isol.epidermis abdomen static
etorphine 411.55 116.2256 215 11.76 3.02 5 2 -2.44 37 full-
thickness
abdominal static
doxycycline
HCL
444.44 113.7208 866 16.55 -1.36 9 6 -5.32 37 full-
thickness
not given static
doxycycline
HCL
444.44 113.7208 866 16.55 -1.36 9 6 -3.68 37 full-
thickness
not given static
doxycycline
HCL
444.44 113.7208 866 16.55 -1.36 9 6 -3.58 37 full-
thickness
not given static
doxycycline
HCL
444.44 113.7208 866 16.55 -1.36 9 6 -2.6 37 epidermis not given static
doxycycline
HCL
444.44 113.7208 866 16.55 -1.36 9 6 -2.6 37 epidermis not given static
methotrexate 454.45 0 195 15.05 -1.28 10 5 -3.5 37 full-
thickness
abdomen static
methotrexate 454.45 0 195 15.05 -1.28 10 5 -3.95 37 full-
thickness
abdomen static
methotrexate 454.45 0 195 15.05 -1.28 10 5 -3.25 37 full-
thickness
abdomen static
methotrexate 454.45 0 195 15.05 -1.28 10 5 -2.95 37 full-
thickness
abdomen static
methotrexate 454.45 0 195 15.05 -1.28 10 5 -3.28 37 full-
thickness
abdomen static
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B.2 Animal datasets
B.2.1 Mouse dataset
B.2.1.1 Experimental conditions
• Skin thickness: Full thickness
• Site: All body cites
• Cell type: Flow-through/Static
• Temperature: 25ºC and 37ºC
• Time: Not specific
• Vehicle: Any
• Receptor fluid: Mainly Saline
B.2.1.2 Data
Name Mwt MR Mpt SP logP Ha HD logKp Temp C membrane Site Cell type
Alachlor 269.77 73.9275 40 9.80 3.37 2 0 -3.42 not given full-
thickness
dorsal flow-through
Alachlor 269.77 73.9275 40 9.80 3.37 2 0 -3.18 not given full-
thickness
dorsal flow-through
atenolol 266.3 73.5041 147 12.49 -0.03 4 3 -1.32 37 full-
thickness
abdomen flow-through
atenolol 266.3 73.5041 147 12.49 -0.03 4 3 -1.32 37 full-
thickness
dorsal flow-through
atenolol 266.3 73.5041 147 12.49 -0.03 4 3 -1.52 37 full-
thickness
abdomen flow-through
atenolol 266.3 73.5041 147 12.49 -0.03 4 3 -1.60 37 full-
thickness
dorsal flow-through
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atenolol 266.3 73.5041 147 12.49 -0.03 4 3 -1.45 37 full-
thickness
abdomen flow-through
atenolol 266.3 73.5041 147 12.49 -0.03 4 3 -1.67 37 full-
thickness
dorsal flow-through
Atrazine 215.69 62.214 175 11.77 2.82 5 2 -3.11 not given full-
thickness
dorsal flow-through
Atrazine 215.69 62.214 175 11.77 2.82 5 2 -3.77 not given full-
thickness
dorsal flow-through
Bisphenol
A
diglycidyl
ether
340.8 95.2347 10 10.38 3.84 4 0 -5.07 not given full-
thickness
dorsal flow-through
n-butanol 74.14 22.1345 -89.8 10.13 0.84 1 1 -2.19 not given full-
thickness
abdomen/dorsal static
n-butanol 74.14 22.1345 -89.8 10.13 0.84 1 1 -2.09 not given full-
thickness
abdomen/dorsal static
n-butanol 74.14 22.1345 -89.8 10.13 0.84 1 1 -1.93 not given full-
thickness
abdomen/dorsal static
n-butanol 74.14 22.1345 -89.8 10.13 0.84 1 1 -1.91 not given full-
thickness
abdomen/dorsal static
n-butanol 74.14 22.1345 -89.8 10.13 0.84 1 1 -1.92 not given full-
thickness
abdomen/dorsal static
n-butanol 74.14 22.1345 -89.8 10.13 0.84 1 1 -1.94 not given full-
thickness
abdomen/dorsal static
n-butanol 74.14 22.1345 -89.8 10.13 0.84 1 1 -1.90 not given full-
thickness
abdomen static
n-butanol 74.14 22.1345 -89.8 10.13 0.84 1 1 -1.63 not given full-
thickness
back static
caffeine 194.2 49.2834 238 32.83 0.16 4 0 -3.59 37 full-
thickness
dorsal/abdominal static
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corticosterone 346.5 96.2312 183 11.91 1.99 4 2 -3.28 37 full-
thickness
abdomen static
coumarin 146.15 41.5486 70.60 11.91 1.51 1 0 -3.00 32 (skin) full-
thickness
dorsal flow-through
o-cresyl
glycidyl
ether
(oCGE)
164.20 46.3071 34.98 10.38 2.16 2 0 -3.75 32 (skin) full-
thickness
dorsal flow-through
decabromodiphenyl
oxide
(DBDPO)
959.17 128.5268 302.5 12.11 8.10 1 0 -5.93 not given full-
thickness
dorsal flow-through
decabromodiphenyl
oxide
(DBDPO)
959.17 128.5268 302.5 12.11 8.10 1 0 -5.79 not given full-
thickness
dorsal flow-through
decabromodiphenyl
oxide
(DBDPO)
959.17 128.5268 302.5 12.11 8.10 1 0 -5.15 not given full-
thickness
dorsal flow-through
deoxycortisone 330.47 94.6393 141.5 11.03 3.12 3 1 -2.47 37 full-
thickness
abdomen static
dibutyl
squarate
226.27 62.2758 176.71 10.58 2.45 4 0 -3.07 not given full-
thickness
not given static
diethyl
squarate
170.16 44.0254 131.55 11.50 4.07 4 0 -3.00 not given full-
thickness
not given static
dodecyl
glycidyl
ether
(C12GE)
242.2 72.4384 58 8.41 5.01 2 0 -4.34 32 (skin) full-
thickness
dorsal flow-through
ethanol 46.07 13.0093 -114.1 10.92 -0.14 1 1 -2.68 not given full-
thickness
abdomen/dorsal static
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ethanol 46.07 13.0093 -114.1 10.92 -0.14 1 1 -2.66 not given full-
thickness
abdomen/dorsal static
ethanol 46.07 13.0093 -114.1 10.92 -0.14 1 1 -2.64 not given full-
thickness
abdomen/dorsal static
ethanol 46.07 13.0093 -114.1 10.92 -0.14 1 1 2.66 not given full-
thickness
abdomen/dorsal static
ethanol 46.07 13.0093 -114.1 10.92 -0.14 1 1 -2.68 not given full-
thickness
abdomen/dorsal static
ethanol 46.07 13.0093 -114.1 10.92 -0.14 1 1 -2.70 not given full-
thickness
abdomen/dorsal static
ethanol 46.07 13.0093 -114.1 10.92 -0.14 1 1 -2.72 not given full-
thickness
abdomen/dorsal static
ethanol 46.07 13.0093 -114.1 10.92 -0.14 1 1 -3.05 not given full-
thickness
abdomen static
ethanol 46.07 13.0093 -114.1 10.92 -0.14 1 1 -2.62 not given full-
thickness
back static
epikote
YX4000
354.4 101.7748 11.00 5.19 4 0 -5.58 32 (skin) full-
thickness
dorsal flow-through
erioglaucine 793.86 283 -1.5 -4.52 37 full-
thickness
abdomen static
etorphine 411.55 116.2256 215 11.76 3.02 5 2 -2.34 37 full-
thickness
abdominal/dorsal static
5-
fluorouracil
130.01 26.1222 281 13.46 -0.81 3 2 -4.22 31 dermatomed
0,42 mm
abdomen flow-through
n-hexanol 102.18 -52 9.71 2.03 1 1 -1.71 not given full-
thickness
Abdomen static
n-hexanol 102.18 -52 9.71 2.03 1 1 -1.54 not given full-
thickness
Abdomen static
n-hexanol 102.18 -52 9.71 2.03 1 1 -1.41 not given full-
thickness
Abdomen static
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n-hexanol 102.18 -52 9.71 2.03 1 1 -1.43 not given full-
thickness
Abdomen static
n-hexanol 102.18 -52 9.71 2.03 1 1 -1.43 not given full-
thickness
Abdomen static
n-hexanol 102.18 -52 9.71 2.03 1 1 -2.42 not given full-
thickness
Abdomen static
n-hexanol 102.18 -52 9.71 2.03 1 1 -1.07 not given full-
thickness
back static
1,6-
hexanediol
diglycidyl
ether
230.2 60.2566 84.83 9.36 0.84 4 0 -3.24 32 (skin) full-
thickness
dorsal flow-through
n-heptanol 116.2 31.3365 -34 9.57 1.82 1 1 -1.18 not given full-
thickness
Abdomen static
n-heptanol 116.2 31.3365 -34 9.57 1.82 1 1 -1.09 not given full-
thickness
Abdomen static
n-heptanol 116.2 31.3365 -34 9.57 1.82 1 1 -0.99 not given full-
thickness
Abdomen static
n-heptanol 116.2 31.3365 -34 9.57 1.82 1 1 -1.01 not given full-
thickness
Abdomen static
n-heptanol 116.2 31.3365 -34 9.57 1.82 1 1 -0.98 not given full-
thickness
Abdomen static
n-heptanol 116.2 31.3365 -34 9.57 1.82 1 1 -0.99 not given full-
thickness
Abdomen static
hydrocortisone 362.5 97.6308 220 12.75 1.62 5 3 -4.00 37 full-
thickness
Abdomen static
hydrocortisone 362.5 97.6308 220 12.75 1.62 5 3 -3.92 37 full-
thickness
dorsal static
hydrocortisone 362.5 97.6308 220 12.75 1.62 5 3 -4.22 37 full-
thickness
Abdomen static
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17a-
hydroxyprogesterone
330.5 94.3367 276 10.98 3.08 3 1 -3.06 37 full-
thickness
Abdomen static
lidocaine 234.34 72.1476 67 8.78 1.66 2 1 -2.05 37 full-
thickness
Dorsal/Ventral flow-through
lidocaine 234.34 72.1476 67 8.78 1.66 2 1 -1.75 37 full-
thickness
Dorsal/Ventral flow-through
lidocaine 234.34 72.1476 67 8.78 1.66 2 1 -1.74 37 full-
thickness
Dorsal/Ventral flow-through
lidocaine 234.34 72.1476 67 8.78 1.66 2 1 -1.59 37 full-
thickness
Dorsal/Ventral flow-through
N-N-
Diethyl
m-
toluamide
191.28 58.9692 -45 10.70 2.26 1 0 -2.46 37 full-
thickness
back flow-through
methanol 32.04 8.2613 -98 11.68 -0.63 1 1 -2.74 not given full-
thickness
Abdomen/dorsal static
methanol 32.04 8.2613 -98 11.68 -0.63 1 1 -2.80 not given full-
thickness
Abdomen/dorsal static
methanol 32.04 8.2613 -98 11.68 -0.63 1 1 -2.77 not given full-
thickness
Abdomen/dorsal static
methanol 32.04 8.2613 -98 11.68 -0.63 1 1 -2.72 not given full-
thickness
Abdomen/dorsal static
methanol 32.04 8.2613 -98 11.68 -0.63 1 1 -2.74 not given full-
thickness
Abdomen/dorsal static
methanol 32.04 8.2613 -98 11.68 -0.63 1 1 -2.74 not given full-
thickness
Abdomen/dorsal static
methanol 32.04 8.2613 -98 11.68 -0.63 1 1 -3.00 not given full-
thickness
Abdomen static
morphine 285.3 79.8346 255 13.68 0.72 4 2 -3.82 37 full-
thickness
dorsal/abdominalflow-through
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nicorandil 211.18 0 92.5 14.40 0.43 3 1 -3.00 37 full-
thickness
abdomen static
n-octanol 130.23 40.5385 -15.5 9.45 2.81 1 1 -1.11 not given full-
thickness
abdomen/dorsal static
n-octanol 130.23 40.5385 -15.5 9.45 2.81 1 1 -0.92 not given full-
thickness
abdomen/dorsal static
n-octanol 130.23 40.5385 -15.5 9.45 2.81 1 1 -1.02 not given full-
thickness
abdomen/dorsal static
n-octanol 130.23 40.5385 -15.5 9.45 2.81 1 1 -1.03 not given full-
thickness
abdomen/dorsal static
n-octanol 130.23 40.5385 -15.5 9.45 2.81 1 1 -1.02 not given full-
thickness
abdomen/dorsal static
n-octanol 130.23 40.5385 -15.5 9.45 2.81 1 1 -1.01 not given full-
thickness
abdomen/dorsal static
prednisolone
21-
heptanoate
472.62 130.9065 186 12.02 4.6 5 2 -4.11 25 (not
given)
not given abdomen not given
prednisolone
21-
octanoate
486.65 135.5075 159 11.89 5.09 5 2 -3.96 25 (not
given)
not given abdomen not given
prednisolone
21-
nonanoate
500.68 140.1085 131 11.78 5.58 5 2 -4.04 25 (not
given)
not given abdomen not given
prednisolone
21-
decanoate
514.7 144.7095 145 11.67 6.07 5 2 -3.95 25 (not
given)
not given abdomen not given
prednisolone
21-
undecanoate
528.73 0 129 11.57 5.54 5 2 -3.83 25 (not
given)
not given abdomen not given
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prednisolone
21-
tridecanoate
556.78 0 140 11.39 6.02 5 2 -3.97 25 (not
given)
not given abdomen not given
prednisolone
21-
pentadecanoate
584.84 0 139 11.23 6.79 5 2 -4.01 25 (not
given)
not given abdomen not given
progesterone 314.5 92.8212 121 10.05 3.67 2 0 -1.96 37 full-
thickness
abdomen static
propranolol
HCL
295 0 233.2 11.96 0.74 3 2 -4.30 37 full-
thickness
abdomen flow-through
salicylic
acid
138.1 34.5105 158 14.39 2.24 2 2 -1.71 25 full-
thickness
dorsal static
salicylic
acid
138.1 34.5105 158 14.39 2.24 2 2 -1.93 25 full-
thickness
dorsal static
salicylic
acid
138.1 34.5105 158 14.39 2.24 2 2 -3.13 25 full-
thickness
dorsal static
squaric acid 114.06 25.027 293 20.47 -0.44 4 2 -3.15 not given full-
thickness
not given static
sucrose 342.3 68.7741 190 18.06 -4.27 11 8 -2.66 37 full-
thickness
not given flow-through
thiourea 76.12 21.3277 176 15.23 -1.31 0 2 -4.02 37 full-
thickness
abdomen static
TDCPP 430.91 0 27 8.67 3.65 1 0 -3.34 not given full-
thickness
dorsal flow-through
TDCPP 430.91 0 27 8.67 3.65 1 0 -3.25 not given full-
thickness
dorsal flow-through
trifluralin 335.28 0 49 9.49 5.31 6 0 -3.55 not given full-
thickness
dorsal flow-through
trifluralin 335.28 0 49 9.49 5.31 6 0 -3.91 not given full-
thickness
dorsal flow-through
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water 18.02 0 0 26.68 -1.38 1 1 -2.66 31 (skin) full-
thickness
dorsal flow-through
water 18.02 0 0 26.68 -1.38 1 1 -2.80 not given full-
thickness
abdomen/dorsal static
water 18.02 0 0 26.68 -1.38 1 1 -2.82 not given full-
thickness
abdomen/dorsal static
water 18.02 0 0 26.68 -1.38 1 1 -2.85 not given full-
thickness
abdomen/dorsal static
water 18.02 0 0 26.68 -1.38 1 1 -2.89 not given full-
thickness
abdomen/dorsal static
water 18.02 0 0 26.68 -1.38 1 1 -2.92 not given full-
thickness
abdomen/dorsal static
water 18.02 0 0 26.68 -1.38 1 1 -4.96 not given full-
thickness
abdomen/dorsal static
water 18.02 0 0 26.68 -1.38 1 1 -2.53 35 (skin) full-
thickness
not given flow-through
water 18.02 0 0 26.68 -1.38 1 1 -2.72 not given full-
thickness
abdomen static
water 18.02 0 0 26.68 -1.38 1 1 -1.70 not given full-
thickness
back static
water 18.02 0 0 26.68 -1.38 1 1 -1.74 37 (not
given)
not given dorsal flow-through
water 18.02 0 0 26.68 -1.38 1 1 -2.00 37 (not
given)
not given dorsal flow-through
urea 60.6 13.0926 135 14.36 -1.56 1 2 -3.52 37 (not
given)
not given dorsal flow-through
urea 60.6 13.0926 135 14.36 -1.56 1 2 -3.15 37 (not
given)
not given dorsal flow-through
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B.2.2 Rat dataset
B.2.2.1 Experimental conditions
• Skin thickness: All types
• Site: All body cites
• Cell type: Flow-through/Static
• Temperature: 30ºC and 37ºC
• Time: Not specific
• Vehicle: Any
• Receptor fluid: Any
B.2.2.2 Data
Name Mwt MR Mpt SP logP Ha HD logKp Temp C membrane Site Cell type
Alizapride 339.9 89.8971 207 12.06 1.8 6 2 -2.24 37 full-
thickness
dorsal flow-through
1,6-
hexanediol
diglycidyl
ether
(HDDGE)
230.2 60.2566 84.83 9.36 0.84 4 0 -3.40 32 (skin) dermatomed dorsal flow-through
2-(2-
methoxyethoxy)ethanol
120.15 30.3483 -70 10.25 -1.18 3 1 -1.10 32 (skin) dermat.
0,56 mm
back static
2,4
dimethy-
lamine
266.13 0 86 9.52 0.84 3 2 -3.51 37 dermat. 0,3
mm
back flow-through
2-
ethoxyethanol
90.12 0 -90 10.33 -0.42 2 1 -4.11 32 dermat.
0,33 mm
dorsal flow-through
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2-
ethoxyethanol
90.12 0 -90 10.33 -0.42 2 1 -3.64 32 full-
thickness
dorsal flow-through
2-
ethoxyethanol
90.12 0 -90 10.33 -0.42 2 1 -3.83 32 dermat.
0,33 mm
dorsal flow-through
2-
ethoxyethanol
90.12 0 -90 10.33 -0.42 2 1 -4.12 32 full-
thickness
dorsal flow-through
2-
phenoxyethanol
138.17 38.8135 14 11.49 1.1 2 1 -2.57 37 dermatom.0,244
mm
dorsal static
2-
phenoxyethanol
138.17 38.8135 14 11.49 1.1 2 1 -4.57 37 dermatom.0,244
mm
dorsal static
2-
phenoxyethanol
138.17 38.8135 14 11.49 1.1 2 1 -4.75 37 dermatom.0,244
mm
dorsal flow-through
2-
phenoxyethanol
138.17 38.8135 14 11.49 1.1 2 1 -2.75 37 dermatom.0,244
mm
dorsal flow-through
2-
phenoxyethanol
138.17 38.8135 14 11.49 1.1 2 1 -2.13 37 dermatom.0,244
mm
dorsal static
2-
phenylphenol
170.21 52.8883 59 12.24 3.28 1 1 -3.01 32 full-
thickness
skin
dorsal/Flank static
2-
phenylphenol
170.21 52.8883 59 12.24 3.28 1 1 -1.58 32 Isolated
Epidermis
dorsal/Flank static
4-
methylaniline
107.2 35.7996 43.7 10.58 1.62 1 1 -1.07 37 isol.epidermis flow-through
4-n-
butylaniline
149 49.6026 -14 9.51 3.1 1 1 -0.64 37 isol.epidermis flow-through
4-n-
hexylaniline
177.3 58.8046 9.68 4.08 1 1 -0.64 37 isol.epidermis flow-through
4-n-
pentylaniline
163.3 54.2036 9.79 3.59 1 1 -0.61 37 isol.epidermis flow-through
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4-n-
propylaniline
135 45.0016 10.10 2.61 1 1 -0.77 37 isol.epidermis flow-through
Aminopyrene 231 70.1104 108 10.7 0.6 3 0 -1.48 32 full-
thickness
static
Aniline 93 30.7584 -6.2 10.83 1.08 1 1 -1.17 37 isol.epidermis flow-through
benzoic
acid
122.1 32.8164 122 11.94 1.87 1 1 -1.54 31,5 (skin) isol.epidermis back flow-through
benzoic
acid
122.1 32.8164 122 11.94 1.87 1 1 -2.02 31,5 (skin) isol.epidermis back flow-through
benzoic
acid
122.1 32.8164 122 11.94 1.87 1 1 -3.46 32 full-
thickness
back static
benzoic
acid
122.1 32.8164 122 11.94 1.87 1 1 -3.54 32 full-
thickness
abdomen static
benzyl
acetate
150.18 42.0254 -51.3 10.10 2.08 1 0 -3.57 32(skin) full-
thickness
dorsal flow-through
benzyl
acetate
150.18 42.0254 -51.3 10.10 2.08 1 0 -4.24 32(skin) full-
thickness
dorsal flow-through
Bisphenol
A
diglycidyl
ether
(BADGE)
340.8 95.2347 10 10.38 3.84 4 0 -5.26 32 (skin) dermatomed
skin
dorsal flow-through
bromopride 344.26 85.8368 152.5 10.74 1.94 4 2 -2.11 37 full-
thickness
dorsal flow-through
bufexamac 223.3 61.002 154 12.43 1.98 3 2 -0.57 32 full-
thickness
static
butyl
salicylate
194.23 53.1528 -6 11.45 4.08 2 1 -4.7 32 (skin) full-
thickness
not given static
caffeine 194.2 49.2834 238 32.83 0.16 4 0 -3.51 32 full-
thickness
back static
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caffeine 194.2 49.2834 238 32.83 0.16 4 0 -2.99 37 full-
thickness
not given flow-through
clebopride 373.9 105.5674 162 11.47 3.21 4 2 -2.13 37 full-
thickness
dorsal flow-through
clotrimazole 344.85 102.1434 148 11.17 6.26 2 0 -2.26 32 full-
thickness
unknown static
cortisone 360.5 96.7062 220 12.10 1.81 5 2 -3.77 32 full-thikness
skin
back static
cortisone 360.5 96.7062 220 12.10 1.81 5 2 -2.91 32 full-thikness
skin
abdomen static
cortisone 360.5 96.7062 220 12.10 1.81 5 2 -3.33 32 full-thikness
skin
abdomen static
coumarin 146.15 41.5486 70.6 11.91 1.51 1 0 -3.12 32(skin) full-thikness
skin
dorsal flow-through
coumarin 146.15 41.5486 70.6 11.91 1.51 1 0 -3.1 32(skin) full-thikness
skin
dorsal flow-through
DDT 354.49 85.3157 108.50 9.45 6.79 0 0 -2.17 37 dermatomed
0,5mm
back flow-through
decane 142.3 47.8122 -29.7 7.58 5.25 0 0 -4.03 not given dermatom.
0,56 mm
back static
DEHP 390.57 113.409 -50 9.39 8.39 2 0 -3.02 31,5 (skin) isol.epidermis back flow-through
DEHP 390.57 113.409 -50 9.39 8.39 2 0 -4.01 31,5 (skin) isol.dermis back flow-through
DEHP 390.57 113.409 -50 9.39 8.39 2 0 -4.89 31,5 (skin) isol.epidermis back flow-through
DEHP 390.57 113.409 -50 9.39 8.39 2 0 -4.32 31,5 (skin) isol.dermis back flow-through
DEP 222.24 58.609 -3 10.51 2.65 2 0 -3.43 30 (not
given)
isol.epidermis abdomen static
dibutylphthalate 278.35 0 -35 10.86 5.11 2 0 -4.43 36 full-thikness
skin
dorsal static
dibutylphthalate 278.35 0 -35 10.86 5.11 2 0 -4.05 30 (not
given)
isol.epidermis abdomen static
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diethylene
glycol
monomethyl
ether
120.2 30.3483 -14.6 10.25 -1.5 3 1 -1.09 32 (skin) dermatomed
0,56 mm
back static
dinoseb 240.22 0 40 11.10 3.67 2 1 -3.06 32 dermatomed
0,35
dorsal static
dinoseb 240.22 0 40 11.10 3.67 2 1 -2.94 32 dermatomed
0,35
dorsal static
dodecane 170.34 57.0142 -9.6 7.69 6.23 0 0 -4.85 32 (skin) dermatomed
0,56 mm
back static
dodecyl
decaethoxy-
late
482.9 0 4.33 -3.37 37 dermatomed
0,244 mm
dorsal static
dodecyl
decaethoxy-
late
482.9 0 4.33 -5.31 37 dermatomed
0,244 mm
dorsal flow-through
dodecyl
decaethoxy-
late
482.9 0 4.33 -3.37 35 dermatomed
0,28 mm
dorsal static
dodecyl
glycidyl
ether
(C12GE)
242.2 72.4384 58 8.41 5.01 2 0 -4.54 32 (skin) dermatomed
skin
dorsal flow-through
dodecyl mo-
noethoxy-
late
230.4 69.986 9.16 4.5 2 1 -2.26 37 dermatomed
0,244 mm
dorsal static
dodecyl mo-
noethoxy-
late
230.4 69.986 9.16 4.5 2 1 -6.49 37 dermatomed
0,244 mm
dorsal flow-through
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domperidone 425.92 115.7121 242.5 12.48 3.35 3 2 -2.55 37 full-
thickness
dorsal flow-through
epikote
YX4000
354.4 101.7748 11.00 5.19 4 0 -1.01 32 dermatomed
skin
dorsal flow-through
erioglaucine 793.86 0 283 -1.5 -5.4 37 full-
thickness
abdomen static
erioglaucine 793.86 0 283 -1.5 -4.88 37 full-
thickness
abdomen static
erioglaucine 793.86 0 283 -1.5 -5.27 37 full-
thickness
abdomen static
erioglaucine 793.86 0 283 -1.5 -4.12 37 full-
thickness
abdomen static
erioglaucine 793.86 0 283 -1.5 -5.00 37 full-
thickness
abdomen static
erioglaucine 793.86 0 283 -1.5 -4.70 37 full-
thickness
abdomen static
erioglaucine 793.86 0 283 -1.5 -4.70 37 full-
thickness
abdomen static
ethanol 46.07 13.0093 -114.1 10.92 -0.14 1 1 -3.38 30 full-
thickness
back static
ethyl
benzene
106.2 35.7002 -94.9 9.04 3.03 0 0 -3.51 32 (skin) dermat.
0,56 mm
back static
ethylaniline 121.2 40.9998 -64 9.73 2.11 1 1 -0.94 37 isol.epidermis Not given flow-through
felodipine 384.3 0 283 10.43 3.86 3 1 -2.40 37 full-
thickness
dorsal flow-through
fenoxapropethyl 361.78 0 84 11.06 4.95 5 0 -3.15 37 dermatom.
0,6 mm
back flow-through
fenoxapropethyl 361.78 0 84 11.06 4.95 5 0 -3.46 37 dermatom.
0,9 mm
back flow-through
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fenoxapropethyl 361.78 0 84 11.06 4.95 5 0 -3.46 37 dermatom.
0,8 mm
back flow-through
haloperidol 375.9 102.5915 151.5 10.78 4.22 4 1 -1.70 37 full-
thickness
abdomen flow-through
hydroquinone 110.11 29.4462 170 15.18 1.03 2 2 -4.66 30 full-
thickness
abdomen static
ketoprofen 254.29 0 94 11.75 3.12 2 1 -1.73 32 full-
thickness
static
linoleic acid 289.45 88.5188 -5 9.05 7.51 1 1 -4.54 37 full-
thickness
sides,abdomen
and back
static
lorazepam 321.16 80.9184 167 12.91 2.41 3 2 -4.29 37 full-
thickness
abdomen static
lorazepam 321.16 80.9184 167 12.91 2.41 3 2 -3.94 37 full-
thickness
abdomen static
lorazepam 321.16 80.9184 167 12.91 2.41 3 2 -4.11 37 full-
thickness
abdomen static
lorazepam 321.16 80.9184 167 12.91 2.41 3 2 -3.70 37 full-
thickness
abdomen static
lorazepam 321.16 80.9184 167 12.91 2.41 3 2 -3.44 37 full-
thickness
abdomen static
lorazepam 321.16 80.9184 167 12.91 2.41 3 2 -3.82 37 full-
thickness
abdomen static
lorazepam 321.16 80.9184 167 12.91 2.41 3 2 -3.25 37 full-
thickness
abdomen static
mannitol 182.17 38.4036 138.97 18.53 -3.01 6 6 -3.49 30 full-
thickness
dorsal static
mannitol 182.17 38.4036 138.97 18.53 -3.01 6 6 -3.64 30 isol.epidermis dorsal static
mannitol 182.17 38.4036 138.97 18.53 -3.01 6 6 -3.24 not given full-
thickness
dorsal static
mannitol 182.17 38.4036 138.97 18.53 -3.01 6 6 -3.06 not given isol.epidermis dorsal static
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mannitol 182.17 38.4036 138.97 18.53 -3.01 6 6 -3.04 32 isol.epidermis dorsal not given
mannitol 182.17 38.4036 138.97 18.63 -3.01 6 6 -3.40 not given dermat.
0,23 mm
dorsal static
mannitol 182.17 38.4036 138.97 18.63 -3.01 6 6 -3.06 32 dermat.
0,23 mm
dorsal flow-through
mannitol 182.17 38.4036 138.97 18.63 -3.01 6 6 -2.87 30 full-
thickness
back static
mefenamic
acid
241.29 71.385 230 11.85 5.28 2 0 -2.11 32 full-
thickness
static
methyl
nicotinate
137.14 35.4286 42.5 11.80 0.64 2 0 -2.49 30(skin) full-
thickness
skin
Abdomen static
methyl
nicotinate
137.14 35.4286 42.5 11.80 0.64 2 0 -2.56 30(skin) full-
thickness
skin
Abdomen static
methyl
nicotinate
137.14 35.4286 42.5 11.80 0.64 2 0 -2.65 30(skin) full-
thickness
skin
Abdomen static
methyl
nicotinate
137.14 35.4286 42.5 11.80 0.64 2 0 -2.18 30(skin) full-
thickness
skin
Abdomen static
metochloropramide354.3 83.0188 182 11.13 1.69 4 2 -2.04 37 full-
thickness
dorsal flow-through
metopimazine 445.61 122.3837 170.5 13.55 2.42 3 1 -2.29 37 full-
thickness
dorsal flow-through
naphthalene 128.2 42.5082 80.6 10.42 3.17 0 0 -3.29 32(skin) dermat.0,56mm back static
nicardipine 479.54 0 136 10.87 3.9 5 1 -2.31 37 full-
thickness
dorsal flow-through
nicorandil 211.18 0 92.5 14.40 0.43 3 1 -3.14 37 full-
thickness
abdomen static
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nifedipine 346.3 0 172 10.92 4.04 4 0 -2.77 37 full-
thickness
dorsal flow-through
nimodipine 418.4 0 125 10.50 3.13 3 1 -2.59 37 full-
thickness
dorsal flow-through
nitrendipine 360.4 0 184.13 11.44 2.99 5 1 -2.41 37 full-
thickness
dorsal flow-through
N-N-
Diethyl
m-
toluamide
191.28 58.9692 -45 10.70 2.26 1 0 -2.77 37 dermat.0,5mm back flow-through
nonane 128.3 43.2112 -53.5 7.51 4.76 0 0 -4.38 32 (skin) dermatom.
0,56 mm
back static
o-cresyl
glycidyl
ether
(oCGE)
164.2 46.3071 30.25 10.38 2.16 2 0 -3.87 32 dermatomed
skin
dorsal flow-through
paraquat 257.16 0 300 10.45 -2.71 0 0 -3.46 30 full-
thickness
back static
propoxur 209.25 56.3432 87 10.31 1.9 2 1 -3.28 32 full-
thickness
dorsal static
propoxur 209.25 56.3432 87 10.31 1.9 2 1 -2.43 32 isol.epidermis dorsal static
salicylamide 137.14 36.3327 140 16.60 1.03 2 2 -4.77 32 (skin) full-
thickness
not given static
salicylic
acid
138.1 34.5105 158 14.39 2.24 2 2 -1.98 25. full-
thickness
dorsal static
salicylic
acid
138.1 34.5105 158 14.39 2.24 2 2 -2.14 25. full-
thickness
dorsal static
salicylic
acid
138.1 34.5105 158 14.39 2.24 2 2 -2.88 25. full-
thickness
dorsal static
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salicylic
acid
138.1 34.5105 158 14.39 2.24 2 2 -1.61 25. full-
thickness
dorsal static
salicylic
acid
138.1 34.5105 158 14.39 2.24 2 2 -4.62 32 (skin) full-
thickness
not given static
scopolamine 303.4 79.7213 59 11.53 0.39 4 1 -2.39 37 full-
thickness
dorsal flow-through
terbinafine 291.4 98.0752 9.33 5.81 1 0 -1.26 32 full-
thickness
unknown static
testosterone 288.4 84.5453 155 10.66 3.27 2 1 -3.70 32 isol.epidermis abdomen static
testosterone 288.4 84.5453 155 10.66 3.27 2 1 -2.74 37(not
given)
full-
thickness
dorsal static
testosterone 288.4 84.5453 155 10.66 3.27 2 1 -3.89 37(not
given)
full-
thickness
dorsal static
testosterone 288.4 84.5453 155 10.66 3.27 2 1 -4.15 37(not
given)
full-
thickness
dorsal static
testosterone 288.4 84.5453 155 10.66 3.27 2 1 -4.70 37(not
given)
full-
thickness
dorsal static
theophylline 180.17 44.3867 273 14.05 -0.39 4 1 -2.03 37 dermatom.
0,45 mm
dorsal flow-through
theophylline 180.17 44.3867 273 14.05 -0.39 4 1 -1.96 37 dermatom.
0,45 mm
dorsal flow-through
theophylline 180.17 44.3867 273 14.05 -0.39 4 1 -1.86 37 dermatom.
0,45 mm
dorsal flow-through
theophylline 180.17 44.3867 273 14.05 -0.39 4 1 -2.66 37 dermatom.
0,45 mm
dorsal flow-through
toluene
(methyl
benzene)
92.1 31.0992 -94.9 9.14 2.54 0 0 -2.96 32(skin) dermatom.
0,56 mm
back static
triclosan 289.55 68.4073 56 10.02 2.47 2 1 0.13 32 dermatomed
0,28 mm
dorsal flow-through
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tridecane 185.4 61.6152 -5.5 7.74 6.73 0 0 -4.82 32(skin) dermatomed
0,56 mm
back static
undecane 156.31 52.4132 -25.6 7.64 5.74 0 0 -4.60 32(skin) dermatom.
0,56 mm
back static
urea 60.6 13.0926 135 14.36 -1.56 1 2 -4.80 32 full-
thickness
back static
urea 60.6 13.0926 135 14.36 -1.56 1 2 -3.80 32 full-
thickness
back static
urea 60.6 13.0926 135 14.36 -1.56 1 2 -2.73 32 full-
thickness
abdomen static
water 18.02 0 0 26.68 -1.38 1 1 -2.13 31,5 (skin) isol.epidermis back flow-through
water 18.02 0 0 26.68 -1.38 1 1 -2.77 31,5 (skin) isol.epidermis back flow-through
water 18.02 0 0 26.68 -1.38 1 1 -1.29 31,5 (skin) isol.dermis back flow-through
water 18.02 0 0 26.68 -1.38 1 1 -2.84 30 full-
thickness
dorsal static
water 18.02 0 0 26.68 -1.38 1 1 -2.94 30 isol.epidermis dorsal static
water 18.02 0 0 26.68 -1.38 1 1 -2.71 not given full-
thickness
dorsal static
water 18.02 0 0 26.68 -1.38 1 1 -2.85 not given isol.epidermis dorsal static
water 18.02 0 0 26.68 -1.38 1 1 -2.7 32 dermatomed
0,23 mm
dorsal flow-through
xylene
(dimethyl
benzene)
106.2 36.1404 -50 9.10 3.09 0 0 -3.77 32(skin) dermatom.
0,56 mm
back static
B.2.3 Pig dataset
B.2.3.1 Experimental conditions
• Skin thickness: Full thicknessepidermal
• Site: Outer ear
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• Cell type: Flow-through/Static
• Temperature: 30ºC and 37ºC
• Time: 4, 24, 48h
• Vehicle: Water, physiological buffer, propylene glycol, ethanol, aqueous satur-
ated solution, isotonic phosphate buffered saline (pH7.4) with ethanol, propyl-
ene glycol, Azone
• Receptor fluid: phosphate buffered saline PH 7.4
B.2.3.2 Data
Name Mwt MR Mpt SP logP Ha HD logKp Temp C membrane Site Cell type
water 18.02 0.00 0.00 26.68 -1.38 1 1 -2.65 not given full-
thickness
outer ear static
salicylic
acid
138.1 34.5105 158.00 14.39 2.24 2 2 0.10 32 dermatomed
0,6 mm
unknown static
2-
phenylphenol
170.21 52.8883 59 12.24 3.28 1 1 -1.80 30 full-
thickness
ear perfused pig ear
mannitol 182.17 38.4036 138.97 18.63 -3.01 6 6 -2.82 32 isol.epidermis outer ear flow-through
caprtopril 217.29 54.7325 106 11.55 0.84 2 2 -3.53 37 fresh
epidermal
membrane
pig ears static
caprtopril 217.29 54.7325 106 11.55 0.84 2 2 -2.83 37 frozen
epidermal
membrane
pig ears static
methyl ester 231.29 52.9845 119 9.31 2.9 2 0 -2.75 37 fresh
epidermal
membrane
pig ears static
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methyl ester 231.29 52.9845 119 9.31 2.9 2 0 -2.44 37 frozen
epidermal
membrane
pig ears static
ethyl ester 245.29 57.7325 105 9.25 3.39 2 0 -1.66 37 fresh
epidermal
membrane
pig ears static
ethyl ester 245.29 57.7325 105 9.25 3.39 2 0 -2.09 37 frozen
epidermal
membrane
pig ears static
propyl ester 259.29 62.2567 116 9.20 3.89 2 0 -1.8 37 fresh
epidermal
membrane
pig ears static
propyl ester 259.29 62.2567 116 9.20 3.89 2 0 -1.91 37 frozen
epidermal
membrane
pig ears static
butyl ester 273.29 66.8577 127 8.14 4.38 2 0 -1.84 37 fresh
epidermal
membrane
pig ears static
butyl ester 273.29 66.8577 127 8.14 4.38 2 0 -1.97 37 frozen
epidermal
membrane
pig ears static
tropicamide 284.4 82.5341 96.50 12.53 1.19 3 1 -6.15 37 epidermal
membrane
pig ears flow-through
pentyl ester 287.29 71.4587 138 9.11 4.87 2 0 -2.16 37 fresh
epidermal
membrane
pig ears static
pentyl ester 287.29 71.4587 138 9.11 4.87 2 0 -2.97 37 frozen
epidermal
membrane
pig ears static
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atropine 289.38 80.8156 116 11.04 1.91 3 1 -5.75 37 epidermal
membrane
pig ears flow-through
hexyl ester 301.29 76.0597 150 9.07 5.36 2 0 -2.91 37 frozen
epidermal
membrane
pig ears static
scopolamine 303.4 79.7213 59.00 11.53 0.39 4 1 -6.29 37 epidermal
membrane
pig ears flow-through
B.3 Enhancement Ratio (ER) dataset
B.3.1 Data
Compound H bond C chain MW Mean logP Mean logS ER Q Group Formula
696.01 7 0 60.06 -1.692 0.565 1.5 0 C1H4N2O1
695.04 3 0 85.11 -0.658 0.595 1.2 0 C4H7N1O1
695.13 1 1 85.15 0.72 0.385 1.4 0 C5H11N1
695.05 2 1 99.13 -0.328 0.685 1 0 C5H9N1O1
695.06 3 1 99.13 -0.164 0.34 1.3 0 C5H9N1O1
695.14 3 1 113.12 -0.688 0.465 1.4 0 C5H7N1O2
695.08 2 2 113.16 0.228 0.445 1.1 0 C6H11N1O1
695.09 6 0 129.12 -1.102 -0.065 1.1 0 C5H7N1O3
694.1 3 1 129.16 -0.598 0.645 1.3 0 C6H11N1O2
694.09 3 1 155.2 0.58 -0.285 4.6 0 C8H13N1O2
695.11 5 2 157.17 -0.226 -0.13 1.1 0 C7H11N1O3
695.16 4 1 159.23 0.214 -0.013 2 0 C8H17N1O2
695.12 2 2 167.25 1.756 -1.02 1.2 0 C10H17N1O1
695.15 2 6 169.27 2.276 -1.365 1.2 0 C10H19N1O1
697.01 2 1 181.26 2.263 -2.54 0.74 0 C9H11N1O1S1
698.15 3 1 198.25 2.52 -3.32 1.47 0 C8H10N2O2S1
698.13 4 1 199.23 1.54 -2.86 9.03 0 C7H9N3O2S1
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443.06 2 9 200.32 4.23 -3.64 8 0 C12H24O2
690.01 4 1 210.28 0.242 -0.335 0.8 0 C11H18N2O2
696.07 5 2 212.25 2.842 -3.37 2 0 C13H12N2O1
698.14 3 1 212.27 2.88 -3.49 1.17 0 C9H12N2O2S1
697.02 2 1 215.7 2.75 -3.05 1.44 0 C9H10N1O1S1Cl1
698.01 3 1 217.31 2.007 -2.18 0.48 0 C8H11N1O2S2
694.06 1 10 224.39 5.77 -5.23 6.7 0 C15H28O1
698.1 4 1 226.26 2.175 -3.61 0.77 0 C9H10N2O3S1
696.08 5 2 228.32 2.752 -4.33 3.7 0 C13H12N2S1
698.12 2 1 228.32 3.49 -5.69 1.16 0 C13H12N2S1
696.02 6 12 228.38 4.466 -3.3 2.8 0 C13H28N2O1
698.06 3 1 231.34 2.492 -2.46 0.93 0 C9H13N1O2S2
694.05 1 10 238.41 6.058 -5.475 7.9 0 C16H30O1
695.03 1 12 239.44 6.492 -5.45 5.2 0 C16H33N1
696.03 5 12 242.4 4.908 -3.295 1.8 0 C14H30N2O1
698.11 3 1 248.31 3.575 -4.92 1.28 0 C12H12N2O2S1
698.08 3 1 251.76 2.6 -2.9 0.4 0 C8H10N1O2S2Cl1
694.02 2 11 253.43 5.19 -4.325 15.6 1 C16H31N1O1
695.01 2 12 253.43 5.494 -4.41 23 1 C16H31N1O1
698.18 1 1 256.58 4.292 -4.69 2.21 0 C8H8N1S1Cl3
698.16 3 2 257.36 3.775 -4.06 2.81 0 C14H15N3S1
696.04 5 12 258.47 5.18 -4.31 5.3 0 C14H30N2S1
698.09 2 1 260.15 2.738 -2.83 23.12 1 C9H10N1O1S1Br1
698.04 5 1 262.31 1.968 -3.33 0.68 0 C8H10N2O4S2
694.04 3 11 267.41 4.946 -3.895 10.1 1 C16H29N1O2
694.01 2 11 267.46 5.65 -4.56 14.7 1 C17H33N1O1
694.14 2 12 267.46 5.82 -4.62 22.2 1 C17H33N1O1
690.07 6 1 268.31 0.156 -0.89 0.6 0 C13H20N2O4
694.12 3 11 269.43 4.488 -3.62 15.1 1 C16H31N1O2
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443.05 5 12 273.46 4.332 -3.62 6.4 0 C16H35N1O2
698.07 5 1 275.35 2.117 -2.94 0.19 0 C10H13N1O4S2
690.02 4 6 280.41 2.69 -2.29 2.1 0 C16H28N2O2
694.03 3 11 281.44 5.36 -4.165 7.7 0 C17H31N1O2
694.99 2 12 281.48 6.254 -4.85 22.1 1 C18H35N1O1
443.03 3 12 285.47 5.22 -4.375 7.8 0 C17H35N1O2
694.07 3 11 285.49 5.422 -4.49 21 1 C16H31N1O1S1
696.09 5 12 304.48 6.675 -3.94 1.1 0 C19H32N2O1
695.02 4 12 311.46 5.308 -4.105 11 1 C18H33N1O3
443.04 3 12 313.52 6.002 -5.045 6.1 0 C19H39N1O2
696.1 5 12 320.54 6.614 -5.085 3.4 0 C19H32N2S1
690.03 4 10 336.52 4.682 -3.945 8.8 0 C20H36N2O2
690.08 6 6 338.45 2.706 -2.605 1 0 C18H30N2O4
698.17 7 1 338.45 1.777 -3.83 0.83 0 C14H18N4O2S2
698.19 8 1 340.43 1.495 -4.3 0.72 0 C13H16N4O3S2
690.04 4 12 364.57 5.688 -4.46 11 1 C22H40N2O2
690.09 6 8 366.5 3.704 -3.505 2.2 0 C20H34N2O4
690.05 4 14 392.63 6.432 -4.97 18.6 1 C24H44N2O2
690.1 6 10 394.55 4.648 -4.16 4 0 C22H38N2O4
694.08 2 12 395.71 9.684 -6.55 8.9 0 C26H53N1O1
696.05 5 12 396.7 9.484 -6.85 1.9 0 C25H52N2O1
696.06 5 12 412.77 9.702 -7.81 1.6 0 C25H52N2S1
690.06 4 16 420.68 7.382 -5.455 9.6 0 C26H48N2O2
690.11 6 12 422.61 5.652 -4.72 9.1 0 C24H42N2O4
690.12 6 14 450.66 6.394 -5.29 9.6 0 C26H46N2O4
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B.4 Magnusson datasets
B.4.1 Magnusson set A
B.4.1.1 Experimental conditions
• Temperature: 298 to 312 Kelvin
B.4.1.2 Data
Compound logJmaxb Texpc Mwd logKowe Mptf Saqg Saq(T)h Hdk Hal
Benzene -5.61 304 78.1 2.22 279 2.30E-05 2.30E-05 0 0
Benzoic acid -5.9 308 122.1 1.9 395 4.10E-05 4.10E-05 1 2
Benzoic acid -5.9 308 122.1 1.9 395 4.10E-05 4.10E-05 1 2
Benzyl alcohol -5.62 298 108.1 1.04 258 4.00E-04 4.00E-04 1 1
Betamethasone-17-valerate -10.65 298 476.6 3.98 457 1.90E-08 1.90E-08 2 6
p-Bromophenol -5.5 298 173 2.49 337 8.70E-05 8.70E-05 1 1
2,3-Butanediol -6.25 303 90.1 -0.99 298 1.1E-2n 1.1E-2n 2 2
Butanol -5.59 303 74.1 0.88 184 8.50E-04 8.50E-04 1 1
Butanol -5.67 298 74.1 0.88 184 8.50E-04 8.50E-04 1 1
2-Butanone -4.86 303 72.1 0.37 187 3.10E-03 3.10E-03 0 1
Chlorocresol -5.72 298 142.6 2.89 340 3.50E-05 3.50E-05 1 1
p-Chlorophenol -5.17 298 128.6 2.43 317 1.90E-04 1.90E-04 1 1
o-Chlorophenol -5.25 298 128.6 2.04 282 1.70E-04 1.70E-04 1 1
Chloroxylenol -6.95 298 156.6 3.35 389 1.90E-06 1.90E-06 1 1
Cortexone -9.87 299 330.5 3.41 415 1.80E-07 1.30E-07 1 3
Corticosterone -9.51 300 346.5 1.76 454 5.70E-07 6.20E-07 2 4
Corticosterone -10.54 299 346.5 1.76 454 5.70E-07 5.90E-07 2 4
Corticosterone -10.89 298 346.5 1.76 454 5.70E-07 5.70E-07 2 4
Corticosterone -8.83 312 346.5 1.76 454 5.70E-07 9.10E-07 2 4
Cortisone -11.19 299 360.5 1.24 495 7.80E-07 8.10E-07 2 5
p-Cresol -5.47 298 108.1 1.94 309 1.90E-04 1.90E-04 1 1
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p-Cresol -4.62 310 108.1 1.94 309 2.00E-04 2.50E-04 1 1
o-Cresol -5.44 298 108.1 1.94 303 2.30E-04 2.30E-04 1 1
m-Cresol -5.45 298 108.1 1.94 285 2.30E-04 2.30E-04 1 1
Decanol -7.73 298 158.3 4.06 279 2.30E-07 2.30E-07 1 1
2,4-Dichlorophenol -5.73 298 163 3 318 3.10E-05 3.10E-05 1 1
beta-Estradiol -9.89 310 272.4 4.13 449 1.30E-08 1.80E-08 2 2
beta-Estradiol -11.88 299 272.4 4.13 449 1.30E-08 1.30E-08 2 2
beta-Estradiol -10.2 305 272.4 4.13 449 1.30E-08 1.60E-08 2 2
Estriol -11.23 299 288.4 2.94 555 1.10E-07 9.30E-08 3 3
Estrone -10.76 299 270.4 3.69 528 1.10E-07 1.20E-07 1 2
Ethanol -4.87 298 46 -0.19 159 1.7E-2n 1.7E-2n 1 1
2-Ethoxy ethanol -5.58 303 90.1 -0.27 183 1.0E-2n 1.0E-2n 1 2
Ethyl ether -4.88 303 74.1 0.98 157 8.20E-04 8.20E-04 0 1
p-Ethylphenol -5.85 298 122.2 2.47 318 4.10E-05 4.10E-05 1 1
5-Fluorouracil (+ - + -) -8.57 305 130.1 -0.78 556 8.50E-05 1.30E-04 2 4
Heptanol -6.27 303 116.2 2.47 238 1.40E-05 1.40E-05 1 1
Heptanol -6.34 298 116.2 2.47 238 1.40E-05 1.40E-05 1 1
Hexanol -6.13 298 102.2 1.94 228 5.80E-05 5.80E-05 1 1
Hydrocortisone (HC) -11.64 299 362.5 1.43 493 8.80E-07 9.20E-07 3 5
Hydrocortisone (HC) -11.6 298 362.5 1.43 493 8.80E-07 8.80E-07 3 5
4-Hydroxybenzyl alcohol -6.97 310 124.1 0.3 393 5.40E-05 8.90E-05 2 2
alfa-(4-Hydroxyphenyl) acetamide -7.37 310 151.2 -0.29 450 9.50E-05 1.40E-04 3 3
17-alfa-Hydroxyprogesterone -10.77 299 330.5 2.89 496 2.00E-08 1.90E-08 1 3
Mannitol -7.05 312 182.2 -4.67 440 9.10E-04 1.80E-03 6 6
Mannitol -7.26 300 182.2 -4.67 440 9.10E-04 1.00E-03 6 6
Mannitol -6.93 303 182.2 -4.67 440 9.10E-04 1.20E-03 6 6
Methanol -4.81 298 32 -0.72 175 3.1E-2n 3.1E-2n 1 1
Methanol -4.3 303 32 -0.72 175 3.1E-2n 3.1E-2n 1 1
Methyl-4-hydroxy benzoate -6.92 298 152.1 1.87 401 1.30E-05 1.30E-05 1 3
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beta-Naphthol -6.71 298 144.2 2.71 396 6.90E-06 6.90E-06 1 1
Nicotinate, ethyl -5.65 310 151.2 1.41 282 3.70E-04 3.70E-04 0 3
Nicotinate, methyl -5.97 310 137.1 0.88 316 3.50E-04 5.20E-04 0 3
p-Nitrophenol -6.25 298 139.1 1.57 387 1.00E-04 1.00E-04 1 4
m-Nitrophenol -6.28 298 139.1 1.93 370 9.30E-05 9.30E-05 1 4
Nonanol -7.23 298 144 3.53 268 9.70E-07 9.70E-07 1 1
Octanol -6.67 298 130.2 3 258 4.10E-06 4.10E-06 1 1
Octanol -6.6 303 130.2 3 258 4.10E-06 4.10E-06 1 1
Pentanol -5.82 298 88.2 1.41 194 2.50E-04 2.50E-04 1 1
Phenol -4.77 310 94.1 1.48 314 8.80E-04 1.20E-03 1 1
Phenol -6.88 295 94.1 1.48 314 8.80E-04 8.20E-04 1 1
Phenol -5.17 298 94.1 1.48 314 8.30E-04 8.30E-04 1 1
2-Phenylethanol -5.86 298 122.2 1.36 259 1.80E-04 1.80E-04 1 1
o-Phenylenediamine -6.74 305 108.1 0.05 377 4.10E-04 3.80E-04 4 2
p-Phenylenediamine -7.09 305 108.1 -0.85 419 3.40E-04 4.50E-04 4 2
Prednisolone -10.56 298 360.4 1.69 514 6.20E-07 6.20E-07 3 5
Pregnenolone -10.09 299 316.5 4.52 466 2.20E-08 1.50E-08 1 2
Progesterone -10.37 299 314.5 4.04 394 2.80E-08 2.90E-08 0 2
Propanol -4.65 303 60 0.34 147 1.3E-2n 1.3E-2n 1 1
Propanol -4.8 298 60 0.34 147 1.3E-2n 1.3E-2n 1 1
Resorcinol -5.81 298 110.1 0.76 384 6.50E-03 6.50E-03 2 2
Sucrose -7.24 310 342.3 -3.85 459 6.10E-03 9.20E-03 8 11
Testosterone -10.46 299 288.4 3.48 428 8.10E-08 8.40E-08 1 2
Testosterone -10.16 298 288.4 3.48 428 8.10E-08 8.10E-08 1 2
Thymol -6.45 298 150.2 3.28 325 6.70E-06 6.70E-06 1 1
Toluene -5.32 310 92.1 2.68 178 5.70E-06 5.70E-06 0 0
Triamcinolone -12.09 298 394.5 1.03 543 2.00E-07 2.00E-07 4 6
Triamcinolone acetonide -12.01 298 434.5 2.6 566 4.80E-08 4.20E-08 2 6
2,4,6-Trichlorophenol -6.57 298 197.5 3.58 342 4.60E-06 4.60E-06 1 1
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Urea -5.6 312 60.1 -2.11 406 9.10E-03 1.40E-02 4 3
Urea -5.76 300 60.1 -2.11 406 9.10E-03 9.60E-03 4 3
Urea -5.87 310 60.1 -2.11 406 9.10E-03 1.30E-02 4 3
Water -4.06 303 18 -1.38 273 5.6E-2n 5.6E-2n 2 1
Water -4.07 305 18 -1.38 273 5.6E-2n 5.6E-2n 2 1
Water -4.32 303 18 -1.38 273 5.6E-2n 5.6E-2n 2 1
Water -4.56 298 18 -1.38 273 5.6E-2n 5.6E-2n 2 1
3,4-Xylenol -5.83 298 122.2 2.4 334 4.10E-05 4.10E-05 1 1
B.4.2 Magnusson set B
B.4.2.1 Experimental conditions
• Temperature: 295 to 310 Kelvin
B.4.2.2 Data
Compound logJmaxb Texpc Mwd logKowe Mptf Saqg Saq(T)h Hdk Hal
Aminopyrine -6.6 310 231.3 0.76 381 2.40E-04 2.90E-04 0 4
Aniline -5.09 303 93.1 0.94 267 3.90E-04 3.90E-04 2 1
Anisole -5.89 303 108.1 2.13 236 9.60E-06 9.60E-06 0 1
Antipyrine -6.53 310 188.2 0.27 385 4.30E-03 4.30E-03 0 3
Benzaldehyde -5.37 303 106.1 1.64 247 6.20E-05 6.20E-05 0 1
Benzene -5.49 310 78.1 2.28 279 2.30E-05 2.30E-05 0 0
Benzoic acid -5.86 308 122.1 1.9 395 4.10E-05 4.10E-05 1 2
Benzyl alcohol -5.25 303 108.1 1.04 258 4.00E-04 4.00E-04 1 1
Betamethasone -10.41 310 392.5 2.06 506 1.50E-07 2.40E-07 3 5
Betamethasone-17-valerate -9.92 310 476.6 3.98 457 1.10E-08 1.80E-08 2 6
Butobarbitone -8.35 303 212.3 1.75 400 2.30E-05 2.70E-05 2 5
Chloroform -5.03 299 119.4 1.76 209 6.70E-05 6.70E-05 0 0
Coumarin -6.93 310 146.1 1.39 344 1.30E-05 2.00E-05 0 2
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Cyclobarbitone -7.99 310 236.3 2.13 446 6.80E-06 1.00E-05 2 5
Dexamethasone -9.76 305 392.5 2.06 535 2.30E-07 3.00E-07 3 5
Diethylcarbamazine -6.3 303 199.3 1.14 321 4.00E-03 4.00E-03 0 4
Digitoxin -12.77 303 764.9 2.73 529 5.10E-09 6.20E-09 5 13
Ephedrine -5.74 303 165.2 1.05 307 3.00E-04 3.00E-04 2 2
beta-Estradiol -10.23 303 272.4 4.13 449 1.10E-08 1.10E-08 2 2
beta-Estradiol -10.24 303 272.4 4.13 449 1.50E-08 1.60E-08 2 2
Ethanol -5.27 303 46 -0.19 159 1.7E-2n 1.7E-2n 1 1
Ethanol -5.3 295 46 -0.19 159 1.7E-2n 1.7E-2n 1 1
5-Fluorouracil (+ - + -) -8.66 304 130.1 -0.78 556 8.50E-05 1.20E-04 2 4
5-Fluorouracil(+ - + -) -8.18 310 130.1 -0.78 556 8.50E-05 1.60E-04 2 4
Formaldehyde -4.82 303 30 0.35 155 1.30E-02 1.30E-02 0 1
Glycolic acid -5.15 305 76.1 -1.05 353 1.8E-2n 1.8E-2n 2 3
Griseofulvin -10.5 310 352.8 2.36 493 2.40E-08 3.80E-08 0 6
Hexanol -5.8 304 102.2 1.94 228 5.80E-05 5.80E-05 1 1
Hydrocortisone (HC) -9.98 303 362.5 1.43 493 8.80E-07 1.10E-06 3 5
HC-yl-propionate -10.12 310 418.5 2.51 469 2.30E-08 3.70E-08 2 6
Isoquinoline -6.23 303 129.2 1.96 299 3.50E-05 3.60E-05 0 1
Isosorbide dinitrate -7.03 310 236.1 0.9 343 2.30E-06 3.20E-06 0 10
Ketorolac (S) -8.8 305 255.3 2.08 449 1.30E-07 1.30E-07 1 4
Ketorolac (R) -8.71 305 255.3 2.08 449 1.40E-07 1.40E-07 1 4
Ketorolac (SR50:50) -8.29 305 255.3 2.08 429 2.50E-07 2.50E-07 1 4
Mannitol -7.25 303 182.2 -4.67 440 9.10E-04 1.20E-03 6 6
Morphine hydrochloride(+) -7.17 310 339.4 -2.53 473 2.40E-04 4.40E-04 2 4
Nicorandil -7.47 309 211.2 -1.02 358 1.90E-04 1.80E-04 1 7
Nicorandil ? -7.31 310 211.2 0.72 366 1.90E-04 1.90E-04 1 7
Nicotine -3.89 303 162.2 0.72 265 6.7E-3n 6.7E-3n 0 2
Nitroglycerine -7.24 303 227.1 2.22 287 5.70E-06 5.70E-06 0 12
Octanol -6.67 295 130.2 3 258 4.10E-06 4.10E-06 1 1
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Ouabain -10.86 303 584.7 -1.35 463 1.70E-05 2.00E-05 8 12
Ouabain -10.09 303 584.7 -1.35 463 2.10E-05 2.40E-05 8 12
Pentanol -5.82 295 88.2 1.41 194 2.50E-04 2.50E-04 1 1
2-Phenylethanol -5.67 303 122.2 1.36 259 1.80E-04 1.80E-04 1 1
Propanol -4.88 295 60 0.34 147 1.3E-2n 1.3E-2n 1 1
Sucrose -7.5 310 342.3 -3.85 459 6.10E-03 9.20E-03 8 11
Tetrachloroethylene -7.66 299 165.9 2.95 251 1.20E-06 1.20E-06 0 0
Trichloroethylene -6 299 131.4 2.26 188 8.40E-06 8.40E-06 0 0
Water -4.11 304 18 -1.38 273 5.6E-2n 5.6E-2n 2 1
Water -4.06 303 18 -1.38 273 5.6E-2n 5.6E-2n 2 1
Water -4.45 303 18 -1.38 273 5.6E-2n 5.6E-2n 2 1
Water -3.81 305 18 -1.38 273 5.6E-2n 5.6E-2n 2 1
B.4.3 Magnusson set C
B.4.3.1 Experimental conditions
• Temperature: 298 to 310 Kelvin
B.4.3.2 Data
Compound logJmaxb Texpc Mwd logKowe Mptf Saqg Saq(T)h Hdk Hal
Aniline -4.7 303 93.1 0.94 267 3.90E-04 3.90E-04 2 1
Anisole -5.04 303 108.1 2.13 236 9.60E-06 9.60E-06 0 1
Benzaldehyde -4.73 303 106.1 1.64 247 6.20E-05 6.20E-05 0 1
Benzene -4.62 304 78.1 2.22 279 2.30E-05 2.30E-05 0 0
Benzene -5.9 303 78.1 2.22 279 2.30E-05 2.30E-05 0 0
Benzyl alcohol -5.3 303 108.1 1.04 258 4.00E-04 4.00E-04 1 1
Butanol -6.19 298 74.1 0.88 184 8.50E-04 8.50E-04 1 1
Decanol -8.38 298 158.3 4.06 279 2.30E-07 2.30E-07 1 1
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Diethylene glycol monobutyl ether -5.74 310 162.23 0.44 205 6.1E-3n 6.1E-3n 1 3
Di (2-ethylhexyl) phthalate -9.59 303 390.56 8.7 223 6.10E-10 6.90E-10 0 4
Ethanol -4.91 299 46 -0.19 159 1.7E-2n 1.7E-2n 1 1
Ethoxyethyl acetate -4.97 310 132.16 0.72 211 1.90E-03 1.90E-03 0 3
Ethyl-3-ethoxypropionate -5.3 303 146.18 1.25 198 3.80E-04 3.80E-04 0 3
Ethylene glycol -5.72 303 62.07 -1.36 260 1.7E-2n 1.7E-2n 0 2
2-Ethylhexanol -6.53 303 130.23 2.82 197 6.80E-06 6.80E-06 1 1
Heptanol -6.74 298 116.2 2.47 238 1.40E-05 1.40E-05 1 1
n-Hexane -8.02 303 86.2 3.9 178 1.10E-07 1.10E-07 0 0
Hexanol -6.37 298 102.2 1.94 228 5.80E-05 5.80E-05 1 1
Methanol -3.59 298 32 -0.72 175 3.1E-2n 3.1E-2n 1 1
Nicotinate, benzyl -7.02 310 213.2 2.66 297 1.60E-06 1.60E-06 0 3
Nicotinate, ethyl -5.85 310 151.2 1.41 282 3.70E-04 3.70E-04 0 3
Nonanol -7.77 298 144 3.53 268 9.70E-07 9.70E-07 1 1
Octanol -7.2 298 130.2 3 258 4.10E-06 4.10E-06 1 1
Parathion -11.59 310 291.3 3.84 279 3.80E-08 3.80E-08 0 6
Pentanol -6.33 298 88.2 1.41 194 2.50E-04 2.50E-04 1 1
2-Phenylethanol -5.27 303 122.2 1.36 259 1.80E-04 1.80E-04 1 1
Propanol -5.67 298 60 0.34 147 1.3E-2n 1.3E-2n 1 1
B.4.4 Magnusson set D
B.4.4.1 Experimental conditions
• Temperature: 298 to 312 Kelvin
B.4.4.2 Data
Compound logJmaxb Texpc Mwd logKowe Mptf Saqg Saq(T)h Hdk Hal
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Acetylsalicylic acid -7.89 305 180.2 1.19 408 2.60E-05 3.20E-05 1 4
2-Amino-4-Nitrophenol -8.4 305 154.1 1.23 415 6.00E-06 7.90E-06 3 5
Amylobarbital -8.22 303 226.3 2.1 431 2.70E-06 3.10E-06 2 5
Aspartic acid (- + and - + -) -8.45 310 133.1 -0.67 543 4.00E-05 6.50E-05 4 5
Aspartic acid (- + and - + -) -8.27 310 133.1 -0.67 543 4.00E-05 6.50E-05 4 5
Atenolol -9.45 305 266.3 -1.4 428 7.10E-06 9.70E-06 4 5
Atropine -10.16 303 289.4 1.53 389 8.30E-06 9.60E-06 1 4
Baclofen -9.07 310 213.7 1.56 480 2.20E-05 3.20E-05 3 3
Barbital -8.34 303 184.2 0.69 463 4.00E-05 4.80E-05 2 5
Caffeine -6.75 303 194.2 -0.08 511 1.10E-04 1.30E-04 0 6
Codeine (+) -9.52 310 299.4 2.04 428 7.10E-06 1.00E-05 1 4
Diclofenac Sodium -7.47 310 296.2 -0.96 557 1.10E-04 1.80E-04 0 3
Diclofenac -9.82 310 296.2 3.28 430 8.00E-09 1.20E-08 0 3
Dopamine hydrochloride(+) -6.48 310 153.2 -3.4 439 3.40E-03 3.40E-03 4 3
Etorphine (+) -8.72 310 411.5 3 487 5.30E-07 5.30E-07 2 5
Fentanyl -9.11 310 336.5 3.93 361 5.90E-07 8.20E-07 0 3
Fentanyl -8.23 303 336.5 3.93 361 5.90E-07 6.80E-07 0 3
Flurbiprofen -7.27 310 244.3 4.12 384 3.30E-08 5.00E-08 1 2
Histidine (- +) -7.79 310 155.2 -1.19 560 2.90E-04 4.80E-04 4 5
Hydromorphone (+) -9.95 310 285.3 1.23 540 N/A N/A 1 4
4-Hydroxyphenyl acetic acid -6.55 310 152.1 0.77 423 1.10E-04 1.80E-04 2 3
Ibuprofen -6.92 310 206.3 3.72 349 1.00E-07 1.40E-07 1 2
Indomethacin -10.15 310 357.8 3.11 431 2.60E-09 3.80E-09 1 5
Indomethacin -8.79 310 357.8 3.11 431 2.60E-09 3.80E-09 1 5
Isoprenaline hydrocloride(+) -7.33 310 211.3 0.25 429 1.60E-03 2.30E-03 4 4
Ketoprofen -7.36 310 254.3 2.81 367 2.00E-07 3.00E-07 1 3
Levodopa (- +) -8.79 310 197.2 -4.7 558 2.50E-05 2.50E-05 5 5
Lidocaine (+) -7.14 310 234.3 2.36 342 1.70E-05 2.10E-05 1 3
Lidocaine (+) -6.54 310 234.3 2.36 342 1.70E-05 2.10E-05 1 3
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L-Lysine -5.35 310 146.2 -1.04 498 9.0E-3n 9.0E-3n 5 4
Meperidine (+) -8.62 310 247.3 2.81 543 1.30E-05 1.70E-05 0 3
Metoprolol -6.6 305 267.4 -0.51 397 3.00E-04 4.00E-04 2 4
Morphine (+) -12.08 310 285.3 1.27 528 5.20E-07 1.00E-06 2 4
Morphine (+) -10.68 310 285.3 1.27 528 5.20E-07 1.00E-06 2 4
Naproxen -8.57 310 230.3 3 426 6.90E-08 1.00E-07 1 3
Nicotinic acid (- +) -8.45 310 123.1 0.82 510 1.50E-04 2.30E-04 1 3
Oxprenolol -6.43 305 265.4 0.08 353 2.40E-04 2.40E-04 2 4
Paraquat dichloride (++) -7.31 303 186.3 -5.65 573 3.80E-03 5.80E-03 0 2
Paraquat dichloride (++) -7.49 303 186.3 -5.65 573 3.80E-03 5.80E-03 0 2
Phenobarbitone -8.66 303 232.2 1.71 449 4.80E-06 5.70E-06 2 5
Piroxicam -7.73 310 331.4 1.71 472 6.90E-08 1.20E-07 2 7
Propranolol -6.94 305 259.4 3.1 369 6.50E-05 8.40E-05 2 3
Propranolol (+) -8.55 310 259.4 3.1 369 2.30E-06 3.70E-06 2 3
Salicylic acid -7.08 298 138.1 2.06 432 1.60E-05 1.60E-05 2 3
Salicylic acid -6.99 303 138.1 2.06 432 1.60E-05 1.90E-05 2 3
Salicylic acid -6.22 310 138.1 2.06 432 1.60E-05 2.40E-05 2 3
Salicylic acid -5.91 310 138.1 2.06 432 1.60E-05 2.40E-05 2 3
Salicylic acid -6.45 310 138.1 2.06 432 1.60E-05 2.40E-05 2 3
Scopolamine -7.9 303 303.4 1.34 332 2.50E-04 2.50E-04 1 5
Sufentanil -8.99 310 386.5 3.42 370 2.00E-07 2.70E-07 0 4
Tetraethylammonium bromide (+) -6.41 300 130.3 -2.82 559 7.70E-03 8.40E-03 0 1
Tetraethylammonium bromide (+) -6.17 312 130.3 -2.82 559 7.70E-03 1.40E-02 0 1
B.4.5 Magnusson set E
B.4.5.1 Experimental conditions
• Temperature: 310 Kelvin
B.4.5.2 Data
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Compound logJmaxb Texpc Mwd logKowe Mptf Saqg Saq(T)h Hdk Hal
Acetaminophen -7.52 310 151.2 0.46 443 9.30E-05 1.37E-04 2 3
Benzoic acid -5.23 310 122.1 1.9 395 4.10E-05 4.33E-05 1 2
Benzyl alcohol -5.01 310 108.1 1.04 258 4.00E-04 3.97E-04 1 1
Caffeine -8.11 310 194.2 -0.08 511 1.10E-04 1.75E-04 0 6
Clonidine -7.22 310 230.1 1.59 403 5.90E-05 8.44E-05 2 3
Dextromethorphan -7.43 310 271.4 4.13 383 N/A N/A 0 2
Dextromethorphan HBr -7.48 310 271.4 -0.05 398 N/A N/A 0 2
Diazepam -7.78 310 284.7 2.82 405 1.80E-07 2.51E-07 0 3
beta-Estradiol -7.39 310 272.4 4.13 449 1.30E-08 1.84E-08 2 2
Ethacrynic acid -5.61 310 303.1 3.69 396 N/A N/A 1 4
5-Fluorouracil -7.61 310 130.1 -0.78 556 8.50E-05 1.59E-04 2 4
Furosemide -9.2 310 330.8 2.03 568 2.20E-07 2.95E-07 4 7
Griseofulvin -9.17 310 352.8 2.36 493 2.40E-08 3.78E-08 0 6
Hydralazine HCl -6.9 310 160.2 -1.53 548 N/A N/A 3 4
Hydrocortisone -8.94 310 362.5 1.43 493 8.80E-07 1.36E-06 3 5
Ibuprofen -5.68 310 206.3 3.72 349 1.00E-07 1.39E-07 1 2
Indolyl-3-acetic acid -7.2 310 175.2 1.41 442 8.60E-06 1.50E-05 2 3
Indomethacin -9.16 310 357.8 3.11 431 2.60E-09 3.83E-09 1 5
Isosorbide dinitrate -7.69 310 236.1 0.9 343 2.30E-06 3.15E-06 0 10
Ketoprofen -7.33 310 254.3 2.81 367 2.00E-07 3.20E-07 1 3
Methyl salicylate -5.05 310 152.1 2.55 265 4.60E-06 4.60E-06 1 3
Minoxidil -8.41 310 209.3 1.24 521 1.10E-05 1.67E-05 4 6
Morphine sulfate -9.18 310 285.3 -1.76 527 N/A N/A 2 4
Naproxen -7.68 310 230.3 3 426 6.90E-08 1.10E-07 1 3
Nicotinic acid -7.75 310 123.1 0.82 510 1.50E-04 2.29E-04 1 3
Nifedipine -9.69 310 346.3 2.2 446 1.60E-07 2.41E-07 1 8
Pentazocine -8.62 310 285.4 4.64 419 N/A N/A 1 2
Pentazocine HCl -8.65 310 285.4 -1.7 527 N/A N/A 1 2
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Piroxicarn -8.68 310 331.4 1.71 472 6.90E-08 1.17E-07 2 7
Propranolol HCl -7.59 310 259.4 -0.45 436 N/A N/A 2 3
Salicylamide -6.41 310 137.1 0.89 415 1.50E-05 2.17E-05 3 3
Salicylic acid -4.86 310 138.1 2.06 432 1.60E-05 2.38E-05 2 3
Sulindac -10.07 310 356.4 3.42 456 8.40E-06 1.26E-05 1 3
Terbutaline sulfate -9.75 310 225.3 -1.9 520 N/A N/A 4 4
Testosterone -6.92 310 288.4 3.48 428 8.10E-08 1.18E-07 1 2
Triamcinolone acetonide -9.38 310 434.5 2.6 566 4.80E-08 7.01E-08 2 6
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P. Ashraﬁa, G.P. Mossb*, S.C. Wilkinsonc, N. Daveya and Y. Suna
aSchool of Computer Science, University of Hertfordshire, Hatﬁeld, UK; bSchool of Pharmacy, Keele
University, Keele, UK; cMedical Toxicology Centre, Institute for Cellular Medicine, University of
Newcastle-upon-Tyne, UK
(Received 12 August 2014; in ﬁnal form 21 January 2015)
Machine learning (ML) methods have been applied to the analysis of a range of biological
systems. This paper reviews the application of these methods to the problem domain of
skin permeability and addresses critically some of the key issues. Speciﬁcally, ML methods
offer great potential in both predictive ability and their ability to provide mechanistic
insight to, in this case, the phenomena of skin permeation. However, they are beset by per-
ceptions of a lack of transparency and, often, once a ML or related method has been pub-
lished there is little impetus from other researchers to adopt such methods. This is usually
due to the lack of transparency in some methods and the lack of availability of speciﬁc
coding for running advanced ML methods. This paper reviews critically the application of
ML methods to percutaneous absorption and addresses the key issue of transparency by
describing in detail – and providing the detailed coding for – the process of running a ML
method (in this case, a Gaussian process regression method). Although this method is
applied here to the ﬁeld of percutaneous absorption, it may be applied more broadly to any
biological system.
Keywords: Gaussian process; machine learning; quantitative structure–permeability
relationships (QSPRs); skin permeation; percutaneous absorption
1. Introduction
1.1 Machine learning methods for predicting percutaneous absorption – a problem of
perception?
In developing mathematical models for percutaneous absorption, it is important to consider
that the endpoint, and the end user or client, is the key driver in developing such models,
rather than the mathematical modeller. In the context of skin absorption this reﬂects the
relevance of the model to those working in transdermal or topical drug delivery, to cosmetic
scientists and to toxicologists working in ﬁelds such as industrial risk assessment and the
absorption of pesticides.
The most obvious application of such models is to generate an algorithm which enables
prediction of absorption of chemicals for which no absorption data exist. Furthermore, mathe-
matical models or algorithms describing percutaneous absorption may yield important mecha-
nistic information on the absorption process. However, as machine learning (ML) methods do
not yield an explicit algorithm [1], they are perceived to give limited mechanistic insight and
*Corresponding author. Email: g.p.j.moss@keele.ac.uk
© 2015 Taylor & Francis
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therefore lack wider applicability to the ﬁeld. There is also a perception that machine learning
methods require the use of specialist software – either particular programmes or the expertise
to develop, within existing packages, speciﬁc codecs and macros to interpret the data cor-
rectly [2]. Furthermore, Cronin and Schultz have commented on the use of non-linear meth-
ods, suggesting that they are prone to over-ﬁtting and can often model the error inherent in
the data [3]. This is a valid criticism, despite the clear understanding that the vast majority of
biological systems are inherently non-linear in nature.
Models must be accessible to the ﬁeld that they are applied to. This means that a
model deﬁning percutaneous absorption, whether represented by an explicit algorithm or
some collation of descriptive statistics, should be comprehensible to, and usable by,
researchers in the ﬁeld to which the model is applied and not solely the developers of
the model. This is perhaps demonstrated by the widespread applicability and use of quan-
titative structure–activity relationship (QSAR) models for percutaneous absorption such as
Potts and Guy [4] or, to a lesser extent, the more recent models by Magnusson et al. [5]
and Moss and Cronin [6], compared with those described by Patel et al. [7], Moss et al.
[1], or indeed any number of machine learning methods that cannot be readily applied to
new data but which simply model existing data and draw inferences from it. Thus, pro-
ducing relevant models is a balance of employing powerful techniques with the ability of
the model to ﬁnd use in its ﬁeld. This means that the ability to develop models is central
to their continued use.
1.2 Aims and objectives
This article demonstrates the ease of use of machine learning models and aids the interpreta-
tion of the perceived limitations of models, including lack of transparency and lack of explicit
outputs. Further, the Gaussian process methods recently used successfully in models of percu-
taneous absorption are examined in more detail and the methods used presented, as a ‘tuto-
rial’, to address the perceived issue of lack of transparency so that other researchers in the
ﬁeld of percutaneous absorption, and related ﬁelds, may more readily employ such methods
in their research.
2. Machine learning methods applied to the pharmaceutical sciences
2.1 The ﬁrst statistical models for the prediction of percutaneous absorption
Traditionally, the prediction of percutaneous absorption using mathematical approaches has
concentrated on predicting two parameters: the steady state ﬂux (Jss), deﬁned as the rate
of chemical absorption (per unit surface area of exposed skin) during the zero-order,
steady-state part of the absorption proﬁle, with dimensions of μg/cm2/h and the permeabil-
ity coefﬁcient, kp. The permeability coefﬁcient is derived by dividing the ﬂux by the con-
centration of the applied penetrant, typically in a saturated aqueous solution, and has
dimensions of cm/h or cm/s. This allows ﬂuxes to be compared across a wide range of
chemicals, but kp is a somewhat artiﬁcial term, being a composite of the diffusion coefﬁ-
cient, skin:vehicle partition coefﬁcient and path length. This subject is reviewed in detail
elsewhere [8,9].
The publication of large amounts of permeability data from a range of experiments led to
the collation of data by Flynn [10]. From this he proposed a series of semi-quantitative expres-
sions (Table 1) which related permeability across human skin to speciﬁc physicochemical
182 P. Ashraﬁ et al.
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properties of molecules: their lipophilicity (represented by the octanol–water partition
coefﬁcient, log P or log Kow) and size (as molecular weight, MW). This work was quantiﬁed
[4,11] to develop quantitative structure–permeability relationships (QSPRs). The early work in
this ﬁeld has been extensively reviewed [8] and more recent work considered by the excellent
review by Mitragotri and colleagues [12].
2.2 New frontiers: Fuzzy logic and artiﬁcial neural networks
One particular problem regarding the prediction of percutaneous absorption is the sparseness
and ambiguity of available data, a point highlighted by Moss et al. [8]. Experimental data
used to derive the early QSPR models exist for relatively few compounds and originate
from a diversity of study designs, not always with the intention of deriving mathematical
models. This prompted Pannier et al. [13] to use the adaptive neural fuzzy interference sys-
tem to model skin permeability via the MatLab software package. Three models were devel-
oped using subtractive clustering to deﬁne structures within the data and to assign
subsequent rules; the models developed were able to successfully predict skin permeability
as well as, or better than, previously published algorithms with fewer inputs. Subsequently
Keshwani et al. [14] developed a rule-based Takagi–Sugeno fuzzy model, which was shown
to predict the permeability across human skin, using a previously published database con-
taining 140 compounds and log P, MW and temperature as input variables. This fuzzy
model was compared with a regression model for the same inputs using both the square of
the correlation coefﬁcient and root mean square error (RMSE) as measures of model qual-
ity, as well as comparison with previously published models. The results indicated that the
fuzzy model performed better than the regression model with identical data and validation
protocols, and was at least comparable with existing published models. However, despite
the success of this modelling approach, it has not been widely adopted in the literature.
This is most likely due to the complexity of the methodologies employed and their limited
use in physical sciences.
Artiﬁcial neural networks (ANNs) are biologically inspired computer programs which aim
to simulate the way in which the human brain processes information. They work by detecting
the patterns and relationships in data, and ‘learn’ or are trained systematically through experi-
ential modiﬁcations rather than from programming. An ANN is formed from hundreds of sin-
gle processing elements (PEs) which are interconnected via a series of coefﬁcients, or
weightings, signifying the relative importance of connections within the network (Figure 1).
Each PE within the network has individually weighted inputs, a transfer/transformation
Table 1. Algorithms for calculating permeability coefﬁcient (Kp).
Low molecular weight compounds
(<150 Da)
High molecular weight compounds
(>150 Da)
log Kow < 0.5 log Kp = –3 log Kp = –5
0.5 ≤ log Kow ≤ 3.0 log Kp = log Kow – 3.5
0.5 ≤ log Kow ≤ 3.5 log Kp = log Kow – 5.5
log Kow > 3.0 log Kp = –0.5
log Kow > 3.5 log Kp = –1.5
Adapted from [10].
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function and a single output which, along with the arrangement (or ‘architecture’ of the net-
work), governs the function of the ANN and the nature of its output. Examples of the typical
structures of feedback and feedforward ANNs are shown in Figure 2. The use of transforma-
tion functions may introduce non-linearity to the model. This function is optimised for each
PE within the network to reduce error in predictions and to make the predictions available
from the ANN as accurate as possible. Once this has been completed new data can be entered
to the ANN (within the same ‘chemical spaces’ as the training dataset) and predictions out-
put, that is, the same or similar domain which represents the range of physicochemical param-
eters of the dataset; in the case of the Potts and Guy model this was deﬁned as −3 < log P <
6 and 150 < MW ≤ 750 [4,12]. This method has enormous potential for application to many
ﬁelds, including pharmaceutical sciences.
For example, the broad application of ANNs to pharmaceutical research has been
reviewed [15]. As such, they also indicate the potential of the Gaussian process methods to
be applied to similar pharmaceutical domains. More broadly, ANNs have been applied to the
interpretation of analytical data [16] to enhance the use of response surface methodology
(RSM) to optimise formulations for drug release [17–22]. They have also been applied to the
analysis of gene classiﬁcation, and protein structure prediction and sequence classiﬁcation
[23,24]; they have also shown potential in the sequencing of biological molecules [25–27].
ANNs have been applied to the ﬁeld of predictive drug absorption via the development of
quantitative structure–permeability relationships (QSPRs). Such studies may employ related
techniques, such as genetic analyses, to optimise descriptor use and subsequent analysis
[28–31].
A number of researchers have applied ANN approaches to predict skin penetration [32–36].
They have also been applied to skin absorption, where a statistically signiﬁcant model
[r2 = 0.854; mean square error (MSE) = 0.04] based on the Abraham’s descriptors was
reported [37]. The resulting ANN models gave very good correlations with experimental data
and in many cases outperformed traditional QSPR models derived by linear regression or
multiple linear regression. Indeed, one research group [35] noted that their ANN model was
non-linear in nature. This is a ﬁnding that has been supported by more recent machine
learning studies [1,2,38].
But despite the superior performance of these ANN models to more traditional
approaches, very few of these techniques have established themselves as ﬁrst choice methods
Figure 1. Model of an artiﬁcial neuron. Modiﬁed from ref. [15].
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in the prediction of drug and/or exogenous chemical absorption via any number of routes.
Nor has their improved performance of ANN-based formulation design resulted in it ousting
response surface methodology as the key tool in this ﬁeld. This is most likely due to the spe-
cialist nature of these methods and the lack of specialist expertise in the pharmaceutical sci-
ences to apply this work correctly. This is emphasised by work of a greater clinical
signiﬁcance where ANN methods have been applied recently to the clinical diagnosis of skin
disease based on the intelligent classiﬁcation of sonogram information [39].
Figure 2. Schematic model of a feed–forward network (a) and a feed–back network (b) Modiﬁed from
[15].
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2.3 Classiﬁcation methods and avoiding over-parameterisation
Classiﬁcation methods were employed to analyse a dataset consisting of 116 structurally
diverse compounds, mainly drugs, characterised by 1630 molecular descriptors and related to
the skin permeability coefﬁcient, represented by log kp [40]. This approach was validated
using 12 compounds not included in the original dataset. Further, stepwise multiple linear
regression analysis was employed to ﬁnd the optimal model. Avoidance of over-parameterisa-
tion, which may be artiﬁcially achieved by adding more terms to the model, was facilitated
by the use of FIT (the Kubinyi function, which is related to the F-value but is less sensitive
to changes in k, where k is the number of variables in the equation that describes the model,
that is, the best model will have the highest FIT value) and AIC (Akaike’s Information Crite-
rion, a corrected measure of the sum of the square residuals, and thus;the best model will
have the lowest value). This allowed the number of parameters to be reduced from 23 to 10,
producing a model which the authors suggested was a good compromise between model com-
plexity and model ﬁtness. The inclusion of additional variables resulted in only minimal
improvements in model quality and resulted in the following expression:
log kpðcm=sÞ ¼ $6:243ð%2:12& 10$1Þ $ 3:14ð%6:17& 10$2ÞH:050$ 1:03ð%2:09
& 10$1ÞHypertens:50þ 1:04& 10$1ð%5:73& 10$2ÞALOGP$ 4:84
& 10$4ð%1:05& 10$4ÞSRW09þ 1:50& 10$1ð%3:09& 10$2ÞRDF075m
$ 1:39& 10$1ð%2:99& 10$2ÞH:052$ 4:84& 10$1ð%8:65& 10$2ÞT:ðS::FÞ
þ 4:77& 10$1ð%1:10& 10$1ÞC:025$ 10:60ð%2:73ÞR1m
þ$6:15ð%2:00ÞRTmþ
(1)
where: H.050 (atom-centred fragment) represents the number of hydrogen atoms attached to a
heteroatom; Hypertens.50 (molecular property class) is the Ghose–Viswanadhan–Wendoloski
50% antihypertensive drug-like index; SRW09 is the self-returning walk count of order 09;
RDF075m is the radial distribution function 7.5, which is weighted by atomic masses (i.e. the
corrected probability distribution associated with ﬁnding an atom in a spherical volume with
radius r); H.052 is the number of hydrogen atoms attached to C(sp30 with one halogen
attached to the next C; T.(S.F) is the sum of topological distances between S and F atoms;
C.025 is the atom-centred fragment R–CR–R; and R1m+ and RTm+ are GETAWAY class
descriptors describing the maximal autocorrelation of lag 1 and the maximal index, respec-
tively, both of which are weighted by atomic masses.
Although this approach produced a novel, statistically robust model that was a signiﬁcant
improvement on others available at the time, it still lacked accessibility – given the parame-
ters returned as signiﬁcant, and their applicability and use more broadly in the ﬁeld by non-
experts in modelling. Sadly it has found little application within the ﬁeld of percutaneous
absorption.
2.4 Embracing non-linearity: Gaussian process models applied to percutaneous absorption
A large skin permeability dataset (n = 142) was subjected to analysis by data visualisation
and both principal and canonical component analysis [1,2,38]. This demonstrated the funda-
mentally non-linear nature of the skin dataset, in contrast to a number of preceding studies
which were based on (multiple) linear regression analysis and related methods. The lack of
an explicit functional output, such as an equation, was addressed using the feature selection
method [2]. This produced a series of models containing every possible permutation of the
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physicochemical descriptors being modelled and therefore allows the best model – and com-
bination of parameters – to be determined. Length-scale analysis [38] indicated that models
of equal statistical quality and predictive ability could be constructed from a certain range of
physicochemical parameters and that certain parameters were effectively interchangeable, or
possibly co-linear. This ﬁnding suggests that the use of small datasets, or subsets, may bias
the output of models to particular physicochemical parameters. It certainly reﬂects the impor-
tance of hydrogen bonding, as described previously [41–43] in the context of models pro-
duced by Potts and Guy and others [4,6]. Application of non-linear methods [44] produced a
statistically robust model by integrating QSPRs, genetic algorithms and neural networks. The
resulting model suggested that size/shape and polarity descriptors accounted for approxi-
mately 70% of the permeability information in their model.
While such methods may superﬁcially appear to lack ‘real world’ relevance, particularly
as they do not yield an easily digestible equation, their relevance was demonstrated when the
performance of a Gaussian process model was compared with the Potts and Guy model [2].
They are characterised by the difference not only in proximity of each model to its intended
experimental target, but in the overall pattern of predictions across the whole dataset. Further,
Moss et al. [45] have shown the relevance of Gaussian process methods in a ‘real world’ situ-
ation when they examined a dataset of chemical penetration enhancers. They were able to
show that the ML methods were able to: (1) provide fewer classiﬁcation errors than discrimi-
nant analysis; and (2) generate predictions of enhancement, something which discriminant
analysis was not able to achieve. So although still a novel method, the use of machine
learning shows great potential but it does so, as all such studies should, within the framework
for developing robust mathematical models of biological processes [3].
2.5 Sources of input data: Literature sources of skin permeability data
The underlying data inputs from which a model is constructed are vital to the relevance and
validity of any model. For example, the applications for QSARs to skin permeation have been
considered by Moss et al. [8]. In this review the authors discussed the range of experiments
from which data were obtained and how this could introduce variance into any model subse-
quently derived. In particular, they focused on several key examples where skin permeability
data was shown to be erroneous [46]. These data were used to develop models of skin absorp-
tion, as they were included in Flynn’s dataset [10], which has been widely used by a large num-
ber of researchers. This led to inferences that, because they appeared as outliers in the dataset
analysis, steroids permeated the skin by a different mechanism to other chemicals due to the
comparatively large number of hydrogen bonds often found on such drugs. It was later deter-
mined that these data were erroneous by at least one order of magnitude [47] and, when they
were replaced and remodelled it was found that steroids were no longer modelled as outliers
[6]. Further, a large multi-centre validation study demonstrated that permeability data from a
number of laboratories, for a standardised protocol, was still highly variable [48]. Thus, these
studies underpin a major issue in the development of models using any statistical methods: the
quality of the underlying data and its validation. In most cases, models are limited in that they
are seldom able to consider such concerns due to a paucity of data and a lack of validation.
2.6 Limitations of skin permeability models: Solvent effects
One of the major limitations of skin permeability models is that they are almost exclusively
based on permeation from saturated aqueous solutions. This is due to Flynn’s description that
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the majority of environmental toxicology situations involve skin permeation from saturated
aqueous solutions [10]. Thus, his and subsequent models were based on this premise. While
addressing a signiﬁcant issue, the Flynn approach does not tackle skin permeation based on
exposures to non-aqueous solvents, which may also include ﬁnite-exposure scenarios; indeed,
few researchers have addressed this issue. However, signiﬁcant studies have developed quan-
titative models of skin permeation under such circumstances [49,50].
Similarly, these authors also developed similar QSAR methods to model solvent effects
on the permeation of a dataset similar to that described above [51]. The study design used a
porcine membrane and considered established models of skin permeability. Stepwise regres-
sion resulted in the following QSAR:
log kp ¼ $0:909$ 0:610logP þ 2:26xp $ 0:00918ðsolBP $ solMPÞ (2)
n ¼ 288; s ¼ 0:438; r2 ¼ 0:729; F ¼ 255:2; p ¼ 0:000(
where: log P is the octanol–water partition coefﬁcient; xp is the nineth-order path molecular
connectivity index; and (SolBP – SolMP) is the difference between the boiling point and the
melting point of the solvent system
This expression features two penetrant descriptors and one solvent mixture descriptor,
highlighting the signiﬁcance of solvent effects in skin permeation. Log P was determined to
be the most signiﬁcant descriptor and had a negative effect on skin permeation, which is sig-
niﬁcantly different from the vast majority of other QSAR models which do not consider non-
aqueous solvents. This was attributed to the lipophilic nature of their model compounds
which, while still sitting within a similar domain to most common QSAR models, was
skewed towards a higher mean log P value. The xp descriptor relates to the presence of
chains of nine atoms in a molecule and is related, in this study, to an ideal molecular weight
for skin permeation of approximately 350 Da. Finally, the difference in melting and boiling
points is considered signiﬁcant in the context of molecular symmetry.
The inﬂuence of skin biology on the utility of QSPR models was also explored by Riviere
and Brooks [52]. Solvent mixtures (16 chemicals and 384 permutations) were applied to por-
cine skin in vitro and QSPRs were thus derived. They produced a QSPR which describes the
effect of solvent mixtures and which was, signiﬁcantly, dependent on the methodology
employed to produce the data. They also described the known parabolic relationship between
skin permeability and log P, with its maxima normally at log P 2–3, and demonstrated that
this plateau is formulation dependent.
It is therefore clear that the advanced methods including fuzzy logic, machine learning
and ANNs have signiﬁcant application to pharmaceutical sciences and, in the case of percuta-
neous absorption, more broadly to the absorption of exogenous chemicals in many ﬁelds. But
although these methods have been applied sporadically, they have seldom taken hold and
established themselves within the ﬁeld. This may be due to the lack of transparency that such
methods feature, which limits any mechanistic interpretation and, in ﬁelds where signiﬁcant
regulatory hurdles exist for product safety and efﬁcacy, the lack of transparency and possibly
validation have been extremely negative issues. Moreover, the use of advanced or specialist
methods outside their normal spheres of use is a signiﬁcant issue, not only in ensuring com-
petent and appropriate use but also in ensuring correct interpretation of results. While multi-
disciplinary practices are recommended, some overlap between disciplines is also necessary.
Therefore, the great promise of these methods appears to have slowly dissipated and, despite
signiﬁcant limitations, the transparent and easy-to-apply regression methods, based mostly on
multiple linear regression analysis, still dominate this research ﬁeld.
188 P. Ashraﬁ et al.
Do
wn
loa
de
d b
y [
2.2
21
.12
0.0
] a
t 1
0:4
6 3
0 A
ug
us
t 2
01
5 
In the remainder of this article, we address these issues in the context of Gaussian process
machine learning methods. To achieve this, the codes used to construct the models are repre-
sented in the following sections as part of an overall description of how to conduct analysis
with these methods. This aims to remove the speciﬁc technical difﬁculties associated with the
application of these methods by researchers in a range of biological science ﬁelds. Ultimately,
this might be best served by the development of an online resource which carries out these
analyses for the uses. However, such a resource simply places an interface onto the model
and ensures that it still lacks transparency, whereas the description of the process that follows
should allow all users to develop their own Gaussian process based methods on any dataset.
3. Gaussian processes
3.1 Background to Gaussian process regression modelling.
Over the last decade Gaussian processes (GPs) have been increasingly favoured in the
machine learning community. Indeed, theoretical and practical developments in the past dec-
ade have seen GPs become the method of choice in a range of applications and ﬁelds [53].
One example of this is in the ﬁeld of percutaneous absorption [1,54], where the application
of GPs has been assessed for their ability to predict the permeability of new chemicals and to
provide mechanistic insight to the general process of skin permeation. It was found that the
GP regression can yield considerable improvements over the QSAR models previously used
for this purpose.
As far as we are aware, we are the only researchers to apply GP methods to the problem
domain of percutaneous absorption. This lack of uptake is a major limitation to the GP
method as, in general, we are essentially discussing our own work, which limits context and
applicability. The lack of uptake is a major criticism of the GP method and reﬂects the lack
of transparency in this, and related ML methods, which manifests itself quite signiﬁcantly as
the method does not yield an explicit functional representation of the process being modelled.
However, this paper aims to address such a shortcoming by providing sufﬁcient information,
notably the MatLab instructions used in our previous research, to allow other researchers to
use these methods.
The Gaussian process works in the following manner. Suppose we are given a number of
data points, each with a ﬁxed number of features (usually called the inputs); in general, ‘fea-
tures’ in this context refer to commonly used physicochemical descriptors of a molecule, and
include lipophilicity (as log P), molecular weight, melting point and the count of hydrogen
bond donors and/or acceptors on a molecule. For each input, there is a corresponding target.
The aim is to model the relationship between the inputs and their targets. For example, if we
consider a dataset with 100 chemical compounds and ﬁve physicochemical features (lipophil-
icity, molecular weight, hydrogen bonding donor and acceptor groups, and melting point).
The target is the deﬁning output for the system which, for models of skin permeability, is
usually the skin permeability coefﬁcient (kp) or the ﬂux (J); for the discussion below, the use
of kp in models is considered. In this case, the aim of the modelling process is to infer a func-
tion from the dataset (using the available descriptors) to their related skin permeability coefﬁ-
cients, and to then use this function to predict the skin permeability coefﬁcient for a new
compound.
There are two alternative approaches to solving such problems (which are generally classi-
ﬁed as regression problems) where the outputs represent the values of continuous variables.
The ﬁrst approach is to use parametric methods which assume a speciﬁc functional form for
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the relationship between the inputs and targets. For example, targets of ANNs can be
expressed either as a single layer or multiple layers of linear combinations of inputs (or hid-
den units, shown in Figure 2), optionally with non-linear activation functions on some of the
inputs (or hidden units). The weightings on these combinations are free parameters. The sec-
ond approach involves the use of non-parametric methods. Non-parametric methods do not
assume a particular functional form, but allow the form of the relationship between inputs
and targets to be determined entirely by the data.
The process of determining the values for the parameters on the basis of the dataset
employed is called ‘supervised learning’ or ‘supervised training’. Since the aim of the model-
ling is to ﬁnd the algorithm having the best performance on new data, the simplest approach
to compare different algorithms is to evaluate the error function of each model using data
which is independent of that used for training the model. Various models are trained to mini-
mise their particular error function deﬁned with respect to a training dataset. In addition, the
performance of each model should be evaluated using an independent test set.
Gaussian process modelling is a non-parametric method and does not produce an explicit
functional representation of the data. In a GP model it is assumed that the underlying function
that produces the data will remain unknown, but that the data are produced from a (poten-
tially inﬁnite) set of functions, with a Gaussian distribution in the function space. Thus, a
Gaussian process is completely characterised by its mean and covariance function. Generally,
a simpliﬁcation of the models sees the mean function being described as the ‘zero every-
where’ function. Thus, all targets are generated from a joint Gaussian distribution with a
mean of zero and a covariance function.
The covariance (or kernel) function, k(xi, xj) is crucial in GP modelling. It expresses the
expected correlation between values of f(x) at two points, xi and xj. Thus, it deﬁnes the near-
ness – or similarity – between data points and allows for specifying a priori information from
training data for solving the regression problem posed by the modelling experiments.
To make a prediction (y*) at a new input (x*) we need to compute the conditional distribu-
tion (deﬁned by p(y∗|y1, . . . yNtrn), where Ntrn denotes the number of training examples). As
the model of interest is a Gaussian process, this distribution is also Gaussian and is com-
pletely deﬁned by its mean and variance, which can be calculated using standard linear alge-
bra [55]. Thus, the prediction of a new input is usually approximated by the corresponding
mean value and the predictive variance can be obtained from the corresponding variance
value. The mean at x* is given by:
E½y*( ¼ kT* ðK þ r2nIÞ$1y (3)
where: k* denotes the vector of covariances between the test point and the Ntrn training data;
I is the identity matrix (with ones on the diagonal and zeros elsewhere); r2n is the variance of
an independent and identically distributed Gaussian noise (which infers that observations are
noisy); and y denotes the vector of training targets.
In addition, it should be noted that (K + r2nI) is a matrix of size Ntrn × Ntrn and is shown
as:
kðx1; x1Þkðx1; x2Þ . . . kðx1; xNtrn; Þ
kðx2; x1Þkðx2; x2Þ . . . kðx2; xNtrn; Þ
. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .
kðxNtrn; x1ÞkðxNtrn; x2Þ . . . kðxNtrn; xNtrn; Þ
2664
3775 (4)
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The predictive variance at x* is given by:
var½y*( ¼ kðx*; x*; Þ $ kT* ðK þ r2nIÞ$1k* (5)
where kðx*; x*Þ denotes the variance of y*.
In the output from these models the mean is used as the predicted value and the variance
as the error bars of the prediction.
GP methods are non-parametric in nature and hence are able to use as much information
as possible from a training dataset. Thus, it has been found that the GP regression algorithm
produces smoother and less biased results [55].
3.2 Gaussian processes regression: A simple example
Suppose we have two values of x, for which we know the values of the dependant variable y,
shown in Table 2. We want to predict the value of y for a new value of x, shown as x* above.
This is achieved in GP modelling by using a weighted average of the known values of y,
with the weighting determined by the closeness of x* to each value for x in the data. So, if x*
= 2, it is equally close to the original x values (1 and 3) so each is given equal weight and
the prediction is the average of y, 3. So, if x* = 2.5, which is 3 times as close to 3 as to 1,
then a weighted average of the known values of y would be [(0.75 × 4) + (0.25 × 2)], or 3.5.
It should also be noted that using the reciprocal of the distance between points is limited as
(1 / distance) approaches zero, yielding inconstant results.
In a GP model, the actual weighting is not exactly proportional to the separation from the
known values; rather, it is a Gaussian function of that distance. For example, Figure 3(a)
shows the Gaussian function of distance plotted for both the data points used in above exam-
ple. The blue Gaussian represents the weighting of x = 1 and the red Gaussian the weighting
of x = 3, and it is apparent that they are identical Gaussian curves which only vary on their
centres.
The green line in Figure 3(a) represents the prediction based on the weighted sum of the
two known values of y, as: greenðx*Þ = [blueðx*Þ × 2] + [redðx*Þ × 4]. However, closer
inspection of Figure 3(a) shows that the green line seems to pass slightly above the value it
should take at both 1 and 3. This is seen more clearly if the second data point is moved left
to x = 2, as shown in Figure 3(b). The prediction is clearly not an interpolation (that is, a
function that passes through the known points). The reason for this observed effect is that
both Gaussian plots are contributing relatively large weights at both data points. For example,
the red Gaussian is still at a value around 0.5 for x = 1, meaning that it will contribute
approximately (0.5 × 4) to the prediction at that point, which explains why the prediction is
nearly double what it should be.
To overcome this problem, the Gaussian weighting functions are modiﬁed so that they are
forced to zero as they pass through the other data points, as is shown in Figure 3(c). This
results in the green function being an interpolation – it passes through both data points; at
Table 2. Example data used to demonstrate the Gaussian
process model.
x y
1 2
3 4
x* ?
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both data points one of the weights is one and the other is zero. With regard to Equation (1),
k* is the vector of values of the Gaussian weights for the new point, x*, with each of the
known x values. The matrix (K + r2nI)
−1 is a linear transformation, independent of any new
data and thus only computed once; this forces the Gaussian weights to perform interpolation;
that is, to be zero for all but one of the known data points. Finally, the transformed weights
are used to calculate the prediction as a weighted sum over all the y values.
One further signiﬁcant feature of the GP regression is that it provides not only a predic-
tion but also the variance associated with the prediction, which can be interpreted as the reci-
procal of a conﬁdence value. This has signiﬁcant application for the real-world modelling of
biological functions, as it provides a mean and variance for the prediction – effectively, a
very simple method to produce a range which has signiﬁcance not only for the output but in
the context of the inherently variable nature of the inputs used in building such models. The
variance is essentially calculated from the size of the vector of weights. If the weights are
large then the variance should be low, and vice versa, as high weights mean that the new data
point must be near some of the original data and the prediction would, in such a case, have a
high level of conﬁdence associated with it. Figure 3(d) adds variance to the examples of
Gaussian plots illustrated in Figures 3(a) to 3(c). Figure 3(d) shows that the variance is zero
at the actual data points and increases towards one as the x-value moves away from the
known data points. It should be noted that the ‘variance’ is only correctly the variance if the
original data has been normalised as Z-scores; nevertheless, in the examples discussed above
and shown in Figure 3, it is perfectly reasonable to treat it as a conﬁdence value.
Figure 3. Schematic representations of Gaussian weights: (a) an example of the prediction using simple
Gaussian weights; (b) an example of the prediction using Gaussian weights, showing the different values
for x and y and how they affect the prediction; (c) an example of a correctly weighted Gaussian process;
and (d) an example of a correctly weighted Gaussian process with variance shown.
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3.3 Gaussian processes: Applied to pharmaceutical examples
The major, and valid, criticism of Gaussian processes lies not in its theoretical basis but the
inability of non-experts to apply these methods to their ﬁelds. While Cronin and Schultz [3]
have commented that research groups should feature experts from each discipline, it is often
the case that statistical and mathematical methods which become popularised in the biological
sciences are those which can be readily used by researchers in those ﬁelds. Therefore, this
and subsequent sections discuss the practical basis of undertaking a Gaussian process regres-
sion, using a small dataset as a guide. The settings of parameters for these models are then
discussed.
3.3.1 Step 1: Get some data
The issues with the underlying nature and quality of datasets (speciﬁcally in the modelling of
percutaneous absorption) have been discussed in detail previously [8] and is a broader subject
than can be addressed here. The data used in this section are taken from a dataset collated
from other literature sources and presented previously [6]. They are shown in Table 3 and
Figure 4. Five compounds have been taken from the dataset as training examples and two
compounds as test examples. Thus, to run this analysis in MatLab the scripts need to be
loaded and the data added to the program.
Loading and opening scripts. The description below relates to MatLab 2014a. To add a new
code script, under the Editor tab select ‘New’ and then ‘Script’. This opens a new page into
which scripts can be written or pasted; included as supplemental material (available via the
multimedia link on the online article webpage) is the full script for performing a Gaussian
process analysis,which can be found as a zip ﬁle at: https://mega.co.nz/#!jQcBSbiJ!GUkuv
TesV-graw1Qw13KjkKdqNTjpo1ttrtWuW-lt4Q. Alternatively, an existing script can be added
using the Editor tab to load an existing script. In the MatLab working directory, navigate to
the directory containing the extracted zip ﬁle; right-click the appropriate folder and select
‘Add to path’ with ‘Selected folders and subfolders’. Open the folder and double-click on the
ﬁle ‘Main.m’.
Adding training and test datasets. If the data source is being imported from a source other
than Microsoft Excel, the code provided will require minor modiﬁcation. For example, the
code provided states the following instructions:
Table 3. Sample data taken from [6].
Name log kp log P Molecular weight
Training set Atropine –4.12 1.83 289.37
Cortexolone –4.13 3.25 346.46
Ethanolamine –4.02 –1.31 61.08
Monomethylhydrazine –3.75 –1.05 46.07
Morpholine –3.86 –0.86 88.12
Test set Aldosterone –4.24 1.08 360.44
Methyl cellosolve –3.73 –0.77 76.09
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% Reading train data from excel sheets
Data = xlsread(‘Train.xlsx’);
% Reading test data from excel sheets
Test = xlsread(‘Test.xlsx’);
where lines beginning with ‘%’ are comments only. To modify these using speciﬁc data, such
as that in the given example, the following codes can be added in place of the above lines:
Data = [1.83 289.37 −4.12;3.25 346.46 −4.13;−1.31 61.08 −4.02;−1.05 46.07
−3.75;−0.86 88.12 −3.86];
Test = [1.08 360.44 −4.24;−0.77 76.09 −3.73];
To run a script in Matlab, under the ‘Editor’ tab select the Run command. It should be
noted that the target values (log kp) are moved to the last columns of the matrix. There are
some options in the code to select the covariance function and its hyperparameters which are
explained later in this paper, but for now we would recommend keeping them as they are.
3.3.2 Step 2: Normalise the data
As can be seen in Table 3, the values of molecular weight differ from the values of log P by
several orders of magnitude. Thus, the importance of log P in determining the outputs may
Figure 4. Plot of the log kp values against molecular weight (MW) and log P values for the sample
dataset shown in Tables 3 and 4.
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be diminished by the values of molecular weight. Thus, the data should be normalised to
address this issue. One way to resolve this issue is to calculate the mean and standard devia-
tion for each variable in the training dataset, and to then subtract the corresponding mean
value from each variable. Then, each variable is re-scaled by dividing it by the standard devi-
ation. In this way, all the variables have zero means and unit standard deviations. For outputs,
the mean value is subtracted from target values.
Table 4 shows the data following this normalisation procedure. It should be noted that the
test set is normalised using the mean and standard deviation values from the training set since
it is assumed that the test data are generated from the same distribution as the training dataset.
In Matlab the zscore(Data); command is used to normalise the training set. To normalise
the test set to synergise with the training data the following codes are used, which take the
mean and standard deviation of the training set and then subtract the mean from the tests set
and divide the obtained value by the standard deviation:
meanP = repmat(mean(x),R,1);
stdP = repmat(std(x),R,1);
normalZ = (z-meanP)./stdP;
where R is the number of rows in the test set. Usually, nothing in the code needs to be changed
as, when you run the ‘Main’ script, the data normalisation is performed automatically.
3.3.3 Step 3: Select kernel and set parameters
Different covariance, or kernel, functions may be applied to Gaussian process regression. They
include, for example, linear, x2 or polynomial kernels. In this example, the simple squared
exponential covariance function is considered and its parameters are set as below. The use of
different covariance functions may be achieved by using the required covariance function in the
‘Main’ script. The available options are: covSEiso (Squared Exponential covariance function),
covMaterniso (Matérn covariance function) and covNNone (Neural Network covariance func-
tion). Only one function can be used at the same time and the default function is covSEiso.
3.3.4 Step 4: Calculate the kernel matrix of the training set
Each element of the matrix M (equal to (K + r2nI) is computed as follows:
Kðxi; xjÞ ¼ r2f exp $
1
2l2
ðxi $ xjÞT ðxi $ xjÞ
! "
þ r2ndij (6)
Table 4. Normalised sample data.
Chemical name log kp log P Molecular weight
Training set Atropine –0.14 0.71 0.88
Cortexolone –0.15 1.41 1.28
Ethanolamine –0.04 –0.82 –0.75
Monomethylhydrazine 0.23 –0.69 –0.85
Morpholine 0.12 –0.60 –0.55
Test set Aldosterone –2.64 0.34 1.38
Methyl cellosolve 0.25 –0.56 –0.64
Original data taken from [6].
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where: l is the characteristic length-scale; rf is the signal variance; rn is the noise variance;
and dij is the Kronecker delta, which is one if i = j, and zero otherwise.
In this case, r2f = 0.0079, l
2 = 0.9952 and r2n = 0.0144. These values are the best hyper-
parameters obtained using the maximised marginal likelihood technique. This is, however,
just an example of how the kernels are calculated. In practice, readers can use either maxi-
mised maginal liklehood (MML) or the cross-validation method to choose the most suitable
hyperparameters. This is discussed later in the ‘model selection’ section. The function is run
in MatLab by using the command:
hyp3 = minimize(hyp, @gp, −100, @infExact, [], covfunc, likfunc, normalX, y_ﬁnal);
The minimise function minimises a differentiable multivariate function using the conjugate
gradient technique, which is a well-known numerical optimisation technique.
The variance of a training example itself (that is, when i = j) is given by:
kðxi; xjÞ ¼ r2f þ r2n (7)
and in this case is equal to 0.0079 + 0.0144 = 0.0223.
Now, it is important to consider the similarity between examples 1 and 2. Since d12 = 0
we have the following expression:
kðxi; xjÞ ¼ 0:0079 exp $ 12x0:9552 ðx1 $ x2Þ
T ðx1 $ x2Þ
! "
(8)
The value of k(x1, x2) is determined by the Euclidean distance of these two points, which
is calculated as follows:
ðx1 $ x2ÞT ðx1 $ x2Þ ¼ ðx11 $ x21Þ2 þ ðx12 $ x22Þ2 ¼ ð0:7119$ 1:4053Þ2 þ 0:8750$ 1:2806Þ2
¼ 0:6453
And we now have:
kðx1; x2Þ ¼ 0:0079& exp $ 12& 0:9552& 0:6453
! "
¼ 0:0056
Similarly, all elements between two different data points can be calculated in the same
way, resulting in a covariance matrix, M:
0:0223 0:0055 0:0055 0:0055 0:0010
0:0055 0:0223 0:0001 0:0001 0:0001
0:0005 0:0001 0:0223 0:0078 0:0075
0:0005 0:0001 0:0078 0:0223 0:0075
0:0010 0:0001 0:0075 0:0075 0:0223
266664
377775
All the mentioned calculations are performed when the ‘Main’ script is run. As an exam-
ple, the calculation of the kernel function is given below for the squared exponential covari-
ance function in the covSEiso function; thus, to calculate K between training set use the
following coding:
K = sq_dist(x′/ell);
Followed by:
K = sf2*exp(-K/2);
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where x is the training set; ell is the length scale; sf2 is the signal variance; exp is a function
built into MatLab which takes the exponential of a value; and sq_dist is a function provided
in the supplemental material (available via the multimedia link on the online article webpage)
which calculates the similarity between points.
3.3.5 Step 5: Compute the inverse of the kernel matrix
The inverse of a square matrix A, which is often called a reciprocal matrix, is a matrix A−1 such
that A.A−1 = I, the identity matrix. Many high-level computing packages, such as Octave or
MatLab, provide an in-built feature that automatically computes the inverse of a square matrix.
In MatLab (R2012a) [56,57], the inverse of matrix M can be obtained by using the command:
>> inv(M)
and the result is shown as follows:
47:8489 $ 11:7902 $ 0:2814 $ 0:2814$ 1:9036
$11:7902 47:8489 $ 0:0495 $ 0:0495 0:3479
$0:2814 $ 0:0495 54:4407 $ 14:5248 $ 13:4118
$0:2814 $ 0:0495 $ 14:5248 54:4407 $ 13:4118
$1:9036 0:3479 $ 13:4118 $ 13:4118 53:9482
266664
377775
In practice, rather than directly inverting the matrix, Cholesky decomposition is recom-
mended as it is faster and numerically more stable [56]. As an example, the inverse function
is calculated in MatLab using the coding:
sn2 = exp(2*hyp.lik);
L = chol(K/sn2+eye(n));
alpha = solve_chol(L,y-m)/sn2;
where: sn2 is signal noise; hyp.lik is the likelihood function of the kernel; n is the rows num-
ber of x; m is the mean function which is set to zero in all examples; Chol is a Matlab built-
in function; and solve_chol is a function provided in the supplemental material which imple-
ments the functionality of the Cholesky decomposition.
However, it should be noted that the main aspects of the code are contain in the ‘Main’
script which, to run a rudimentary analysis, does not require modiﬁcation.
3.3.6 Step 6: Compute k*
Using the method described in Step 4, we can obtain kT* :
0:0064 0:0042 0:0003 0:0003 0:0006
0:0009 0:0001 0:0075 0:0076 0:0078
# $
In MatLab, to calculate K between the training and test sets the following command is used:
K = sq_dist(x′/ell,z′/ell);
Followed by:
K = sf2*exp(-K/2);
where: x is the training set; z is the test set; ell is the length scale; and sf2 is the signal variance.
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3.3.7 Step 7: Predict the skin permeability
The prediction of skin permeability can now be computed by multiplying kT* , ðK þ @2nIÞ$1
and y. In the case of the example data used here, this returns values of 0.0201 and 0.0176.
The mean value of targets in the training dataset (in this case, –3.9760) is added. Thus, the
ﬁnal predicted log kp value for aldosterone is –4.0303 and the ﬁnal predicted log kp value for
methyl cellosolve is –3.9170, which compare well with the values listed in Table 3. To obtain
the prediction using MatLab the ‘Main’ script should be run; the output will depend on the
covariance function chosen. The code used to obtain the predictions is:
[Prediction var MSE_GP ION_GP corrcoef_GP] = Result_CV (Data, Test);
The outputs (predictions) will be displayed in the ‘work space’ window in MatLab, in
which the predictions obtained are displayed, followed by the performance measures MSE
(Mean Squared Error), ION (Improve over Naïve model) and Correlation Coefﬁcient (Corr-
Coef). Higher values of ION and CorrCoef generally mean better GP performances. However,
high values of MSE show poor performance of the model.
3.3.8 Step 8: Compute variance
The ﬁnal step is to calculate the variance, r2*. This is calculated as r
2
* ¼ var½y*( þ r2n, where
var½y*( is given by Equation (2). The noise variance, r2n, is included as function values them-
selves are not assessed but they are assessed as values with a noise. In this case the values of
var½y*( are 0.0201 and 0.0176, and r2n is 0.0144. Therefore, the predictive variances of aldo-
sterone and methyl cellosolve are 0.0345 and 0.0320, respectively. In MatLab the variation is
obtained from the code discussed in Step 7 and is saved in ‘var’ variable.
3.4 Model selection
Generally, cross-validation is applied to choose a suitable kernel function and its parameters.
Since the key aim of this method is to ﬁnd the GP model with the best performance on new
data points, the simplest appraoch to the comparison of different models is to evaluate the
error function using data which is independent of that used for training the model [53]. In the
methods described here, and published previously [1,2,39,54], the training set is randomly
divided into S distinct segments. A GP regression is then trained from (S – 1) of the segments
with its performance being assessed by evaluation of the error function using the remaining
segment, the validation dataset. This process is repeated for each of S possible choices. Sev-
eral different sets of parameters may be pre-set, as required. This process is repeated for each
set and an average of S validation dataset errors can be calculated. Thus, a ﬁnal model with a
minimum average of validation set errors may be selected. Since this procedure may poten-
tially lead to over-ﬁtting of the validation set, the performance of the selected model should
be conﬁrmed by measuring its performance on a third, independent set of data called the ‘test
set’ [53].
When the training set is small, a special cross-validation method – the leave-one-out tech-
nique – of often used. This means that one compound is used for testing and all others are
used for training, and this is repeated for each member of the dataset in turn. In the Matlab
code provided in the supplemental material which is available via the multimedia link on the
online article webpage, this is achieved using the ‘Result_CV’ function. A simple example of
this process is shown below:
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3.4.1 Simple example
Suppose we have 100 data points, 50 in class A and 50 in B:
(1) Remove a random test set of 20 points with equal numbers of A and B (10 each).
(2) Now remove a further 20 points from the training set, as a validation set (10 A, 10 B).
(3) For each of the following values of length scale and signal variance (for example) l
from {0.1, 10}, @2f from {0.1, 3.16}. For simplicity, the noise is constantly considered
to be log(0.1):
(a) Train the GP on the 60 remaining points.
(b) Report the performance (for example ION, MSE, CORR) of the trained model on
the validation set.
(c) Choose the values of l and @2f that give the best result.
(4) Using the best parameter values train the GP on the 80 points in the full training set.
(5) Finally report the performance on the test set.
There is one ﬁnal consideration, which is that the value of l and @2f found by cross-valida-
tion may only work well for the particular training/validation set used and this might lead to
poor performance on the test set. So, typically ﬁve- (or ten-) fold cross-validation is used. In
this case the training set is divided into ﬁve equally sized subsets, which means that ﬁve dif-
ferent training/validation pairs can be constructed, from which an average accuracy (for a
given l/@2f ) can be calculated. For example, if the training data is divided into ﬁve subsets (A,
B, C, D, E), then the ﬁve different train/validate pairings are:
• Train on A B C D and validate on E
• Train on A B C E and validate on D
• Train on A B D E and validate on C
• Train on A C D E and validate on B
• Train on B C D E and validate on A
So, for a given parameter setting, an overall performance measure can be found by taking
the average of the ﬁve individual accuracies. This gives a more reliable assessment of a particu-
lar l/@2f setting. Different covariance functions can then be assessed to obtain the best performing
results. It should be noted that this process occurs before the test set has been predicted.
Another way to set parameters is to maximise the marginal likelihood. Parameters
obtained at the maximised marginal likelihood are the most suitable for the model. In prac-
tice, the initial values for parameters are usually used ﬁrst and then numerical methods for
non-linear partial differential equations may be involved to search for the best parameter val-
ues. The ‘Main’ Matlab script has two options for selecting the hyperparameters: cross valida-
tion or maximised maginal liklehood (MML). Finding the best hyperparameters by cross-
validation requires an expert to consider proper ranges for the hyperparameters and their ini-
tialisation. Using automatic hyperparameters (with MML) makes the process easier, but;it
may end up with local minima or maxima. So, automatic hyperparameter selection is gener-
ally recommended and there is no need to change the default hyperparameter selection
method in MatLab. The supplemental code lets the user choose the method to ﬁnd the hyper-
parameters and also select the covariance functions:
% Change the way to optimise the hyperparameters
% Please choose 1 for MML hyperparameter optimisation or 2 for Cross
% validation hyperparameter optimisation, default is 1
opt_hyper_parameter =1;
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% change the covariance function
% Please choose 1 for SE Covariance function, 2 for Matérn Covariance
% function and 3 for Neural Network covariance function, default is 1
Covariance_func =1;
3.5 Software
A range of software packages may be used to undertake Gaussian process regression analysis
of datasets. The ‘Gaussian Process’ webpage [56] provides a comprehensive list of available
packages. The GP software used in the analysis of skin permeability datasets and highlighted
above is based in Matlab (R2012a) [57]. Speciﬁc toolboxes and add-on packages are avail-
able elsewhere [58]. Figure 5 shows a schematic representation of how the software is used
to perform the Gaussian process regression.
Figure 5. Flow chart for undertaking a Gaussian processs regression in MatLab, with (left) examples
of the commands used for each step of the process and (right) examples of how to complete a ﬁve-fold
cross-validation analysis, including selection of the covariance function and its hyperparameters.
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4. Conclusions
Gaussian process regression has been applied to the problem domain of skin permeability,
both in terms of predicting permeability for new chemicals and in developing our understand-
ing of the mechanisms of skin permeability. Such applications are not necessarily conﬁned to
skin permeability, but clearly have application in other models of membrane permeability.
The GP models have consistently shown better predictive ability than quantitative structure–
permeability models for skin and, with the use of feature selection and related methods [2],
they also demonstrate the ability – in the absence of a descriptive algorithm – to yield signiﬁ-
cant mechanistic information. This is achieved by a statistical comparison of all possible per-
mutations of descriptors employed in this study, as described in the Introduction. In the case
of Lam’s study [2], this involved the potential interchangeability of physicochemical descrip-
tors, where a number of different permutations of physicochemical descriptors resulted in
models that were, in terms of statistical quality and predictive ability, the same. The implicit
understanding from this study is that the use of algorithms featuring discrete terms may not
necessarily be the most appropriate models to use.
Therefore, the use of Gaussian processes offers a potentially powerful and widely applica-
ble tool for the analysis of complex biological processes. It has shown an ability to provide
higher quality predictive models compared to existing methods and to provide mechanistic
insight to the processes associated with permeation.
References
[1] G.P. Moss, Y. Sun, M. Prapopoulou, N. Davey, R. Adams, W.J. Pugh, and M.B. Brown, The appli-
cation of Gaussian Processes to the prediction of percutaneous absorption, J. Pharm. Pharmacol.
61 (2009), pp. 1147–1153.
[2] L.T. Lam, Y. Sun, N. Davey, R.G. Adams, M. Prapopoulou, M.B. Brown, and G.P. Moss, The
application of feature selection to the development of Gaussian Process models for percutaneous
absorption, J. Pharm. Pharmacol. 62 (2010), pp. 738–749.
[3] M.T.D. Cronin and T.W. Schultz, Pitfalls in QSAR, J. Mol. Struct. 622 (2003), pp. 39–51.
[4] R.O. Potts and R.H. Guy, Predicting skin permeability, Pharm. Res. 9 (1992), pp. 663–669.
[5] B.M. Magnusson, Y.G. Anissimov, S.E. Cross, and M.S. Roberts, Molecular size as the main
determinant of solute maximum ﬂux across the skin, J. Invest. Dermatol. 122 (2004), pp. 993–999.
[6] G.P. Moss and M.T.D. Cronin, Quantitative structure–permeability relationships for percutaneous
absorption: Re-analysis of steroid data, Int. J. Pharm. 238 (2002), pp. 105–109.
[7] H. Patel, W. ten Berge, and M.T.D. Cronin, Quantitative structure–activity relationships (QSARs) for
the prediction of skin permeation of exogenous chemicals, Chemosphere 48 (2002), pp. 603–613.
[8] G.P. Moss, J.C. Dearden, H. Patel, and M.T.D. Cronin, Quantitative structure-permeability relation-
ships (QSPRs) for percutaneous absorption, Toxicol. In Vitro 16 (2002), pp. 299–317.
[9] A.C. Williams, Transdermal and Topical Drug Delivery, Pharmaceutical Press, London, 2003.
[10] G.L. Flynn, Physicochemical determinants of skin absorption, in Principles of Route-to-Route
Extrapolation for Risk Assessment, T.R. Gerrity and C.J. Henry, eds., Elsevier, New York, 1990,
pp. 93–127.
[11] R.O. Potts and R.H. Guy, A predictive algorithm for skin permeability: The effects of molecular
size and hydrogen bond activity, Pharm. Res. 12 (1995), pp. 1628–1633.
[12] S. Mitragotri, Y.G. Anissimov, A.L. Bunge, H.F. Frasch, R.H. Guy, J. Hadgraft, G.B. Kasting,
M.E. Lane, and M.S. Roberts, Mathematical models of skin permeability: An overview, Int. J.
Pharm. 418 (2011), pp. 115–129.
[13] A.K. Pannier, R.M. Brand, and D.D. Jones, Fuzzy modelling of skin permeability coefﬁcients,
Pharm. Res. 20 (2003), pp. 143–148.
SAR and QSAR in Environmental Research 201
Do
wn
loa
de
d b
y [
2.2
21
.12
0.0
] a
t 1
0:4
6 3
0 A
ug
us
t 2
01
5 
[14] D.R. Keshwani, D.D. Jones, and R.M. Brand, Tagaki–Sugeno fuzzy modelling of skin permeability,
Cutan. Ocul. Toxicol. 24 (2005), pp. 149–163.
[15] S. Agatonovic-Kustrin and R. Beresford, Basic concepts of artiﬁcial neural network (ANN)
modelling and its application in pharmaceutical research, J. Pharm. Biomed. Anal. 22 (2000),
pp. 717–727.
[16] S. Agatonovic-Kustrin, R. Beresford, A. Pauzi, and M. Yusof, ANN modeling of the penetration
across a polydimethylsiloxane membrane from theoretically derived molecular descriptors, J.
Pharm. Biomed. Anal. 26 (2001), pp. 241–254.
[17] J. Bourquin, H. Schmidt, P. Van Hoogevest, and H. Leuen-Berger, Application of artiﬁcial neural
networks (ANN) in the development of solid dosage forms, Pharm. Dev. Technol. 2 (1997),
pp. 111–121.
[18] J. Bourquin, H. Schmidt, P. Van Hoogevest, and H. Leuen-Berger, Comparison of artiﬁcial neural
networks (ANN) with classical modelling technologies using different experimental designs and
data from a galenical study on a solid dosage form, Eur. J. Pharm. Sci. 7 (1998), pp. 1–12.
[19] J. Takahara, K. Takayama, and T. Nagai, Multi-objective simultaneous optimization technique
based on an artiﬁcial neural network in sustained release formulations, J. Cont. Rel. 49 (1998),
pp. 11–20.
[20] R.G. Alany, S. Agatonovic-Kustrin, T. Rades, and I.G. Tucker, Use of artiﬁcial neural network to
predict quaternary phase systems from limited experimental data, J. Pharm. Biomed. Anal. 19
(1999), pp. 443–452.
[21] T. Fan, K. Takayama, Y. Hattori, and Y. Maitani, Formulation optimisation of paclitaxel carried by
PEGylated emulsions based on artiﬁcial neural network, Pharm. Res. 21 (2004), pp. 1692–1697.
[22] Y. Hayashi, S. Kikuchi, Y. Onuki, and K. Takayama, Reliability of nonlinear design space in phar-
maceutical product development, J. Pharm. Sci. 101 (2012), pp. 333–341.
[23] Z. Sun, X. Rao, L. Peng, and D. Xu, Prediction of protein supersecondary structures based on the
artiﬁcial neural network method, Protein Eng. 10 (1997), pp. 763–769.
[24] C.H. Wu, Artiﬁcial neural networks for molecular sequence analysis, Comput. Chem. 21 (1997),
pp. 237–256.
[25] J. Sun, W.Y. Song, L.H. Zhu, and R.S. Chen, Analysis of tRNA gene sequences by neural network,
J. Comput. Biol. 2 (1995), pp. 409–416.
[26] M. Tacker, P.F. Stadler, E.G. Bornbergbauer, I.L. Hofacker, and P. Schuster, Algorithm independent
properties of RNA secondary structure predictions, Eur. Biophys. J. 25 (1996), pp. 115–130.
[27] C.M. Reidys, P.F. Stadler, and P. Schuster, Generic properties of combinatory maps – Neural net-
works of RNA secondary structures, Bull. Math. Biol. 59 (1997), pp. 339–397.
[28] P. Willett, Genetic algorithms in molecular recognition and design, Trends Biotechnol. 13 (1995),
pp. 516–521.
[29] S.S. So and M. Karplus, Evolutionary optimization in quantitative structure–activity relationship:
An application of genetic neural networks, J. Med. Chem. 39 (1996), pp. 1521–1530.
[30] S.S. So and M. Karplus, Three-dimensional quantitative structure-activity relationships from molec-
ular similarity matrices and genetic neural networks. 1. Methods and validations, J. Med. Chem.
40 (1997), pp. 4347–4359.
[31] S.S. So and M. Karplus, Three-dimensional quantitative structure–activity relationships from molec-
ular similarity matrices and genetic neural networks. 2. Applications, J. Med. Chem. 40 (1997),
pp. 4360–4371.
[32] T. Degim, J. Hadgraft, S. Illbasmis, and Y. Ozkan, Prediction of skin penetration using artiﬁcial
neural network (ANN) modelling, J. Pharm. Sci. 92 (2003), pp. 656–664.
[33] M. Hosseini, D.J. Madalena, and I. Spence, Using artiﬁcial neural networks to classify the activity
of capsaicin and its analogues, J. Chem. Inf. Comput. 37 (1997), pp. 1129–1137.
[34] L.J. Chen, G.P. Lian, and L.J. Han, Prediction of human skin permeability using artiﬁcial neural
network (ANN) modelling, Acta Pharmacol. Sinica. 28 (2007), pp. 591–600.
[35] M.H. Abraham, F. Martins, and R.C. Mitchell, Algorithms for skin permeability using hydrogen
bond descriptors: The problem of steroids, J. Pharm. Pharmacol. 49 (1997), pp. 858–865.
202 P. Ashraﬁ et al.
Do
wn
loa
de
d b
y [
2.2
21
.12
0.0
] a
t 1
0:4
6 3
0 A
ug
us
t 2
01
5 
[36] C.W. Lim, S. Fujiwara, F. Yamashita, and M. Hashida, Prediction of human skin permeability using
a combination of molecular orbital calculations and artiﬁcial neural network, Bio. Pharm. Bull. 25
(2002), pp. 361–366.
[37] S. Siani, S.K. Singh, A. Garg, K. Khanna, A. Shandil, and D.N. Mishra, Prediction of skin penetra-
tion using artiﬁcial neural network, Int. J. Eng. Sci. Tech. 2 (2010), pp. 1526–1531.
[38] Y. Sun, G.P. Moss, N. Davey, R. Adams, and M.B. Brown, The application of stochastic
Machine Learning methods in the prediction of skin penetration, App. Soft Comput. 11 (2011),
pp. 2367–2375.
[39] S. Kia, S. Setayeshi, M. Shamsaei, and M. Kia, Computer-aided diagnosis (CAD) of the skin dis-
ease based an intelligent classiﬁcation of sonogram using neural network, Neural Comput. Applic.
22 (2013), pp. 1049–1062.
[40] B. Baert, E. Deconinck, M. van Gele, M. Slodicka, P. Stoppie, S. Bode, G. Slegers, Y. van der
Heyden, J. Lambert, J. Beetens, and B. de Spiegeleer, Transdermal penetration behaviour of drugs:
CART-clustering, QSPR and selection of model compounds, Bioorg. Med. Chem. 15 (2007), pp.
6943–6955.
[41] M.S. Roberts, W.J. Pugh, J. Hadgraft, and A.C. Watkinson, Epidermal permeability-penetrant
structure relationships: 1. An analysis of methods of predicting penetration of monofunctional sol-
utes from aqueous solutions, Int. J. Pharm. 126 (1995), pp. 219–233.
[42] M.S. Roberts, W.J. Pugh, and J. Hadgraft, Epidermal permeability–penetrant structure relation-
ships. 2. The effect of H-bonding groups in penetrants on their diffusion through the stratum cor-
neum, Int. J. Pharm. 132 (1996), pp. 23–32.
[43] W.J. Pugh, M.S. Roberts, and J. Hadgraft, Epidermal permeability–penetrant structure relation-
ships: 3. The effect of hydrogen bonding interactions and molecular size on diffusion across the
stratum corneum, Int. J. Pharm. 138 (1996), pp. 149–165.
[44] B. Neely, S. Madihally, R.J. Robinson, and K. Gasem, Nonlinear quantitative structure–property
relationship modeling of skin permeation coefﬁcient, J. Pharm. Sci. 98 (2009), pp. 4069–4084.
[45] G.P. Moss, A.J. Shah, R.G. Adams, N. Davey, S.C. Wilkinson, W.J. Pugh, and Y. Sun, The appli-
cation of discriminant analysis and Machine Learning methods as tools to identify and classify
compounds with potential as transdermal enhancers, Eur. J. Pharm. Sci. 45 (2012), pp. 116–127.
[46] R.J. Scheuplein, I.H. Blank, G.I. Brauner, and D.J. MacFarlane, Percutaneous absorption of ste-
roids, J. Invest. Dermatol. 52 (1969), pp. 63–70.
[47] M.E. Johnson, D. Blankstein, and R. Langer, Permeation of steroids through human skin, J. Pharm.
Sci. 84 (1995), pp. 1144–1146.
[48] R.P. Chilcott, N. Barai, A.E. Beezer, S.L. Brain, M.B. Brown, A.L. Bunge, S.E. Burgess, S. Cross,
C.H. Dalton, M. Dias, A. Farinha, B.C. Finnin, S.J. Gallagher, D.M. Green, H. Gunt, R.L.
Gwyther, C.M. Heard, C.A. Jarvis, F. Kamiyama, G.B. Kasting, E.E. Ley, S.T. Lim, G.S.
McNaughton, A. Morris, M.H. Nazemi, M.A. Pellett, J. Du Plessis, Y.S Quan, S.L. Raghavan, M.
Roberts, W. Romonchuk, C.S. Roper, D. Schenk, L. Simonsen, A. Simpson, B.D. Traversa, L.
Trottet, A. Watkinson, S.C. Wilkinson, F.M. Williams, A. Yamamoto, and J. Hadgraft, Inter- and
intra-laboratory variation of in vitro diffusion cell measurements: An international multicenter
study using quasi-standardised methods and materials, J. Pharm. Sci. 94 (2005), pp. 632–638.
[49] J.E. Riviere and J.D. Brooks, Predicting skin permeability from complex chemical mixtures, Toxi-
col. Appl. Pharmacol. 208 (2005), pp. 99–100.
[50] J.E. Riviere and J.D. Brooks, Prediction of dermal absorption from complex chemical mixtures:
Incorporation of vehicle effects and interactions into a QSPR framework, SAR QSAR Environ.
Res. 18 (2007), pp. 31–44.
[51] T. Ghafourian, E.G. Samaras, J.D. Brooks, and J. Riviere, Modelling the effect of mixture compo-
nents on permeation through skin, Int. J. Pharm. 398 (2010), pp. 28–32.
[52] J.E. Riviere and J.D. Brooks, Predicting skin permeability from complex chemical mixtures: Depen-
dency of quantitative structure permeation relationships on biology of skin models used, Toxicol.
Sci. 119 (2011), pp. 224–232.
[53] C.M. Bishop, Neural Networks for Pattern Recognition, Oxford University Press, New York, 1995.
SAR and QSAR in Environmental Research 203
Do
wn
loa
de
d b
y [
2.2
21
.12
0.0
] a
t 1
0:4
6 3
0 A
ug
us
t 2
01
5 
[54] Y. Sun, G.P. Moss, M. Prapodopolou, N. Davey, R. Adams, and M.B. Brown, Predictions of skin
penetration using Machine Learning methods, in ICDM2008 Proceedings of 8th IEEE International
Conference on Data Mining, F. Giannotti, D. Gunopulos, F. Turini, C. Zaniolo, N. Ramakrishnan,
X.D. Wu, eds., IEEE Computer Society, Los Alamitos, CA, USA, pp. 1049–1054.
[55] C.E. Rasmussen and C. Williams, Gaussian Processes for Machine Learning, MIT Press, Boston,
2006.
[56] A. Geiger, Gaussian Process software; software available at: http://www.gaussianprocess.org/#code.
[57] MatLab2012a. MathWorks Ltd, Nitick, MA, USA, 2012; software available at http://jmlr.org/
papers/v11/rasmussen10a.html.
[58] C.E. Rasmussen and H. Nickisch, Gaussian Processes for Machine Learning (GPML) toolbox, J.
Mach. Learn. Res. 11 (2010), pp. 3011–3015.
Appendix
The supplemental material which is available via the multimedia link on the online article webpage
contains full MatLab codes for running Gaussian Process analyses and speciﬁc scripts for particular
covariance functions. It also contains a short guide on loading the scripts into MatLab and running
them.
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Introduction
It is well established that changes to the input of a system will significantly affect the output. For example, a review of the development of quantitative structure-
permeability relationships (QSPRs) for percutaneous absorption1 indicates that a wide range of different models have been developed in the last twenty years. These
models have mostly been produced using the same, or very similar methods of analysis and yet by changing the dataset the output (the resulting QSPR algorithm) is also
changed significantly – with this, the implications forpredicting skin permeation and developing a mechanistic understanding of the skin permeability process are notably
affec ted. It follows that the inference made by each model is therefore also different; this is seen best in the two landmark studies byPotts and Guy2,3. Machine Learning
techniques have recently shown that they can outperform classical QSPR-based approaches, in terms of prediction accuracy and statistical robustness, to predict skin
permeability4,5,6,7. These studies have also shown that the relationship between permeability and the physicochemical descriptors of a molecule are inherently non-linear.
The datasets used in these studies are comparatively small and raises the concern that normal likelihood maximisation-based selection of hyperparameters may not
necessarily work with such small datasets as are available to those res earching percutan eous absorption. Thus, the current study has systematically examined this
problem bydividing a large dataset discussed previously4,5 into smaller subsets which reflect particular aspects of experimental design, removing possible bias in the data
and potentially providing a clearer picture on whether the underlying trends in the data are linear or non-linear. In order to investigate this question GP regressors in
which the hyperparameters are s et using likelihood maximisation-based selection were compared with regressors in which the hyperparameters are found by a manual
search through the hyperparameter space.
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Methods
The dataset employed in this studywas collated from the literature and has been presented previosuly4,5. This dataset was subdivided into six different test sets, reflec ting
the diverse range of experimental protocols used in the studies from which this data was abstracted. Subset A (n=9) – flow-through cells, abdominal skin 0.2-0.5mm
thickness, 32oC skin surface temperatu re, 24h duration, aqueous donor vehicle, PBS receptor; subset B (n=25) – as subset A but contains all skin thicknesses listed; subset
C (n=21)– as subset B but using static, Franz-type cells rather than flow-through cells; subset D (n=57)– as above but with increasingly non-aqueous components added to
the donor vehicle and deploying flow-through or static diffusion cells; subset E (n=51) - as subset D but using flow-through cells only; subset F (n=86) – as subset E except
deploying only static diffusion cells. There is also a degree of overlap between datasets. For instance, dataset E includes the majority of chemicals in datasets A and B.
Similarly, dataset F includes most chemicals in dataset C. For each data point in each dataset five physicochemical descriptors were used (log P, molecular weight,
solubility parameter and counts of the hydrogen bond donors and acceptors on each molecule). The Potts and Guy algorithm2 was applied to each dataset. Further,
Gaussian Process modelling was used, as reported previously, for non-linear regression4,5,6,7. As reported previously the selection of the covariance function is central to
model quality. Thus, training points that are near to a tes t point could be helpful in better predicting the new test point. In this study the Matérn Polynomial and Squared
Exponential covariance functions were applied to thedata. The Matérn covariance function, which is theproduct of an exponential and a polynomial of orderm (where m
= 0, 1 or 2, with m = 1 yielding the best performance in initial studies), resulted in better prediction for the datasets examined and its outputs only are presented herein.
The details of the covariance function are specified by its hyperparameters which in this experiment are the length scale (which defines the scalingof the separation along
the x-axis), signal variance and noise variance. These parameters can be inferred or learned from the data, based on using either themarginal likelihood maximisation or
methods of cross-validation8. One of the key concerns of this study is that inferring the hyperparameters f rom data could be problematic given the small sizes of some of
the datas ets. Therefore, a manual search within the space of the hyperparameters was also perfo rmed. Performance measures were used as reported previously4,5,6,7 –
correlation coefficient (CORR), improvement over the naïve model (ION) andmean squared error (MSE).
Results and Discussion
In the initial experiments, the GP was applied to the datasets using the automatic
hyperparameter selection method (using marginal likelihood maximisation) for the
covariance function. Due to the small number of data points in each dataset, leave-one-
out cross validation was also employed. Thus, the average GP prediction performances
are shown in Table 1. In addition, the table shows the average and standard deviation
of the three hyperparameters in each dataset. It can be seen that the QSPR model
significantlyunderperforms compared to the naïve model – in all cases the QSPR model
has a negative value for ION, indicating a worse performance than the naïve model. This
suggests that these datasets are not well suited to linear predictors. Similarly, GP
models in all but one case make a minor improvement over the naïve model but,
overall do not do perform significantly or consistently better. Given the poor outcome
of the initial experiment the hypothesis subsequently proposed was that the small size
of the datasets may affect the automatic setting of the hyperparameters. Thus, a
systematic search to find effective hyperparam eters for these data was undertaken.
This required a three-dimensional grid search to keep it computationally tractable;
therefore four orders of magnitude of signal variance and over 100 values each of the
other hyperparameters were used. The GP model was trained using a leave-one-out
methodology and the ION and best hyperparameters were reported; if no improvement
in the ION was observed the search was refined by repeating it in a more detailed
fashion. Finally, the model with the best outcome for these parameters and correlation
was proposed. Table 2 shows the best handcrafted hyperparameters obtained from this
search and the ION and CORR performances. Comparison with the results in Table 1
shows a significant improvement in the quality of the model’s performance in most of
the datasets. Figure 1 shows how the changes in the values of the hyperparameters
affec t the ION – it should be noted that the figure contains a log-scale for the signal
variance). It can be clearly seen from Table 2 that using handcrafted hyperparameters
increases the prediction performance in all datasets. In one case an increase of 78%
over the naïve model is observed for datas et A which is, incidentally, the smallest
dataset.
Therefore, it is clear that the quality of the model produced is affected significanty by
the dataset size. This has significant implications for the use of single-dataset analyses
of skin absorption. It is also clear that the use of smaller subsets – although logical in
terms of removing any variance introduced by different experimental protocols – has
limitations, given the overall quality (as determined, for example, by the CORR values
obtained). This is significantin the wider understanding of error and variance associated
with quantitative models of skin absorption. However, despite such limitations the
application of Machine Learning methods has shown that model quality can be
substantially improved and that the use of – in this case – handcrafted
hyperparameters can significantly improve the predictive ability and statistical quality
of the models.
Figure	1.	Effect	of	 changing	hyperparameters 	on	the	 ION	values .	Hyperparameters 	used	are	length-scale	(l),	
and	s ignal	variance	(σ2 f)	in	dataset	E	with	fixed	noise	value	(0.1)	over	the	range	10-3 – 103 .
Table	 1.	Automatic	hyperparameters	(mean	and	standard	deviation):	application	of 	GP
with	Matérn Covariance	function	(m	=	1)	and	automatic	hyperparameter	generation.
Table	 2.	Handcrafted	hyperparameters	f ixed	values:	 application	of 	GP	with	Matérn
Covariance	 function	(m	=	1) 	and	handcrafted	hyperparameter	selection.
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Introduction
Skin permeability datasets are often criticised for exhibiting a significant degree of variation in their source data. This is generally due to the nature of data
collation which, in the case of the skin permeability datasets used, has been the result of accumulated studies from a range of different researchers and
laboratories. Inherent in such a strategy for generating databases of sufficient size to be viable is the inter-laboratory variation which adds to the biological
variation associated with such studies1. Such inherent variation is often cited as a major limitation in models of percutaneous absorption and a reason for their
broader lack of application by those investigating skin absorption2,3,4. The aim of a Monte Carlo simulation is to generate values for uncertain values in a model
through random sampling. Thus, the Monte Carlo techniques apply random sampling methods to complex datasets which often exhibit inconsistent target
values, such as the simulation of risk or, in this case, the analysis of inherently variable biological data. It is therefore the aim of this study to use the Monte Carlo
method to examine a skin permeability data set, with the aim of determining whether this technique can improve the model quality and address issues of data
variability.
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Methods
The data set used in this study has been reported previously4,5. Briefly, this is a data set of in vitro human skin permeability studies whose core is the Flynn data
set as modified by Moss and Cronin6,7 and added to by Prapopoulou4 (n=642). Each experiment involves the random selection of one of the target values for the
same compounds; this process was repeated 10,000 times and therefore 10,000 data sets were generated. For each data set the performance was assessed by
comparing the quality of predictive performance, where the data was randomly split into training (two-thirds) and test (one-third) data sets. Performance
measures were the mean squared error (MSE; estimates vs. laboratory results), improvement over the naïve model (ION) and the correlation coefficient (r, or
CORR). Monte Carlo experiments were benchmarked against normal methods of analysis5, including QSARs, where the mean values of reported experimental
results were used to construct a model.
Results and Discussion
By applying the Monte Carlo method the ION improved from 0.34 to 0.41, and the correlation
coefficient improved from 0.55 to 0.64, in cases were the Monte Carlo method was applied to
a data set constructed from mean permeability values for each relevant chemical; these are
the values obtained from the best Monte Carlo simulation of all 10,000 variants that were run.
For clarity of comparison (estimates vs. experimental values) Figures 1 and 2 show a summary
of the total results – they highlight the estimates for 35 chemicals taken from the “best”
Monte Carlo data set. From these results it is apparent that, in most cases, the application of
the Monte Carlo method works better than using a data set containing mean values of
chemicals in that it produces better estimates. This analysis also yields an “optimal” data set;
starting with the complete data set repetitive data points were removed and the best target
values of the statistical metrics were produced. This results in a smaller data set which yielded
the best-performingmodel. This data set is discussed below.
Using the optimal dataset a QSAR equation was developed using multiple linear regression
analysis (SPSS v21). This yielded an algorithm of poor statistical quality:
log kp = -0.003MW – 2.681 (r2 = 0.2). This suggests the inherent lack of linearity in this dataset,
which is in agreement with previous findings3,5.
In examining the data returned as producing the most effective model it is clear that, in terms
of experimental conditions, few specific trends are identified. The types of membranes used
are evenly distributed between full thickness, dermatomed and heat-separated epidermal
sheets, with a small number (6 out of 129) using different methods of membrane pre-
treatment or preparation, particularly the use of isolated stratum corneum. While diffusion
experiments were performed using mostly abdominal skin the use of back, breast, dorsal and
leg skin was also common. No anatomical site was listed in fourteen of the 129 experiments.
Experiments were divided between static, Franz-type diffusion cells (80) and flow-through cells
(49). While the majority of donor phase vehicles were aqueous in nature the optimal data set
did feature a significant subset of experiments which were conducted using non-aqueous
solvents, mostly various alcohols, isopropyl myristate or acetone. In terms of qualitative
examination of the data no clear trends were apparent between estimates and experimental
data when investigated based on the degree of error (estimates vs. experiments) on a
chemical-by-chemical basis.
It may therefore be suggested that, given the overall variation in the dataset, the effects of
specific conditions, such as receptor compartment composition, vehicle, skin thickness and
diffusion cell design, on the outcome of experiments, are either not significant or are difficult
to detect due to the inherent biological variation associatedwith the data.
Figure	1.	Comparison	of	estimates	with	targets	(Monte	Carlo	method).
Figure	2.	Comparison	of	estimates	with	targets	(conventional	GP	methods).
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Introduction
There are numerous studies which describe the many and varied mathematical models of percutaneous absorption developed from experimental data1,2. These
studies are reviewed extensively and they describe a series of models, mostly quantitative structure-permeability relationships (QSPRs), which simply collate
existing literature data and then develop relationships between molecular physicochemical descriptors and a biological process (i.e. skin permeability)1,2,3.
However, in recent years, models are being developed with more consideration given to the input data used, utilising data from as few sources as possible and
considering in the construction of models a greater range of input factors4,5,6. This is partially due to new methods which may allow more accurate estimates to
be produced but also due to an increase in data availability which allows data sets to be constructed more appropriately. More recently, Machine Learning
techniques have recently shown that they can outperform classical QSPR-based approaches, in terms of prediction accuracy and statistical robustness, to predict
skin permeability5,6,7,8. These studies have also shown that the relationship between permeability and the physicochemical descriptors of a molecule are
inherently non-linear. Thus, the aim of this study is to determine the effect of diffusion cell type (i.e. ‘static’, Franz-type cells and ‘flow-through’ Bronaugh-type
cells) on the construction of models of skin permeability. This work is complimentary to our other poster (on Monte Carlo analysis of skin permeability) and
should be considered in the context of that study.
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Methods
The Gaussian Process Regression methods reported previously were employed5,6,7,8. All the human skin data was collated into two categories; experiments
conducted with static, Franz-type diffusion cells or with flow-through cells. Five molecular descriptors were used: log P, MW, HA, HD and melting point. The
target values used in the model development were the measured permeability coefficient values taken from the source literature. The data set used, after
removing inconsistent data, has 143 members (85 static cell experiments and 53 flow-through cell experiments). Analyses on separate flow-through and static
cell experiments were carried out, followed by experiments examining mixtures of both, using the leave-one-out method. To analyse the data 10 datasets were
constructed. Each of them, in the second type of experiments, includes the mixed static and flow-through cell data4,5 randomly selected from 143 members in
order to remove possible bias in analysis. Two-thirds of the data was used as the training set. Each pair – of training set and test set – was checked to ensure that
there was no common data between them (hence, repetitions between training and test sets were removed). The ten training sets were trained separately and
the predictions obtained for the ten test. Model quality was assessed as described before4,5 by using the ION (improvement of the naïve model) and CORR
(correlation coefficient).
Results and Discussion
GP prediction performances were obtained for flow-through and static cell experimental data
in order to assess the models. The results are shown in Table 1, where it can be seen that the
performance of the flow-through model is poor whereas the model using only static cell data
was substantially better (ION = 0.04FT vs. 0.42STAT; correlation coefficient = 0.20FT vs. 0.66STAT).
The data from flow-through and static cell experiments was then collated and analysed
together as a single data set. The results are shown in Table 2 and the average performance
indicates that the best predictive models are always obtained when data from static diffusion
cell experiments is used (i.e. Table 1: 42% and 66% for ION and CORR, respectively) compared
to models constructed from flow-through cell experiments
(i.e. Table 2: -7% and 19% for ION and CORR, respectively). These results were obtained
regardless of whether data from static or flow-through cells, or mixtures of both, were used to
train models. Further, training models based on flow-through cell data only, and predicting the
permeability of ‘unseen’ test data, resulted in poor models with a performance of 4% and 20%
for ION and CORR, respectively (Table 1). Using data from Franz-type cell experiments to train a
predictive model for flow-through diffusion cells, and vice versa (Table 3) resulted in poorly
predictive models, suggesting a lack of comparability between both types of cells.
It is apparent that the quality of the model is directly affected by the nature of the input data,
and that the inclusion of data from flow-through experiments may reduce overall model
quality and predictive power, while models based solely on such data offer poor predictions of
skin permeability. This is in significant contrast to models developed from static diffusion cell
experiments, which resulted in comparatively highly predictive models. It may therefore be
suggested that, in order to optimise the model quality, data from only static, Franz-type,
experiments should be used to construct the model. Interestingly however, this should be
taken in the context of our Monte Carlo simulation study9 which demonstrated that models
constructed from mixtures of diffusion cell experiments were not necessarily reduced in their
predictive qualities by combining such data together – this may indicate that the influence of
variable data does, in some cases, make it difficult to fully discern trends such as those
observed in this study.
Flow-through cell Static cell
Mean STD Mean STD
MSEGP 0.84 0.12 0.98 0.13
IONGP 0.04 0.04 0.42 0.09
MSENaiveGP 0.87 0.13 1.68 0.09
CORRGP 0.20 0.13 0.66 0.06
Table	1.	Prediction	performances	for	static	and	flow-though	diffusion	cells
used	to	assess	the	models.	
Flow-through cell Static cell
Mean STD Mean STD
MSEGP 0.93 0.23 0.96 0.09
IONGP -0.07 0.09 0.43 0.05
MSENaiveGP 0.86 0.14 1.70 0.09
CORRGP 0.19 0.16 0.67 0.05
Table	2.	Prediction	performances	for	a	single	dataset	(with	collated	data	from
flow-through	and	static	diffusion	cell	experiments)	used	to	assess	the	models.	
Static cell data to train 
a predictive model for 
a flow-through cell 
model
Flow-through cell data 
to train a predictive 
model for a static cell 
model
Mean STD Mean STD
MSEGP 1.17 0.32 1.64 0.06
IONGP -0.35 0.22 0.05 0.04
MSENaiveGP 0.07 0.24 0.19 0.16
CORRGP 0.86 0.14 1.73 0.10
Table	3.	Performance	measures	for	training	flow-through	or
static	cell	models	with	data	from	the	other	experiments.	
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Introduction
Mathematical models of skin permeation have been widely researched but uncommonly applied to relevant endpoints for the last twenty years. Statistically derived relationships between
chemical transport across the skin (usually characterised as either permeability, kp, or steady-state flux, Jss) and the physicochemical properties of a penetrant – usually presented in the form
of an easily understood algorithm – have found utility in this field1. However, such models have limitations, including their lack of relevance to formulation issues as they are predominately
derived from permeability studies where permeation was determined from simple solutions, inferring that such models do not consider the influence of formulation on absorption1. Several
approaches have been used to model formulation effects. For example, hybrid quantitative structure–permeability relationships (QSPRs) were used to examine the effect of solvent mixtures
on the skin permeation of model penetrants2. 12 compounds and 24 mixtures were used, and this approach was able to yield improved models for the permeation of complex chemical
mixtures. Finite dose systems were also considered by measuring the permeability of four chemicals from a range of 24 solvent blends in a finite dose in vitro model using a pig skin
membrane3. This resulted in four quantitative structure–activity relationships (QSARs) which described permeability in terms of both physicochemical properties and solvent blends, and
suggested that compounds formulated with a small difference in the boiling point and melting point of the vehicle resulted in higher skin permeation.
Machine Learning methods have shown considerable promise in providing accurate estimates of skin permeability4,5. The support vector regression (SVR) method has not previously been
applied to a pharmaceutically relevant endpoint. The support vector classification (SVC) method previously reported does offer significant improvements in model quality compared with
discriminant analysis6. SVC is limited as it is a classification method and was able to provide class membership only, as defined by the degree of enhancement benefit (the ER ratio), rather
than estimates of performance Improvement7. Further, the novel comparison of two machine learning methods in this study will test the current perception that a single, ‘global’, model
should be used to model a data set. A direct comparison between different methods (Gaussian processes and SVR) will allow us to explore whether these methods provide distinct
differences in model prediction and whether certain models should be used within a particular part of the ‘chemical space’ to optimise predictive power and subsequent significance of the
pharmaceutically relevant endpoint. Thus, the aims of the current study were to therefore assess the viability of the SVR method in providing improved estimates of the enhancement ratio
of chemicals and whether the best approach to modelling such systems is to use a single model or a range of models which optimise predictive power in certain parts of the chemical space
of the data set studied.
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Methods
The dataset used in this study has been published previously7 and consists of 71 chemical used to enhance the permeation of hydrocortisone across mouse skin. Data visualisation was
conducted via Principal Component Analysis. Development of models was accomplished by using a range of simple regression models, Gaussian Process Regression (GPR) and Support Vector
Regression (SVR)7,8 – both the ε-SVR and ν-SVR methods – with up to five physicochemical descriptors6 and a range of kernels, including the linear and Radial Basis Function (RBF) kernels.
Errors in prediction for the GPR and SVR methods were compared with a two-tailed binomial test.
Results and Discussion
Data description
A quantile – quantile plot of the dataset used (Figure 1) suggests that the data has two defined subsets
(‘good’ or ‘poor’ enhancers, defined by MW) with different distributions. Comparison of the distributions of
the values in the two subsets by a two-sample Kolmogorov–Smirnov test suggests that the two subsets are
not from the same continuous distribution. The quantile-quantile plot suggested that ‘good’ and ‘poor’
enhancers could not be discriminated from each other based on hydrogen bonding, even though PC2 is
strongly correlated to hydrogen bonding. Removal of hydrogen bonding from the model reduces model
quality only slightly – this may be a possible synergistic effect similar to that associated with the use of
models of skin permeability featuring, for example, only log P or a combination of log P and MW. Principal
component analysis indicates that the first principal component (PC1 = 0.05HB – 0.47CC – 0.49 MW –
0.53logP + 0.51logS) accounts for 66.97% of the total variance, and the second principal component (PC2 =
0.93HB – 0.10CC + 0.29MW – 0.20logP + 0.08logS) accounts for 22.64% of the variance.
Different experimental conditions
Comparison of models with three descriptors (carbon chain length, CC, molecular weight, MW and the
number of hydrogen bonding groups per molecule, HB) indicate no significant differences in statistical
measured used to assess model quality (MSE or r2) for GP or different SVR methods (ε-SVR and ν-SVR) . Five
descriptor models (MW, CC, HB and adding logP, logS) indicate that the ν−SVR method is significantly better
than ε-SVR method. While models are better differences are small, this is possibly due to variance in the
source (experimental) data. Fitted linear regression was shown to be unsuitable for analysis as there are 11
chemicals where log ER > 1.0, and the estimates provided are all < 1.0. This is possibly due to the nature of
the data, where 59 (out of 71) chemicals have ER < 1.0. Application of the RBF and Matern kernels (with 3
and 5 molecular features) indicates that the GPR method gives the best results. The ε-SVR method has the
same performance on both linear and RBF kernels with three molecular features. The ν-SVR method gives a
slight improvement on the r2measurement using the RBF kernel, while the MSE measurement remains the
same for both kernels with three features. The ν−SVR method resulted in the best model when five
descriptors were used – MSE and r2 improved by 23% and 7%, respectively, compared to ε-SVR (Figure 2).
Errors in prediction (MSE) between GP and SVR methods were not significantly different (Spearman test;
p=0.12, suggesting a degree of correlation between SVR and GP methods; Wilcoxon signed rank; P=0.34
suggesting that the GP and SVM predictionsmay be froma distribution with the same median).
Discussion
Overall, the SVR methods produce models of similar statistical quality to the GP methods. The ν−SVR
method is better in estimating ER for 40 out of 71 chemicals. However, it is important to note that GP and
SVR methods perform better at certain points of the ‘chemical space’ of the data set. For example, GP has a
better performance where PC1 ≥ 3 and GPR gives a more reliable estimate on 8 of 12 chemicals that have a
PC1 ≥ 2.3. In addition, GP has a better performance at PC1 [1.17, 0.94] on all six chemicals (Figures 3 and 4).
This indicates that, while it is important for model quality to consider the physicochemical descriptors used,
it is also important to consider that different models may produce different predictions and that the concept
of using a single, ‘global’ model may not always be appropriate. Thus, combining classification and
regression methods to provide model optimisation at different parts of the chemical space may provide a
significant new approach to improving model quality and relevance.
Figure	1.	A	quantile-quantile	plot	of	MW	for	those	enhancers	classified	as	“good”	and	“poor”.
Figure	2.	Plot	of	the	relative	values	of	differences	of	actual	logER	values	and	estimates	against	the
first	principal	component.
Figure	3.	Contour	plot	of	the	principal	components	for	the		Gaussian	Process
Regression	(GPR)	method.
Figure	4.	Contour	plot	of	the	principal	components	for	the		Support	Vector
Regression	(SVR)	method.
υ
υ
υ
Bibliography
M. H. Abraham, H. S. Chadha, and R. C. Mitchell. The factors that influence skin penetra-
tion of solutes*. Journal of pharmacy and pharmacology, 47(1):8–16, 1995.
M. H. Abraham, F. Martins, and R. C. Mitchell. Algorithms for skin permeability using
hydrogen bond descriptors: the problem of steroids*. Journal of pharmacy and pharma-
cology, 49(9):858–865, 1997.
M. H. Abraham, H. S. Chadha, F. Martins, R. C. Mitchell, M. W. Bradbury, and J. A. Grat-
ton. Hydrogen bonding part 46: A review of the correlation and prediction of transport
properties by an lfer method: Physicochemical properties, brain penetration and skin
permeability. Pesticide Science, 55(1):78–88, 1999.
M. Abramowitz and I. A. Stegun. Handbook of Mathematical Functions: With Formulars,
Graphs, and Mathematical Tables, volume 55. DoverPublications. com, 1964.
H. L. Anderson. Metropolis, monte carlo, and the maniac. Los Alamos Science, 14:96–108,
1986.
P. Ashrafi, G. Moss, S. Wilkinson, N. Davey, and Y. Sun. The application of machine
learning to the modelling of percutaneous absorption: an overview and guide. SAR and
QSAR in Environmental Research, 26(3):181–204, 2015.
R. Bardenet and B. Kégl. Surrogating the surrogate: accelerating gaussian-process-based
global optimization with a mixture cross-entropy algorithm. In 27th International Con-
ference on Machine Learning (ICML 2010), pages 55–62. Omnipress, 2010.
250
M. Barratt. Quantitative structure-activity relationships for skin permeability. Toxicology
in Vitro, 9(1):27–37, 1995.
J. Bergstra and Y. Bengio. Random search for hyper-parameter optimization. The Journal
of Machine Learning Research, 13(1):281–305, 2012.
J. S. Bergstra, R. Bardenet, Y. Bengio, and B. Kégl. Algorithms for hyper-parameter op-
timization. In Advances in Neural Information Processing Systems, pages 2546–2554,
2011.
R. L. Bronaugh and H. I. Maibach. Percutaneous absorption: mechanisms–methodology–
drug delivery, volume 8. Marcel Dekker Inc, 1989.
S. L. Brown and J. E. Rossi. A simple method for estimating dermal absorption of chemi-
cals in water. Chemosphere, 19(12), 1989.
D. Büche, N. N. Schraudolph, and P. Koumoutsakos. Accelerating evolutionary algorithms
with gaussian process fitness function models. Systems, Man, and Cybernetics, Part C:
Applications and Reviews, IEEE Transactions on, 35(2):183–194, 2005.
F. R. Burden. Quantitative structure-activity relationship studies using gaussian processes.
Journal of chemical information and computer sciences, 41(3):830–835, 2001.
C.-C. Chang and C.-J. Lin. LIBSVM: A library for support vector machines. ACM Trans-
actions on Intelligent Systems and Technology, 2:27:1–27:27, 2011. Software available
at http://www.csie.ntu.edu.tw/~cjlin/libsvm.
O. Chapelle and V. Vapnik. Model selection for support vector machines. In NIPS, pages
230–236, 1999.
L.-j. Chen, G.-p. Lian, and L.-j. Han. Prediction of human skin permeability using artificial
neural network (ann) modeling. Acta Pharmacologica Sinica, 28(4):591, 2007.
V. Cherkassky and Y. Ma. Selecting of the loss function for robust linear regression. Neural
computation, 2002.
251
V. Cherkassky and F. M. Mulier. Learning from data: concepts, theory, and methods. John
Wiley & Sons, 2007.
R. Chilcott, C. Dalton, I. Hill, C. Davison, K. Blohm, E. Clarkson, and M. Hamilton. In
vivo skin absorption and distribution of the nerve agent vx (o–ethyl–s–[2 (diisopropy-
lamino) ethyl] methylphosphonothioate) in the domestic white pig. Human & experi-
mental toxicology, 24(7):347–352, 2005.
R. L. Cleek and A. L. Bunge. A new method for estimating dermal absorption from chem-
ical exposure. 1. general approach. Pharmaceutical research, 10(4):497–506, 1993.
I. Cortes-Ciriano, A. Bender, and T. E. Malliavin. Comparing the influence of simulated
experimental errors on 12 machine learning algorithms in bioactivity modeling using 12
diverse data sets. Journal of chemical information and modeling, 2015.
J. Couto. Kernel k-means for categorical data. In A. Famili, J. Kok, J. Pena, A. Siebes,
and A. Feelders, editors, Advances in Intelligent Data Analysis VI, volume 3646 of Lec-
ture Notes in Computer Science, pages 46–56. Springer Berlin Heidelberg, 2005. ISBN
978-3-540-28795-7. doi: 10.1007/11552253_5. URL http://dx.doi.org/10.1007/
11552253_5.
Cronin and Schultz. Pitfalls in qsar. Journal of Molecular Structure: THEOCHEM,
622(1):39–51, 2003. doi: doi:10.1016/S0166-1280(02)00616-4. URL
http://www.ingentaconnect.com/content/els/01661280/2003/00000622/
00000001/art00616.
M. Cronin, J. Dearden, G. Moss, and G. Murray-Dickson. Investigation of the mechanism
of flux across human skin in vitro by quantitative structure–permeability relationships.
European Journal of Pharmaceutical Sciences, 7(4):325–330, 1999.
S. Dreiseitl and L. Ohno-Machado. Logistic regression and artificial neural network clas-
sification models: a methodology review. Journal of biomedical informatics, 35(5):352–
359, 2002.
252
N. El Tayar, R.-S. Tsai, P. Vallat, C. Altomare, and B. Testa. Measurement of partition
coefficients by various centrifugal partition chromatographic techniques: a comparative
evaluation. Journal of Chromatography A, 556(1):181–194, 1991.
P. M. Elias, E. R. Cooper, A. Korc, and B. E. Brown. Percutaneous transport in relation to
stratum corneum structure and lipid composition. Journal of Investigative Dermatology,
76(4):297–301, 1981.
A. Fick. V. on liquid diffusion. The London, Edinburgh, and Dublin Philosophical Maga-
zine and Journal of Science, 10(63):30–39, 1855.
G. L. Flynn. Physicochemical determinants of skin absorption, 1990.
B. Fritzke et al. A growing neural gas network learns topologies. Advances in neural
information processing systems, 7:625–632, 1995.
N. Gibson, S. Aigrain, S. Roberts, T. Evans, M. Osborne, and F. Pont. A gaussian process
framework for modelling instrumental systematics: application to transmission spec-
troscopy. Monthly Notices of the Royal Astronomical Society, 419(3):2683–2694, 2012.
N. Hansen and A. Ostermeier. Completely derandomized self-adaptation in evolution
strategies. Evolutionary computation, 9(2):159–195, 2001.
T. Hastie, R. Tibshirani, and J. J. H. Friedman. The elements of statistical learning, vol-
ume 1. Springer New York, 2001.
C. R. Houck, J. Joines, and M. G. Kay. A genetic algorithm for function optimization: a
matlab implementation. NCSU-IE TR, 95(09), 1995.
I. Jolliffe. Principal component analysis. Wiley Online Library, 2002.
D. P. Kroese, T. Brereton, T. Taimre, and Z. I. Botev. Why the monte carlo method is so
important today. Wiley Interdisciplinary Reviews: Computational Statistics, 6(6):386–
392, 2014. ISSN 1939-0068. doi: 10.1002/wics.1314. URL http://dx.doi.org/10.
1002/wics.1314.
253
L. T. Lam, Y. Sun, N. Davey, R. Adams, M. Prapopoulou, M. B. Brown, and G. P. Moss.
The application of feature selection to the development of gaussian process models
for percutaneous absorption. Journal of Pharmacy and Pharmacology, 62(6):738–749,
2010.
E. J. Lien and H. Gaot. Qsar analysis of skin permeability of various drugs in man as
compared to in vivo and in vitro studies in rodents. Pharmaceutical research, 12(4):
583–587, 1995.
C. W. Lim, S. ichi Fujiwara, F. Yamashita, and M. Hashida. Prediction of human skin
permeability using a combination of molecular orbital calculations and artificial neural
network. Biological and Pharmaceutical Bulletin, 25(3):361–366, 2002. doi: 10.1248/
bpb.25.361.
M. Linting and A. van der Kooij. Nonlinear principal components analysis with catpca: a
tutorial. Journal of personality assessment, 94(1):12–25, 2012.
H. S. Loos and B. Fritzke. Demogng v1. 5, 1998.
D. J. MacKay. Gaussian processes-a replacement for supervised neural networks? 1997.
B. M. Magnusson, Y. G. Anissimov, S. E. Cross, and M. S. Roberts. Molecular size as
the main determinant of solute maximum flux across the skin. Journal of Investigative
Dermatology, 122(4):993–999, 2004.
A. N. Martin, J. Swarbrick, A. Cammarata, and A. Chun. Physical pharmacy: physical
chemical principles in the pharmaceutical sciences. 1993.
L. Michielan and S. Moro. Pharmaceutical perspectives of nonlinear qsar strategies. Jour-
nal of chemical information and modeling, 50(6):961–978, 2010.
T. P. Minka and R. W. Picard. Learning how to learn is learning with point sets. Web.
Revised, 1999.
M. Mitchell. An introduction to genetic algorithms. MIT press, 1998.
254
G. Moss, J. Dearden, H. Patel, and M. Cronin. Quantitative structure permeability re-
lationships (qsprs) for percutaneous absorption. Toxicology in Vitro, 16(3):299 – 317,
2002. ISSN 0887-2333. doi: http://dx.doi.org/10.1016/S0887-2333(02)00003-6. URL
http://www.sciencedirect.com/science/article/pii/S0887233302000036.
G. P. Moss and M. T. Cronin. Quantitative structure–permeability relationships for percu-
taneous absorption: re-analysis of steroid data. International journal of pharmaceutics,
238(1):105–109, 2002.
G. P. Moss, Y. Sun, M. Prapopoulou, N. Davey, R. Adams, W. J. Pugh, and M. B. Brown.
The application of gaussian processes in the prediction of percutaneous absorption. Jour-
nal of Pharmacy and Pharmacology, 61(9):1147–1153, 2009.
G. P. Moss, Y. Sun, S. C. Wilkinson, N. Davey, R. Adams, G. P. Martin, M. Prapopopolou,
and M. B. Brown. The application and limitations of mathematical modelling in the pre-
diction of permeability across mammalian skin and polydimethylsiloxane membranes.
Journal of Pharmacy and Pharmacology, 63(11):1411–1427, 2011.
G. P. Moss, S. C. Wilkinson, and Y. Sun. Mathematical modelling of percutaneous absorp-
tion. Current Opinion in Colloid & Interface Science, 17(3):166–172, 2012.
G. P. Moss, D. R. Gullick, and S. C. Wilkinson. Predictive methods in percutaneous ab-
sorption. 2015.
I. Nabney. NETLAB: algorithms for pattern recognition. Springer, 2002.
D. Neumann, O. Kohlbacher, C. Merkwirth, and T. Lengauer. A fully computational model
for predicting percutaneous drug absorption. Journal of chemical information and mod-
eling, 46(1):424–429, 2006.
U. Norinder. Support vector machine models in drug design: applications to drug transport
processes and qsar using simplex optimisations and variable selection. Neurocomputing,
55(1):337–346, 2003.
255
O. Obrezanova and M. D. Segall. Gaussian processes for classification: Qsar modeling of
admet and target activity. Journal of chemical information and modeling, 50(6):1053–
1061, 2010.
O. Obrezanova, G. Csányi, J. M. Gola, and M. D. Segall. Gaussian processes: a method
for automatic qsar modeling of adme properties. Journal of chemical information and
modeling, 47(5):1847–1857, 2007.
W. Pedrycz and S. Chen. Time series analysis, modeling and applications. A Computational
Intelligence Perspective (e-book Google), 2013.
D. Petelin, A. Grancharova, and J. Kocijan. Evolving gaussian process models for pre-
diction of ozone concentration in the air. Simulation modelling practice and theory, 33:
68–80, 2013.
R. O. Potts and R. H. Guy. Predicting skin permeability. Pharmaceutical research, 9(5):
663–669, 1992.
R. O. Potts and R. H. Guy. A predictive algorithm for skin permeability: the effects of
molecular size and hydrogen bond activity. Pharmaceutical research, 12(11):1628–1633,
1995.
M. Prapopoulou. The development of a mathematical / computational model to predict
drug absorption across the skin. PhD thesis, PhD thesis, King’s College London, 2012.
W. Pugh, R. Wong, F. Falson, B. Michniak, and G. Moss. Discriminant analysis as a tool to
identify compounds with potential as transdermal enhancers. Journal of pharmacy and
pharmacology, 57(11):1389–1396, 2005.
C. E. Rasmussen. Gaussian processes in machine learning. Springer, 2004.
C. E. Rasmussen. Christopher ki williams gaussian processes for machine learning, 2006a.
C. E. Rasmussen. Gaussian processes for machine learning. 2006b.
C. E. Rasmussen and H. Nickisch. The gpml toolbox version 3.5. 2015.
256
K. I. W. Rasmussen. Gaussian processes for machine learning @ONLINE, 2006c. URL
http://www.gaussianprocess.org/gpml/.
M. Roberts, R. Anderson, and J. Swarbrick. Permeability of human epidermis to phenolic
compounds. Journal of pharmacy and pharmacology, 29(1):677–683, 1977.
R. J. Scheuplein. Mechanism of percutaneous absorption: Ii. transient diffusion and the
relative importance of various routes of skin penetration** from the research laboratories
of the department of dermatology of the harvard medical school at the massachusetts
general hospital, boston, massachusetts 02114. Journal of Investigative Dermatology, 48
(1):79–88, 1967.
R. J. Scheuplein. Permeability of the skin. Comprehensive Physiology, 2011.
A. Shah, G. P. Moss, Y. Sun, R. Adams, N. Davey, and S. Wilkinson. Using a support vector
machine and sampling to classify compounds as potential transdermal enhancers. In Ar-
tificial Neural Networks and Machine Learning–ICANN 2012, pages 499–506. Springer,
2012.
A. Shah, Y. Sun, R. G. Adams, N. Davey, S. C. Wilkinson, and G. P. Moss. Support vector
regression to estimate the permeability enhancement of potential transdermal enhancers.
Journal of Pharmacy and Pharmacology, 2016.
J. R. Shewchuk. An introduction to the conjugate gradient method without the agonizing
pain, 1994.
J. Shlens. A Tutorial on Principal Component Analysis. ArXiv e-prints, Apr. 2014.
A. J. Smola and B. Schölkopf. A tutorial on support vector regression. Statistics and
computing, 14(3):199–222, 2004.
E. L. Snelson. Flexible and efficient Gaussian process models for machine learning. PhD
thesis, Citeseer, 2007.
J. Snoek, H. Larochelle, and R. P. Adams. Practical bayesian optimization of machine
learning algorithms. In Advances in neural information processing systems, pages 2951–
2959, 2012.
257
E. W. Steyerberg, M. J. Eijkemans, F. E. Harrell, and J. D. F. Habbema. Prognostic mod-
elling with logistic regression analysis: a comparison of selection and estimation methods
in small data sets. Statistics in medicine, 19(8):1059–1079, 2000.
Y. Sun, G. P. Moss, M. Prapopoulou, R. Adams, M. B. Brown, and N. Davey. Prediction
of skin penetration using machine learning methods. In Data Mining, 2008. ICDM’08.
Eighth IEEE International Conference on, pages 1049–1054. IEEE, 2008.
Y. Sun, G. P. Moss, M. Prapopoulou, R. Adams, M. B. Brown, and N. Davey. The applica-
tion of gaussian processes in the prediction of percutaneous absorption for mammalian
and synthetic membranes. In ESANN, 2010.
Y. Sun, M. Brown, M. Prapopoulou, N. Davey, R. Adams, and G. Moss. The application of
stochastic machine learning methods in the prediction of skin penetration. Applied Soft
Computing, 11(2):2367–2375, 2011.
Y. Sun, M. B. Brown, M. Prapopoulou, R. Adams, N. Davey, and G. P. Moss. The appli-
cation of gaussian processes in the predictions of permeability across mammalian mem-
branes. In Artificial Neural Networks and Machine Learning–ICANN 2012, pages 507–
514. Springer, 2012.
V. N. Vapnik. Statistical learning theory, volume 1. Wiley New York, 1998.
E. Wakelam, N. Davey, Y. Sun, A. Jefferies, P. Alva, and A. Hocking. The mining and
analysis of data with mixed attribute types. In Proceedings: IMMM 2016: Sixth Interna-
tional Conference on Advances in Information Mining and Management, pages 55–62,
2016.
A. Williams. Transdermal and topical drug delivery, volume 17. Pharmaceutical Press
London, 2003.
A. Wilschut, F. Wil, P. J. Robinson, and T. E. McKone. Estimating skin permeation. the val-
idation of five mathematical skin permeation models. Chemosphere, 30(7):1275–1296,
1995.
258
G. Winter, J. Periaux, M. Galan, and P. Cuesta. Genetic algorithms in engineering and
computer science. John Wiley & Sons, Inc., 1996.
D. Woolfson and D. McCafferty. Percutaneous local anaesthesia. CRC Press, 1993.
C. Xue, R. Zhang, H. Liu, X. Yao, M. Liu, Z. Hu, and B. T. Fan. Qsar models for the
prediction of binding affinities to human serum albumin using the heuristic method and a
support vector machine. Journal of chemical information and computer sciences, 44(5):
1693–1700, 2004.
259
